COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection
Amendment 07 (31-May-2017)

Amendment rationale

The purpose of this protocol Amendment 07 is:

- Perform the primary analysis of RFS using a data cut-off at approximately 2.5 years after Last patient First Dose which also corresponds to a projected median follow up of 3.3 years for all subjects.
- Add an additional interim OS analysis when approximately 299 death events have occurred, i.e., at 50% information fraction of originally targeted 597 OS events.
Changes to the protocol

Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font for deletions and red underline for insertions.

- Updated Sponsor Contact information
- Section 9.1.: Added language to state the primary analysis of RFS can be performed using a data cut-off at approximately 2.5 years after Last patient First Dose. Updated data-cut-off date for final RFS analysis and provided related updated statistical assumptions.
- Section 9.2.1: Clarified that the primary analysis for RFS will be a first interim analysis for Overall Survival and added a second interim analysis for survival after approximately 299 events. Statistical rationale and updated assumptions were also added.
- Section 11 References: Section updated to include additional reference noted in the rationale for this amendment.

IRBs/IECs

A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.

The changes described in this amended protocol do not change any study procedures or the safety management of the on-going patients, and therefore, do not require IRB/IEC approval prior to implementation.
### Summary of previous amendments

<table>
<thead>
<tr>
<th>Revision Chronology:</th>
<th>2012-JUL-05</th>
<th>Original</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012N135295_00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012N135295_01</td>
<td>2012-OCT-10</td>
<td>Amendment No. 1</td>
</tr>
</tbody>
</table>
Amendment No. 1:

1. Updated RFS and OS analysis and study completion definitions
2. Deleted the formal interim efficacy analysis.
3. Added details of randomization capping and interim analysis for OS at the time of the RFS analysis.
4. Updated male contraception requirements to align with current standard for dabrafenib and trametinib.
5. Updated dosage and administration guidelines for grapefruit and grapefruit juice, Seville oranges, or pommelos consumption before randomization from 7 days to 24 hours.
6. Updated Table 3 Dose Modification Guidelines for General Toxicity and corresponding text.
7. Revised Dose Modification Guidelines for:
   - Pyrexia
   - Visual Changes
   - LVEF
8. Changes to the Time and Events Tables including modification to frequency of cfDNA and biomarker, cytokine and biomarkers of pyrexia blood sample collection, addition of PK sample at Month 1, update to instruction for MRI substitution of CT, correction of typographical errors, modification of visit window during the treatment period, clarification of central lab schedule during follow-up and removal of Month 21 CT scan.
9. Added table showing statistical power scenario for OS analysis.
10. Minor changes for clarification and consistency throughout the protocol including:
    - Patients that present with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.
    - Patients with history of another malignancy including melanoma or concurrent malignancy are not eligible.
    - Clinical examination and biopsy of recurrence are considered efficacy assessments.
    - Ophthalmic examination must be performed by an ophthalmologist.
    - Added text referring to information and requirements for head and neck examinations and dermatologic examinations provided in the SPM.
11. Minor administrative changes, and correction to typographical errors throughout the document

---

2012N135295 02  2012-NOV-12  Amendment No. 2

Amendment No. 2:
<table>
<thead>
<tr>
<th>Amendment No. 3:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Added CT/MRI assessment at Month 21.</td>
</tr>
<tr>
<td>2. Included 80% power calculation for OS.</td>
</tr>
<tr>
<td>3. Provide the rationale for use of the Pike estimator of the treatment hazard ratio.</td>
</tr>
<tr>
<td>4. Updated male and female contraception requirements.</td>
</tr>
<tr>
<td>5. Clarified exclusion #12.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment No. 04:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-JAN-17</td>
</tr>
</tbody>
</table>
### Amendment No. 05:

1. Clarifications and updates to eligibility criteria.
2. Deleted exclusion for glucose-6-phosphate dehydrogenase (G6PD) deficiency.
3. Clarified follow-up assessments required for subjects that discontinue treatment prior to Month 12 without evidence of disease recurrence.
4. Updated dosing instructions.
5. Updated dose modification guidelines for visual changes.
6. Updated guidance for symptomatic decreased left ventricular ejection fraction (LVEF).
7. Updated guidelines for QTc prolongation.
8. Updated prohibited and cautionary medications.
9. Clarifications and updates to the Time and Events tables including:
   - Addition of dermatologic skin assessments at Months 8 and 10.
   - Deletion of dermatologic skin assessment at Month 9.
   - Addition of column and footnotes to describe follow up assessments for subjects that discontinue treatment prior to Month 12 without evidence of disease recurrence.
   - Clarification of PK, cfDNA, cytokines and other biomarkers of pyrexia testing.
10. Clarified imaging requirements for efficacy assessments.
11. Added collection of new malignancy information.
12. [Redacted]
13. Minor administrative changes, clarifications and corrections to typographical errors throughout the document.

### Amendment No. 06:

1. Delete or replace references to GSK or its staff with that of Novartis/Novartis and its authorized agents.
2. Make administrative changes to align with Novartis processes and procedures.
### Regulatory Agency Identifying Number(s):

<table>
<thead>
<tr>
<th>Description</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigational New Drug (IND) Number</td>
<td>113,557</td>
</tr>
<tr>
<td>European Drug Regulatory Authorities Clinical Trials (EudraCT) Number</td>
<td>2012-001266-15</td>
</tr>
<tr>
<td>Universal Trial Number (UTN)</td>
<td>U1111-1148-3778</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>17</td>
</tr>
<tr>
<td>PROTOCOL SUMMARY</td>
<td>20</td>
</tr>
<tr>
<td>1 INTRODUCTION</td>
<td>23</td>
</tr>
<tr>
<td>1.1 Background</td>
<td>23</td>
</tr>
<tr>
<td>1.1.1 The BRAF Inhibitor Dabrafenib as Monotherapy</td>
<td>24</td>
</tr>
<tr>
<td>1.1.2 The MEK Inhibitor Trametinib as Monotherapy</td>
<td>25</td>
</tr>
<tr>
<td>1.1.3 BRAF and MEK Inhibitors as Combination Therapy</td>
<td>25</td>
</tr>
<tr>
<td>1.1.3.1 Nonclinical Biology</td>
<td>25</td>
</tr>
<tr>
<td>1.1.3.2 Clinical</td>
<td>26</td>
</tr>
<tr>
<td>1.2 Study Rationale</td>
<td>27</td>
</tr>
<tr>
<td>2 OBJECTIVES AND ENDPOINTS</td>
<td>29</td>
</tr>
<tr>
<td>3 STUDY DESIGN</td>
<td>31</td>
</tr>
<tr>
<td>3.1 Discussion of Design</td>
<td>32</td>
</tr>
<tr>
<td>3.1.1 Dose Rationale</td>
<td>33</td>
</tr>
<tr>
<td>4 SUBJECT SELECTION AND DISCONTINUATION/COMPLETION CRITERIA</td>
<td>34</td>
</tr>
<tr>
<td>4.1 Subject Selection Criteria</td>
<td>34</td>
</tr>
<tr>
<td>4.1.1 Number of Subjects</td>
<td>34</td>
</tr>
<tr>
<td>4.1.2 Inclusion Criteria</td>
<td>34</td>
</tr>
<tr>
<td>4.1.3 Exclusion Criteria</td>
<td>35</td>
</tr>
<tr>
<td>4.2 Permanent Discontinuation from Study Treatment and Subject Completion Criteria</td>
<td>37</td>
</tr>
<tr>
<td>4.2.1 Subject Completion</td>
<td>38</td>
</tr>
<tr>
<td>5 STUDY TREATMENT</td>
<td>38</td>
</tr>
<tr>
<td>5.1 Investigational Products</td>
<td>39</td>
</tr>
<tr>
<td>5.1.1 Dabrafenib</td>
<td>39</td>
</tr>
<tr>
<td>5.1.2 Trametinib</td>
<td>39</td>
</tr>
<tr>
<td>5.1.3 Placebos</td>
<td>39</td>
</tr>
<tr>
<td>5.2 Dosage and Administration</td>
<td>39</td>
</tr>
<tr>
<td>5.3 Handling and Storage of Study Treatment</td>
<td>40</td>
</tr>
<tr>
<td>5.4 Treatment Assignment</td>
<td>40</td>
</tr>
<tr>
<td>5.5 Blinding</td>
<td>40</td>
</tr>
<tr>
<td>5.6 Product Accountability</td>
<td>41</td>
</tr>
<tr>
<td>5.7 Treatment Compliance</td>
<td>41</td>
</tr>
<tr>
<td>5.8 Dose Modification Guidelines</td>
<td>41</td>
</tr>
<tr>
<td>5.8.1 General supportive guidelines</td>
<td>42</td>
</tr>
<tr>
<td>5.8.1.1 Skin Toxicity (Rash, Palmar-Plantar Erythrodysthesia syndrome)</td>
<td>42</td>
</tr>
</tbody>
</table>
5.8.1.2 Diarrhea .................................................................................................................. 42
5.8.2 Dose Modification for General Toxicities ............................................................... 43
5.8.3 Dose Modification Guidelines - Adverse Events of Special Interest ................. 44
5.8.3.1 Pyrexia .................................................................................................................. 44
5.8.3.2 Visual changes ...................................................................................................... 47
5.8.3.3 Cardiovascular toxicity ....................................................................................... 48
5.8.3.3.1 Decreased Left Ventricular Ejection Fraction (LVEF) .................................. 49
5.8.3.3.2 Hypertension .................................................................................................... 50
5.8.3.3.3 QTc prolongation ............................................................................................. 50
5.8.3.3.4 Valvular Toxicity ............................................................................................. 50
5.8.3.4 Cutaneous squamous cell carcinoma (cutSCC) and keratoacanthoma (KA) ....... 51
5.9 Monitoring, Interruption, and Stopping Criteria for Hepatobiliary Events .......... 51
5.9.1 Liver chemistry stopping criteria ........................................................................... 51
5.9.1.1 Liver Event Follow Up Assessments .................................................................. 53
5.9.1.2 Liver Chemistry Monitoring Criteria .................................................................. 54
5.9.1.3 Restarting Investigational Product ..................................................................... 55
5.9.1.3.1 Drug Restart/Rechallenge Following Liver Events that are Possibly Related to Study Treatment ........................................................................................................ 55
5.9.1.3.2 Drug Restart Following Transient Resolving Liver Events Not Related to Study Treatment ........................................................................................................ 55
6 CONCOMITANT MEDICATIONS AND NON-DRUG THERAPIES ...................... 56
6.1 Permitted Medications and Non-Drug Therapies ..................................................... 56
6.2 Prohibited Medications and Non-Drug Therapies .................................................. 56
6.3 Medications to be Used with Caution ..................................................................... 57
6.4 Treatment after Discontinuation of Study Treatment or Withdrawal from Completion of Study ...................................................................................................... 59
6.5 Treatment of Study Treatment Overdose ............................................................... 59
7 STUDY ASSESSMENTS AND PROCEDURES ....................................................... 60
7.1 Critical Baseline Assessments .................................................................................. 71
7.1.1 Baseline Confirmation of BRAF Mutation-positive Melanoma ......................... 71
7.2 Efficacy ..................................................................................................................... 71
7.2.1 Efficacy Endpoints ............................................................................................... 71
7.2.1.1 Primary Endpoint ............................................................................................. 71
7.2.1.2 Secondary Endpoints ....................................................................................... 72
7.2.1.3 Efficacy Assessment ......................................................................................... 72
7.2.1.4 Assessment Guidelines .................................................................................... 73
7.2.1.5 Follow-up Assessments for Subjects Permanently Discontinued from Study Treatment prior to protocol treatment period (12 months) ........................................ 73
7.2.1.6 Assessment of Subject Completion .................................................................. 73
7.3 Safety ....................................................................................................................... 74
12.5 Appendix 5: QT interval on electrocardiogram corrected using the Bazett’s formula (QTcB) ................................................................. 107
12.6 Appendix 6: New York Heart Association (NYHA) Guidelines ..................... 108
12.7 Appendix 7: Liver Chemistry Monitoring, Interruption Stopping and Follow-up Criteria ........................................................................... 109
12.8 Appendix 8: Health-related Quality of Life (HRQOL) Questionnaire .............. 110
12.9 Appendix 9: Pharmacogenetic Research ..................................................... 113
12.10 Appendix 10: Country Specific Requirements ........................................... 118
12.11 Appendix 11: Protocol Changes for Amendment 01 ................................ 119
12.12 Appendix 12: Protocol Changes for Amendment 02 ................................. 141
12.13 Appendix 13: Protocol Changes for Amendment 03 ............................... 142
12.14 Appendix 14: Protocol Changes for Amendment 04 ............................... 148
12.15 Appendix 15: Additional monitoring................................................................ 149
12.16 Appendix 16: Protocol Changes for Amendment 05 ............................... 150
12.17 Protocol Changes for Amendment 6 (dated 05-Oct-2016) from Amendment 5 (dated 24-October-2013) ......................................................... 172
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine Aminotransferase</td>
</tr>
<tr>
<td>ANC</td>
<td>Absolute neutrophil count</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate Aminotransferase</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BCC</td>
<td>Basal cell carcinoma</td>
</tr>
<tr>
<td>BID</td>
<td>Twice daily</td>
</tr>
<tr>
<td>bMX</td>
<td>bioMerieux</td>
</tr>
<tr>
<td>BRAF</td>
<td>Protein with an important role in cell signalling</td>
</tr>
<tr>
<td>BUN</td>
<td>Blood Urea Nitrogen</td>
</tr>
<tr>
<td>CAF</td>
<td>Cytokines and angiogenic factors</td>
</tr>
<tr>
<td>cfDNA</td>
<td>Circulating cell-free DNA</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
</tr>
<tr>
<td>CL/F</td>
<td>Apparent clearance following oral dosing</td>
</tr>
<tr>
<td>CPK</td>
<td>Serum creatine phosphokinase</td>
</tr>
<tr>
<td>CR</td>
<td>Complete Response</td>
</tr>
<tr>
<td>CRO</td>
<td>Clinical Research Organization</td>
</tr>
<tr>
<td>CRAF</td>
<td>protein functioning in the MAPK/ERK signal transduction pathway as part of a protein kinase cascade</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CSR</td>
<td>Central serous retinopathy</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common terminology criteria for adverse events</td>
</tr>
<tr>
<td>cuSCC</td>
<td>Cutaneous squamous cell carcinoma</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DMFS</td>
<td>Distant metastasis-free survival</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DTIC</td>
<td>Dacarbazine</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO</td>
<td>Echocardiogram</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signalling-regulated kinase</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>EuroQol-5D</td>
</tr>
<tr>
<td>FDA</td>
<td>United States Food and Drug Administration</td>
</tr>
<tr>
<td>FDG-PET</td>
<td>Fluorodeoxyglucose positron emission tomography</td>
</tr>
<tr>
<td>FFR</td>
<td>Freedom From Relapse</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GCPh</td>
<td>Global Clinical Program Head</td>
</tr>
<tr>
<td>GCSP</td>
<td>Global Clinical Safety and Pharmacovigilance</td>
</tr>
<tr>
<td>GLP</td>
<td>Good Laboratory Practice</td>
</tr>
<tr>
<td>HA</td>
<td>Health Authority</td>
</tr>
<tr>
<td>Hg</td>
<td>Mercury</td>
</tr>
<tr>
<td>HPLC</td>
<td>High Performance Liquid Chromatography</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HPMC</td>
<td>Hydroxypropylmethylcellulose</td>
</tr>
<tr>
<td>HR</td>
<td>Hazard ratio</td>
</tr>
<tr>
<td>HRQOL</td>
<td>Health related quality of life</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IP</td>
<td>Investigational product</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>ITT</td>
<td>Intent to Treat</td>
</tr>
<tr>
<td>IUO</td>
<td>Investigational Use Only</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive Voice Response System</td>
</tr>
<tr>
<td>KA</td>
<td>Keratoacanthoma</td>
</tr>
<tr>
<td>KRAS</td>
<td>KRAS gene makes KRAS protein which is involved in cell signaling pathways, cell growth and apoptosis. When mutated the KRAS gene may cause cancer.</td>
</tr>
<tr>
<td>LDH</td>
<td>Lactate dehydrogenase</td>
</tr>
<tr>
<td>LLN</td>
<td>Lower limit of normal</td>
</tr>
<tr>
<td>LN</td>
<td>Lymph node</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MEK1 and MEK2</td>
<td>Mitogen-activated extracellular signal-related kinases 1 and 2</td>
</tr>
<tr>
<td>mm</td>
<td>Millimeter</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>msec</td>
<td>Milliseconds</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NR</td>
<td>Not Reached</td>
</tr>
<tr>
<td>NRAS</td>
<td>NRAS gene makes NRAS protein which is involved in regulating cell division</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
<tr>
<td>ORR</td>
<td>Overall response rate</td>
</tr>
<tr>
<td>OS</td>
<td>Overall survival</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PD</td>
<td>Progressive Disease</td>
</tr>
<tr>
<td>PFS</td>
<td>Progression-free survival</td>
</tr>
<tr>
<td>PGx</td>
<td>Pharmacogenetics</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetic</td>
</tr>
<tr>
<td>PPES</td>
<td>Palmar-Plantar Erythrodysesthesia Syndrome</td>
</tr>
<tr>
<td>PR</td>
<td>Partial Response</td>
</tr>
<tr>
<td>PT</td>
<td>Prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>Partial thromboplastin time</td>
</tr>
<tr>
<td>QT</td>
<td>Electrocardiogram interval from onset of the QRS complex to the end of the T wave representing duration of repolarisation</td>
</tr>
<tr>
<td>QTcB</td>
<td>QT duration corrected for heart rate by Bazett's formula</td>
</tr>
<tr>
<td>RAF</td>
<td>Serine threonine-protein kinase activating downstream effectors involved in tumorigenesis</td>
</tr>
<tr>
<td>RAP</td>
<td>Reporting and Analysis Plan</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>RAS</td>
<td>Protein activating signaling cascades (promoting cell proliferation, neoplastic transformation and oncogenesis)</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumours</td>
</tr>
<tr>
<td>RFS</td>
<td>Relapse Free Survival</td>
</tr>
<tr>
<td>RR</td>
<td>Response Rate</td>
</tr>
<tr>
<td>RVO</td>
<td>Retinal vein occlusion</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event(s)</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SCC</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>SD</td>
<td>Stable Disease</td>
</tr>
<tr>
<td>SGOT</td>
<td>Serum glutamic oxaloacetic transaminase</td>
</tr>
<tr>
<td>SGPT</td>
<td>Serum glutamic pyruvic transaminase</td>
</tr>
<tr>
<td>SPM</td>
<td>Study Procedures Manual</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
<tr>
<td>US/USA</td>
<td>United States</td>
</tr>
<tr>
<td>V/F</td>
<td>Volume of distribution</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cell</td>
</tr>
</tbody>
</table>
PROTOCOL SUMMARY

RATIONALE
Cutaneous melanoma is the most aggressive form of all skin cancers. Although it represents only 4% of all cancers, its incidence is continuing to rise in the world at a rate exceeding all other cancers [Jemal, 2007]. Worldwide it is expected that approximately 132,000 people will be diagnosed with melanoma each year and approximately 37,000 people are expected to die of the disease annually [WHO, 2012].

Surgical resection is the treatment of choice for localized melanoma and frequently results in cures for early stage (I and II) disease, with a 90% long term (10-year) survival rate for stage I disease [Balch, 2009]. However, patients with lymph node involvement ≥1mm, including those detected only by sentinel lymph node biopsy, are at high risk of both local and distant relapse after definitive surgery due to the frequent presence of distant micrometastatic disease at presentation [Kirkwood, 2001; Van Akkooi, 2009]. Approximately half of these patients will ultimately die of metastatic disease [Markovic, 2007], and the morbidity from uncontrolled relapses is also considerable. Thus there is a need for effective adjuvant therapy for high-risk patients to prevent disease relapse after surgical resection of the primary tumor.

Although significant progress has been made recently with new treatments for metastatic melanoma, therapeutic options in the adjuvant setting remain limited. Many agents have been evaluated as potential therapies for the adjuvant treatment of melanoma however almost all have demonstrated little or no benefit [Schuchter, 2004]. The National Comprehensive Cancer Network (NCCN) treatment guidelines for melanoma recommend clinical trials, observation and interferon as the three therapy options for the adjuvant treatment of melanoma with clinical trials as the preference [NCCN, 2012]. Although high-dose interferon is currently the only approved therapy for the adjuvant treatment of melanoma it is not widely accepted as the standard of care. Increasing evidence surrounding a questionable survival benefit, a high incidence of serious toxicities, and negligible benefit for patients with bulkier disease makes it an unattractive therapy for most patients and clinicians [Schuchter, 2004]. Thus there is a need for more effective therapies with an acceptable safety profile in the adjuvant setting.

The RAS/RAF/MEK/ERK pathway (i.e., the MAP kinase pathway) is a critical proliferation pathway in many human cancers, including melanoma. Oncogenic mutations in BRAF signal through MEK1 and MEK2, and occurrence of this is an early event. This study will evaluate the combination of two small-molecule, cral agents, dabrafenib and trametinib. Dabrafenib is a potent and selective RAF kinase inhibitor of human wild type BRAF and CRAF enzymes as well as the mutant forms BRAFV600E, BRAFV600K and BRAFV600D. The mode of action of dabrafenib is consistent with competitive inhibition of adenosine triphosphate (ATP) binding. By contrast, trametinib is a reversible, highly selective, allosteric inhibitor of MEK1 and MEK2. Trametinib is non-competitive towards ATP and inhibits both MEK activation and kinase activity. Because BRAF and MEK are in the same pathway, and because MEK is a substrate of activated BRAF, inhibiting both proteins simultaneously rather than individually could provide more effective pathway inhibition and also decrease the likelihood of developing resistance. Preliminary clinical experience, along with data generated in cell line, mouse xenograft, and rat safety models with BRAF and MEK inhibitor combinations suggest enhanced effects on efficacy and less potential for proliferative skin lesions or stimulation
of dormant tumors containing RAS mutations compared to treatment with a BRAF inhibitor alone.

**OBJECTIVE(S)**

**Primary Objective**
The primary objective for this study is to evaluate the efficacy of dabrafenib and trametinib combination therapy compared to two placebos with respect to relapse-free survival (RFS) in patients with completely resected, histologically confirmed, BRAF V600E/K high-risk, stage III cutaneous melanoma.

**Secondary Objectives**
- To evaluate the overall survival (OS) of dabrafenib and trametinib combination therapy compared to placebo
- To assess distant metastasis-free survival (DMFS)
- To assess freedom from relapse (FFR)
- To evaluate the safety of dabrafenib and trametinib in combination

**Exploratory Objectives**
Exploratory objectives for this study are to assess the effect of dabrafenib and trametinib in combination versus two placebos on subject health related quality of life, to characterize the population pharmacokinetics of dabrafenib, dabrafenib metabolites and trametinib in combination in a subset of subjects during the treatment phase, to explore the exposure-response of dabrafenib and trametinib on clinical endpoints, and translational research.

**STUDY DESIGN**
This is a two-arm, randomized, double-blind Phase III study of dabrafenib (BRAF inhibitor) in combination with trametinib (MEK inhibitor) versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIla (maximum diameter of the largest lymph node (LN) metastasis >1 mm), IIIB or IIIC] cutaneous melanoma will be screened for eligibility. Approximately 852 subjects will be randomized in a 1:1 ratio to receive either dabrafenib [150 mg, twice daily (BID)] and trametinib [2 mg, once daily] combination therapy or two placebos for each for 12 months. Subjects will be stratified by BRAF mutation status (V600E, V600K) and stage of disease (IIla, IIlb, IIIC).

Doses of study treatment may be modified and/or interrupted for management of toxicities associated with study treatment (Section 5.8).

**STUDY ASSESSMENTS**
The RFS, DMFS and FFR endpoints will be determined by investigator assessment of disease recurrence. Subjects will be assessed with computed tomography (CT) or magnetic resonance imaging (MRI) at Screening and during treatment and the post-treatment follow-up period (refer to the Time and Events Schedule in Section 7 for scanning frequency). Subjects will also be followed for survival. Safety will be evaluated by clinical assessments including vital signs and complete physical
examinations, eye exams, 12-lead electrocardiograms (ECG), and echocardiograms (ECHO), chemistry and hematology laboratory values and adverse events (AEs).
1 INTRODUCTION

1.1 Background
Cutaneous melanoma is the most aggressive form of all skin cancers. Although it represents only 4% of all cancers, its incidence is continuing to rise in the world at a rate exceeding all other cancers [Jemal, 2007]. Worldwide it is expected that approximately 132,000 people will be diagnosed with melanoma each year and approximately 37,000 people are expected to die of the disease annually [WHO, 2012]. Surgical resection is the treatment of choice for localized melanoma and frequently results in cures for early stage (I and II) disease, with a 90% long term (10-year) survival rate for stage I disease [Balch, 2009]. However, patients with lymph node involvement ≥1mm, including those detected only by sentinel lymph node biopsy, are at high risk of both local and distant relapse after definitive surgery due to the frequent presence of distant micrometastatic disease at presentation [Kirkwood, 2001; Van Akkooi, 2009]. Approximately half of these patients will ultimately die of metastatic disease [Markovic, 2007], and the morbidity from uncontrolled relapses is also considerable. Thus there is a need for effective adjuvant therapy for high-risk patients to prevent disease relapse after surgical resection of the primary tumor.

Although significant progress has been made recently with new treatments for metastatic melanoma, therapeutic options in the adjuvant setting remain limited. Many agents have been evaluated as potential therapies for the adjuvant treatment of melanoma however almost all have demonstrated little or no benefit [Schuchter, 2004]. The National Comprehensive Cancer Network (NCCN) treatment guidelines for melanoma recommend clinical trials, observation and interferon as the three therapy options for the adjuvant treatment of melanoma with clinical trials as the preference [NCCN, 2012]. Although high-dose interferon is currently the only approved therapy for the adjuvant treatment of melanoma it is not widely accepted as the standard of care. Increasing evidence surrounding a questionable survival benefit, a high incidence of serious toxicities, and negligible benefit for patients with bulkier disease makes it an unattractive therapy for most patients and clinicians [Schuchter, 2004]. Thus there is a need for more effective therapies with an acceptable safety profile in the adjuvant setting.

The RAS/RAF/MEK/ERK pathway (i.e., the MAP kinase pathway) is a critical proliferation pathway in many human cancers, including melanoma. Over 80% of cutaneous melanomas harbor activating mutations of either BRAF or NRAS [Nikolaev, 2011]. Oncogenic mutations in BRAF signal through MEK1 and MEK2 and this is an early event. This study will evaluate the combination of two, small-molecule, oral agents, dabrafenib and trametinib. Dabrafenib is a potent and selective RAF kinase inhibitor of human wild type BRAF and CRAF enzymes as well as the mutant forms BRAFV600E, BRAFV600K and BRAFV600D. The mode of action of dabrafenib is consistent with competitive inhibition of ATP binding. By contrast, trametinib is a reversible, highly selective, allosteric inhibitor of MEK1 and MEK2. Trametinib is non-competitive towards ATP and inhibits both MEK activation and kinase activity. Because BRAF and MEK are in the same pathway, and because MEK is a substrate of activated BRAF, inhibiting both proteins simultaneously rather than individually could provide more effective pathway inhibition and also decrease the likelihood of developing
resistance. Data generated in cell line, mouse xenograft, and rat safety models with BRAF and MEK inhibitor combinations suggest enhanced effects on efficacy and less potential for proliferative skin lesions or stimulation of dormant tumors containing RAS mutations compared to treatment with a BRAF inhibitor alone. Based on the demonstrated efficacy of both dabrafenib and trametinib as monotherapies along with preliminary clinical data suggesting that the combination may prevent resistance and improve efficacy, phase III clinical studies of the dabrafenib/trametinib combination are being initiated in advanced melanoma and as adjuvant therapy for high-risk Stage III disease.
1.2 Study Rationale

Although the role of the MAP kinase pathway has not yet been studied in early melanoma, there is adequate scientific rationale and data to expect that the combination of dabrafenib and trametinib will provide similar responses on V600 mutant cells in the adjuvant setting as for more advanced disease. BRAF mutations are present in primary lesions, and are preserved in corresponding metastatic lesions indicating a common clonal origin [Nissan, 2011]. Based on early and continued involvement of V600 mutation throughout melanoma disease progression, MAP kinase inhibition would be expected to provide similar responses regardless of disease stage.

The combination of dabrafenib with trametinib in the adjuvant setting is further supported by in vitro and in vivo preclinical data which has demonstrated that the combination can enhance the levels of apoptosis, abrogate the onset of resistance, and prevent the development of proliferative skin lesions compared to BRAF monotherapy. This combination has demonstrated enhanced activity against parental (non-drug-resistant) as well as dabrafenib-resistant cell lines, suggesting that potential benefits of combination may result from overall improved activity relative to single agents as well as an attenuation of tumor growth resulting from acquired resistance. Although the mechanisms of resistance to BRAF treatment are not completely understood, emerging
data have demonstrated MEK activation at the time of relapse, thus the addition of a MEK inhibitor to dabrafenib represents an attractive therapeutic strategy [Goetz, 2012]. Cell line data generated by GSK are similar to in vitro data with other BRAF/MEK inhibitor combinations [Corcoran, 2010; Emery, 2009]. Similar to cell line data, in mouse xenograft studies with A375 cells which harbor a BRAFV600E mutation, the combination of dabrafenib and trametinib was significantly better than either agent alone. The combination in the adjuvant setting also prevents MEK activation in normal tissues, a mechanistic side effect of BRAF monotherapy, which can lead to development of low-grade squamous-cell carcinomas. The combination of BRAF/MEK inhibitors prevented the development of proliferative skin lesions (epithelial hyperplasia and hyperkeratosis of the skin, nonglandular stomach and/or footpads) observed in rats following treatment with a BRAF inhibitor alone, suggesting that the addition of MEK to BRAF may potentially mitigate the risk of developing epithelial proliferative effects (i.e., cutaneous squamous cell carcinoma) as observed in the clinic. Observations on proliferative skin effects are similar to those published with another BRAF/MEK inhibitor combination [Carnahan, 2010]. More importantly, emergence of clinically-significant RAS-driven tumors is far less likely to occur when there is combined BRAF/MEK inhibition than with BRAF alone [Lacouture, 2012]. Together the preclinical studies and clinical data support further clinical evaluation of dabrafenib and trametinib combination therapy in subjects with BRAF-V600E/K mutation-positive melanoma in the adjuvant setting.
## 2 OBJECTIVES AND ENDPOINTS

<table>
<thead>
<tr>
<th>Primary</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Endpoints</strong></td>
</tr>
<tr>
<td>To evaluate the efficacy of dabrafenib and trametinib combination therapy compared to two placebos with respect to relapse-free survival (RFS) in patients with completely resected, histologically confirmed, BRAF V600E/K high-risk, stage III cutaneous melanoma</td>
<td>Relapse Free Survival (RFS), defined as the time from randomization to disease recurrence or death from any cause. Recurrence of or death from the same cancer and all deaths from other causes are events. Treatment emergent malignancy(ies) other than second melanomas will not be considered as events, and loss to follow-up is censored. Patients without RFS events will be censored at the last adequate assessment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Endpoints</strong></td>
</tr>
<tr>
<td>To compare overall survival (OS) of dabrafenib and trametinib as a combination therapy versus two placebos.</td>
<td>OS defined as the interval from randomization to the date of death, irrespective of the cause of death; patients still alive will be censored at the date of the last contact.</td>
</tr>
<tr>
<td>To compare distant metastasis-free survival (DMFS) of dabrafenib and trametinib as a combination therapy versus two placebos.</td>
<td>DMFS defined as the interval from randomization to the date of first distant metastasis or date of death, whichever occurs first. Patients alive and without distant metastasis are censored at the date of last assessment.</td>
</tr>
<tr>
<td>To compare freedom from relapse (FFR) of dabrafenib and trametinib as a combination therapy versus two placebos.</td>
<td>FFR defined as interval from randomization to local or distant recurrence with censoring of patients dying from causes other than melanoma or treatment-related toxicity at the date of death. Patients alive without recurrence or with second primary cancer will be censored at the date of last assessment.</td>
</tr>
<tr>
<td>To evaluate the safety of dabrafenib and trametinib as a combination therapy in the overall study population including incidences of squamous cell carcinoma (SCC), new cancers in other sites, and other proliferative cutaneous lesions</td>
<td>Safety as measured by clinical assessments including vital signs and physical examinations, 12-lead electrocardiograms (ECG), echocardiogram (ECHO), eye exams, chemistry and hematology laboratory values, and adverse events (AEs).</td>
</tr>
<tr>
<td>Exploratory</td>
<td>Endpoints</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
<tr>
<td>[Redacted]</td>
<td>[Redacted]</td>
</tr>
</tbody>
</table>

Refer to Section 7 for further details on endpoint definitions.
3 STUDY DESIGN

Protocol waivers or exemptions are not allowed with the exception of immediate safety concerns. Therefore, adherence to the study design requirements, including those specified in the Time and Events Tables (Section 7), are essential and required for study conduct.

This is a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection (Figure 2). Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanoma will be screened for eligibility. Approximately 852 subjects will be randomized in a 1:1 ratio to receive either dabrafenib (150 mg BID) and trametinib (2 mg once daily) combination therapy or two placebos for each for 12 months. Subjects will be stratified by BRAF mutation status (V600E, V600K) and stage of disease (Stage IIIa, IIIb, IIIc).

Doses of study treatment may be modified and/or interrupted for management of toxicities associated with study treatment (Section 5.8). Refer to Section 5.8.3 for guidelines for events of special interest and Section 5.9.1 for liver stopping criteria.

Figure 2  BRF115532 Study Design Schema (N=852)

The benefit of the dabrafenib/trametinib combination compared to placebos will be evaluated through the primary endpoint of investigator-assessed RFS. Crossover is not permitted. The treatment effect of dabrafenib and trametinib combination therapy is anticipated to improve RFS by 40% over placebos (median RFS of 21 months and 15 months, respectively). See Section 9 for statistical considerations.

Subjects in both arms will receive treatment for 12 months or until disease recurrence, death, unacceptable toxicity, or withdrawal of consent. Subjects will be followed for disease recurrence and survival during and after the treatment period. Refer to the Time and Events Tables (Section 7) for required assessments for the following study periods:

Screening: Assessments must be completed within 28 days of randomization, unless stated otherwise in the Time and Events table (Table 10).
Treatment: The treatment period is 12 months. Discontinuation of study treatment may occur earlier than 12 months for disease recurrence, death, unacceptable toxicity or withdrawal of consent.

Post Treatment Follow-Up (Before Recurrence): Subjects will be followed for disease recurrence every 3 months after the end of treatment until Month 24 and every 6 months after Month 24 (Table 11).

Post Treatment Follow-Up (After Recurrence): After disease recurrence subjects will remain on study for follow-up assessments every three months until Month 24, and then every 6 months after Month 24 (Table 11). Follow-up assessments will include updates on anti-cancer treatments and responses to those treatments as well as survival and quality of life information. Subjects who have not died, but are no longer being followed for disease recurrence or survival are considered to have discontinued from the study. The study will be considered complete, and the final OS analysis will be conducted when approximately 70% of the total number of randomized subjects have died (i.e. 597 deaths).

Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying Study Procedures Manual (SPM). The SPM will provide the site personnel with administrative and detailed technical information that does not impact subject safety.

3.1 Discussion of Design

The ultimate goal of adjuvant therapy is to improve the cure rate after surgery through eradication of occult micrometastatic disease. Notable successes have been achieved in oncology when highly effective therapies were available for advanced stage disease (e.g., breast cancer, Hodgkin’s and non-Hodgkin’s lymphoma, embryonal tumors, osteosarcoma). High-risk, resected BRAF V600E/K mutation positive melanoma represents another attractive setting for testing this paradigm since: 1) the population is at high risk for relapse and death without further therapy; 2) the BRAF/MEK combination is both highly effective and can be targeted to the population most likely to benefit, and 3) the combination of dabrafenib and trametinib should be at least as well tolerated as cytotoxic chemotherapy or high-dose interferon and thus have acceptable risk/benefit if the study objectives are met.

This study is designed to compare dabrafenib and trametinib in combination versus two placebos with regard to RFS, which is a direct measurement of anti-tumor effect. RFS was selected as the primary endpoint based upon historical precedent (peginterferon alfa-2b, Sylatron) and because it will not be subject to confounding from subsequent therapy, as would OS. Since relapses are accompanied by considerable disease- and treatment-related morbidity, RFS is a true measure of patient benefit.

Data from preclinical studies and clinical experience with the dabrafenib/trametinib combination in patients with BRAF V600E or V600K mutations suggest that efficacy may be observed in the adjuvant setting for either population, thus both mutation types have been included.

Placebo has been selected as the control arm due to the absence of an acceptable standard of care for the adjuvant treatment of patients with high-risk resectable melanoma. Although high-dose interferon is currently the only approved therapy for the adjuvant treatment of melanoma it is not widely accepted as the standard of care. Increasing
evidence surrounding a questionable survival benefit, a high incidence of serious
toxicities, and negligible benefit for patients with bulkier disease makes it an unattractive
therapy for most patients and clinicians [Schuchter, 2004]. Dabrafenib and trametinib
will be administered at the dose recommended for further development of the
combination (150 mg BID and 2.0 mg once daily, respectively), based on the extensive
monotherapy experience for both inhibitors along with the preliminary results of
BRF113220 with combination therapy. An Independent Data Monitoring Committee
(IDMC) will be chartered to regularly review safety data.

3.1.1 Dose Rationale

Preliminary clinical data for the proposed dabrafenib/trametinib combination are
described in Section 1.1.3.2. Approximately 168 subjects have received combination
therapy with dabrafenib and trametinib at the proposed study doses (150 mg BID
dabrafenib and 2 mg once daily trametinib) with a median follow-up time of 12.8 months.
In the dose-escalation phase (Part B), PFS was longest for the group receiving the highest
doses of dabrafenib and trametinib with an acceptable safety profile. Based on these data
the combination of 150 mg BID of dabrafenib and 2.0 mg once daily of trametinib has
been selected for further development.

Considerable experimental and clinical evidence has been amassed demonstrating the
importance of maintaining dose intensity in the adjuvant setting. Studies of high-risk
breast cancer patients have repeatedly demonstrated inferior outcomes, including
diminished survival, when attenuated dose regimens were compared to standard
chemotherapy [Muss, 2009; Budman, 1998; Citron, 2003; EBCTCG, 2011]. Since the
dabrafenib/trametinib combination induces apoptosis in BRAF V600 mutation-positive
melanoma cells, the same theoretical considerations should apply as with cytotoxic
chemotherapy. Specifically, maximum clinical benefit should occur when the disease
burden is lowest, i.e. in the adjuvant setting when micrometastases can be eliminated with
effective therapy. Therefore, the adjuvant study will use the combination regimen that
has already been selected as providing optimal efficacy for use in metastatic disease.

The duration of therapy (12 months) is based upon expert consensus and does not exceed
that administered in other pivotal studies of adjuvant treatment in similar populations
where treatment ranged from 12 to 60 months [EORTC18991, EORTC18071, DERMA,
EORTC18592, ECOG1690, AVAST-M, GO27826]. In the absence of a reliable
biomarker for minimal residual disease, empiric dosing for durations much shorter than
the predicted median relapse free interval (median of 15 months) may increase the risk of
treatment failure. The design does include predictive biomarkers (e.g. circulating cell-
free DNA (cfDNA) analyses) which may allow further refinement of dosing once the
study has been completed. Safety of continuous dosing of dabrafenib and trametinib for
over a year as monotherapies has been established along with preliminary safety of
combination dosing for a similar interval. Safety precautions will include clear
guidelines for management of toxicity, including enhanced surveillance for adverse
events of special interest along with instructions for dose modification (Section 5.8). An
IDMC will regularly review safety data, starting at an early timepoint (e.g. N=100). The
inclusion/exclusion criteria will also serve to minimize participation of those at greatest
risk for known or suspected toxicities of the combination.
4 SUBJECT SELECTION AND DISCONTINUATION/COMPLETION CRITERIA

4.1 Subject Selection Criteria

4.1.1 Number of Subjects
Approximately 852 subjects will be randomized, 1:1 to combination therapy (n=426) and to placebos (n=426). Refer to Section 9.2.1 for sample size assumptions.

4.1.2 Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on dabrafenib and trametinib that may impact subject eligibility is provided in the Investigator’s Brochures. Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.
Subjects eligible for enrolment in the study must meet all of the following criteria:

1. Is ≥18 years of age.
2. Has signed written informed consent.
3. Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis >1 mm), IIIb or IIIc; refer to Appendix 1 for Staging Guidelines] cutaneous melanoma determined to be V600E/K mutation positive using the bioMerieux (bMX) THxD BRAF Assay. The testing will be conducted by a central reference laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible. Patients with an unknown primary melanoma are not eligible.
4. Must be surgically rendered free of disease (defined as the date of the most recent surgery) no more than 12 weeks before randomization.
5. Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains). For minimum surgical requirements see Appendix 2.
6. Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
8. Must have adequate organ function as defined in Table 1:
Table 1  Definitions for Adequate Baseline Organ Function

<table>
<thead>
<tr>
<th>System</th>
<th>Laboratory Values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematologic</strong></td>
<td></td>
</tr>
<tr>
<td>ANC</td>
<td>( \geq 1.2 \times 10^9 / \text{L} )</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>( \geq 9 \text{ g/dL} )</td>
</tr>
<tr>
<td>Platelet count</td>
<td>( \geq 100 \times 10^9 / \text{L} )</td>
</tr>
<tr>
<td>PT/INR(^a) and PTT</td>
<td>( \leq 1.5 \times \text{ULN} )</td>
</tr>
<tr>
<td><strong>Hepatic</strong></td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>( \geq 2.5 \text{ g/dL} )</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>( \leq 1.5 \times \text{ULN} )</td>
</tr>
<tr>
<td>AST and ALT</td>
<td>( \leq 2.5 \times \text{ULN} )</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td></td>
</tr>
<tr>
<td>Serum creatinine(^b)</td>
<td>( \leq 1.5 \text{ mg/dL} )</td>
</tr>
<tr>
<td><strong>Cardiac</strong></td>
<td></td>
</tr>
<tr>
<td>Left Ventricular Ejection fraction (LVEF)(^c)</td>
<td>( \geq \text{LLN by ECHO} )</td>
</tr>
</tbody>
</table>

Abbreviations: ALT = alanine transaminase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; INR = international normalized ratio; LLN = lower limit of normal; PT = prothrombin time; PTT = partial thromboplastin time; ULN = upper limit of normal.

- a. Subjects receiving anticoagulation treatment may be allowed to participate with NR established within the therapeutic range prior to randomization.
- b. If serum creatinine is > 1.5 mg/dL, calculate creatinine clearance using standard Cockcroft-Gault formula (Appendix 4). Creatinine clearance must be \( \geq 50 \text{ mL/min} \) to be eligible.
- c. ECHO scans must be used throughout the study.

9. Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, as defined in Section 7.3.3 from 14 days prior to randomization, throughout the treatment period and for 4 months after the last dose of study treatment.

10. French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

4.1.3 Exclusion Criteria

Deviations from exclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

Subjects meeting any of the following criteria must not be enrolled in the study:

1. Known mucosal or ocular melanoma or the presence of unresectable in-transit metastases.

2. Evidence of distant metastatic disease on screening evaluation.

3. Prior anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) including radiotherapy for melanoma. Prior surgery for melanoma is allowed.

4. Taken an investigational drug within 28 days or 5 half-lives, whichever is longer, prior to randomization.
5. Current or expected use of a prohibited medication (See Protocol Section 6.2 for a list of prohibited medications).

6. Known immediate or delayed hypersensitivity reaction or idiosyncracy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).

7. Known Human Immunodeficiency Virus (HIV).

8. History of another malignancy including melanoma or a concurrent malignancy except as noted below. Patients who have previously had Stage III melanoma or any malignancy with confirmed activating RAS mutation at any time are not eligible. Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.

Exceptions:
- Patients with a history of any malignancy that have been disease-free for at least 5 years are eligible except those with confirmed activating RAS mutations.
- Patients with a history of completely resected non-melanoma skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma) are eligible irrespective of the time since the resection.
- Patients with successfully treated in situ carcinoma are eligible.
- Patients presenting with multiple primary melanomas are eligible only if the lesions are concurrent. Patients who have concurrent multiple primary melanomas that are “distant” are eligible provided each lesion is considered local disease or resectable regional disease. These cases should be discussed with the Medical Lead.

9. A history or evidence of cardiovascular risk including any of the following:
   a. A QT interval corrected for heart rate using the Bazett’s formula (QTcB; Appendix 5) ≥480 msec;
   b. A history or evidence of current clinically significant uncontrolled arrhythmias;
   c. A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
   d. A history or evidence of current ≥Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines (See Appendix 6)
   e. Patients with intra-cardiac defibrillators.
   f. Abnormal cardiac valve morphology (≥grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
   g. Treatment refractory hypertension defined as a blood pressure of systolic > 140 mm Hg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy.
10. A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) including:
   a. Presence of predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes); or
   b. Visible retinal pathology as assessed by ophthalmic examination that is considered a risk factor for RVO or CSR such as:
      i. Evidence of new optic disc cupping;
      ii. Evidence of new visual field defects on automated perimetry;
      iii. Intraocular pressure ≥21 mm Hg as measured by tonography.
11. History of clinically significant or active interstitial lung disease or pneumonitis.
12. Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that, in the opinion of the investigator, could interfere with the subject’s safety, obtaining informed consent, or compliance with study procedures.
13. Pregnant or nursing females.

4.2 Permanent Discontinuation from Study Treatment and Subject Completion Criteria

Subjects will receive study treatments for twelve months or until disease recurrence. During the protocol defined treatment period study treatment(s) may be permanently discontinued for the following reasons:

- death
- unacceptable adverse event, including meeting stopping criteria for liver chemistry defined in Section 5.9.1 and/or for hematologic and other non-hematologic toxicity.
- deviation(s) from the protocol
- request of the subject or proxy
- investigator’s discretion
- subject is lost to follow-up
- study is closed or terminated.

The primary reason each study treatment was permanently discontinued must be documented in the subject’s medical records and in the electronic case report form (eCRF). Refer to Section 5.2 for additional information on discontinuation of dabrafenib and/or trametinib.

If disease recurs prior to the completion of the 12 month treatment period, study treatment should be discontinued and follow-up assessments should be conducted according to the schedule for “Follow-up after recurrence” (Table 11). Such follow-up assessments should start at the next regularly scheduled disease assessment visit (i.e.
Month 3, 6, 9 or 12) and continue thereafter according to Table 11. For example, if disease recurrence is observed at Month 6, the subject would complete the discontinuation visit and follow-up assessments after recurrence would start at Month 9, and continue according to the visit schedule in the Time and Events Table (Table 11). If the subject voluntarily discontinues from treatment due to toxicity, ‘adverse event’ will be recorded as the primary reason for permanently discontinuation in the eCRF.

All subjects who permanently discontinue from study treatment will have assessments at the time of discontinuation and during post study treatment follow-up as specified in Time and Events Tables (See Section 7). In addition, all subjects who permanently discontinue study treatment without evidence of disease recurrence will also be followed for disease recurrence according to the protocol schedule until:

- Withdrawal of consent
- Death, or
- Study completion (as defined in Section 3)

Subjects that permanently discontinue from study treatment before the end of the 12 month treatment period without evidence of disease recurrence will return for disease assessment visits starting at the next regularly scheduled disease assessment visit (i.e. Month 3, 6, 9 or 12) and continue thereafter according to Table 11. If a subject experiences disease recurrence at any time subsequent follow up visits should be conducted according to the “After Recurrence” follow-up schedule in Table 11.

Follow-up for survival, new anti-cancer therapy (including radiotherapy) and response to new anti-cancer therapy will continue for all subjects including those with disease recurrence, according to the Time and Events Tables (Table 10 and Table 11) until the study is considered to be complete after which all protocol-required assessments and procedures will be discontinued. The study will be considered complete, and the final OS analysis will be conducted when approximately 70% of the total number of randomized subjects have died (i.e. 597 deaths). Follow-up contact to assess survival and new anti-cancer therapy may be made via clinic visit or another form of communication (e.g. phone, email, mail etc.). Additional information on declaring subjects lost to follow-up can be found in the SPM.

4.2.1 Subject Completion
A subject will be considered to have completed the study if the subject dies during the study treatment or follow-up period. Document the cause of death in the eCRF. A subject will be considered to have withdrawn from the study if the subject has not died and is lost to follow-up, has withdrawn consent, at the investigator’s discretion is no longer being followed or if the study is closed/terminated. Subjects who are ongoing at the time the study is closed/terminated will be considered to have completed the study.

5 STUDY TREATMENT
The term ‘study treatment’ is used throughout the protocol to describe the combination of products received by the subject as per the protocol design. Study treatment may therefore refer to the individual study treatments or the combination of those study treatments.
5.1 **Investigational Products**

No special preparation of study treatment is required. Under normal conditions of handling and administration, investigational product is not expected to pose significant safety risks to site staff. Material Safety Data Sheets (MSDS) describing the occupational hazards and recommended handling precautions will be provided to site staff if required by local laws or will otherwise be available from Novartis upon request.

5.1.1 **Dabrafenib**

Dabrafenib will be provided as 50 mg and 75 mg capsules to sites by Novartis. The contents of the label will be in accordance with all applicable regulatory requirements. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).

5.1.2 **Trametinib**

Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets to sites by Novartis. The contents of the labels will be in accordance with all applicable regulatory requirements. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate).

5.1.3 **Placebos**

Matching placebo capsules for dabrafenib (50 mg and 75 mg) and placebo tablets for trametinib (0.5 mg and 2.0 mg) will be provided to sites by Novartis. The placebo capsules/tablets will contain the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment. The contents of the labels will be in accordance with all applicable regulatory requirements.

5.2 **Dosage and Administration**

- Dabrafenib, 150 mg twice daily (BID) or placebo.
- Trametinib, 2.0 mg, once daily or placebo.

Both study treatments should be administered **in the morning** at approximately the same time every day. The second dose of dabrafenib (150 mg) or dabrafenib placebo should be administered approximately 12 hours after the morning dose. Study medication should be taken orally with approximately 200 mL of water under fasting conditions, either 1 hour before or 2 hours after a meal. If administration of trametinib or trametinib placebo is interrupted or permanently discontinued, administration of dabrafenib or dabrafenib placebo may be continued. If administration of dabrafenib or dabrafenib placebo is interrupted or permanently discontinued, administration of trametinib or trametinib placebo may continue.

If a subject vomits after taking study treatment, the subject should be instructed not to retake the dose and should take the next dose as originally scheduled.

If a subject misses a dose of dabrafenib or dabrafenib placebo, the subject may take the dose immediately if the next dose is scheduled for at least 6 hours later. If the next scheduled dose is due in less than 6 hours, the subject should skip the dose and resume dosing at the next scheduled dose. If a subject misses a dose of trametinib or trametinib placebo, the subject may take the dose immediately if the next dose is scheduled for at least 12 hours later.
Subjects should start treatment as soon as possible after randomization and no later than 72 hours post-randomization.

### 5.3 Handling and Storage of Study Treatment

Dabrafenib, dabrafenib placebo, trametinib and trametinib placebo must be stored in a secure area under the appropriate physical conditions for the products. Study treatments are to be stored at the temperature specified on the label. Maintenance of a temperature log (manual or automated) is required. Access to and administration of the study treatment will be limited to the investigator and authorized site staff. Dabrafenib, dabrafenib placebo, trametinib and trametinib placebo must be dispensed or administered only to subjects enrolled in the study and in accordance with the protocol.

Procedures for final disposition of unused study treatments will be provided in the SPM.

### 5.4 Treatment Assignment

Subjects will be identified by a unique subject number that will remain consistent for the duration of the study.

Upon completion of all the required screening assessments, eligible subjects will be registered into RAMOS (Registration and Medication Ordering System), the interactive voice response system (IVRS), by the investigator or authorized site staff.

The following information for stratification must be entered into the system in order to obtain the blinded treatment assignment:

- Mutation type (V600E or V600K);
- Disease stage (IIIa, IIIb, IIIc)

Randomization will be done centrally using a randomization schedule generated by the GSK Biostatistical Department, the sponsor at the time will assign subjects in a 1:1 ratio to:

- dabrafenib and trametinib combination therapy;
- dabrafenib and trametinib placebos

Once a randomization number has been assigned it must not be re-assigned even in cases of errors.

Detailed RAMOS user instructions, worksheets and telephone contact numbers will be provided to the study site at study start.

### 5.5 Blinding

Study treatment will be double-blinded. Novartis, the site personnel (including the investigator) and the subject will not know the treatment assignment. Every effort must be made to maintain the blind until all analyses have been performed.

The investigator or treating physician may unblind a subject’s treatment assignment only in the case of an emergency, when knowledge of the study treatment is essential for the appropriate clinical management or welfare of the subject. Whenever possible, the investigator must first discuss options with the Novartis Medical Lead or appropriate Novartis study personnel before unblinding the subject’s treatment assignment. If this is
impractical, the investigator must notify Novartis as soon as possible, but without revealing the treatment assignment of the unblinded subject, unless that information is important for the safety of subjects currently in the study. The date and reason for the unblinding must be recorded in the eCRF. A subject should remain in the study for survival follow-up even if the treatment code is unblinded.

Novartis’ Drug Safety and Epidemiology Department (DS&E) staff may unblind the treatment assignment for any subject with an SAE. If the SAE requires that an expedited regulatory report be sent to one or more regulatory agencies, a copy of the report, identifying the subject’s treatment assignment, may be sent to clinical investigators in accordance with local regulations and/or Novartis policy.

5.6 Product Accountability

In accordance with local regulatory requirements, the investigator, designated site staff, or head of the medical institution (where applicable) must document the amount of investigational product dispensed and/or administered to study subjects, the amount returned by study subjects, and the amount received from and returned to Novartis, when applicable. Product accountability records must be maintained throughout the course of the study. Refer to the SPM for further detailed instructions on product accountability.

5.7 Treatment Compliance

Subjects will be instructed to return treatment bottles at each visit. Compliance with study treatment will be assessed through querying the subject during the site visits and documented in the source documents and eCRF.

A record of the number of study treatment capsules/tablets dispensed to and taken by each subject must be maintained and reconciled with study treatment and compliance records. Treatment start and stop dates, including dates of dose modifications and/or interruptions or dose reductions will also be recorded in the eCRF. The investigator will make every effort to bring non-compliant subjects in to compliance.

5.8 Dose Modification Guidelines

The severity of adverse events will be graded utilizing the National Cancer Institute (NCI) CTCAE, version 4.0. This section includes:

- Supportive guidelines for managing common toxicities
- General dose modification guidelines for toxicities related to study treatments
- Specific management guidelines for pyrexia, cardiovascular adverse events, and cutaneous squamous cell carcinoma/keratoacanthoma

Guidelines for management of hepatobiliary events are given separately in Section 5.9. Investigators should also refer to the dabrafenib and trametinib combination Investigator’s Brochure for the most current product safety information.
5.8.1 General supportive guidelines

5.8.1.1 Skin Toxicity (Rash, Palmar-Plantar Erythrodysesthesia Syndrome)

Rash and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) are frequently observed in subjects receiving trametinib, dabrafenib, or the combination of both therapies. Guidelines for management are based on experience with other MEK inhibitors and EGFR inhibitors [Balagula, 2010; Lacouture, 2012] and include:

- Prevention/prophylaxis: promote sunscreen use and avoidance of unnecessary sun exposure, use alcohol-free emollient creams, topical steroids and antibiotics as needed.

- Pruritic lesions: cool compresses and oral antihistamines

- Fissuring lesions: Monsel’s solution, silver nitrate or zinc oxide cream

- Desquamation: thick emollients and mild soap

- Paronychia: antiseptic bath, local potent corticosteroids, antibiotics, surgery as needed

- Infected lesions: topical or systemic antibiotics

Additional measures for PPES should include:

- Lifestyle modification: avoidance of hot water, traumatic activity, constrictive footwear, or excessive friction on the skin and the use of thick cotton socks and gloves, and shoes with padded insoles

- Symptomatic treatments: apply moisturizing creams frequently, topical keratolytics (e.g., urea 20-40% cream, salicylic acid 6%, tazarotene 0.1% cream, fluorouracil 5% cream), clobetasol propionate 0.05% ointment for erythematous areas, topical lidocaine 2%, and/or systemic pain medication such as nonsteroidal anti-inflammatory drugs, codeine, and pregabalin for pain.

Dose modification may also be required (refer to Table 3 - General Dose Modification Guidelines).

5.8.1.2 Diarrhea

Episodes of diarrhea have been reported in subjects receiving dabrafenib and trametinib combination therapy. Other causes for diarrhea including concomitant medications (e.g., stool softeners, laxatives, antacids, etc.), infections by C. difficile or other pathogens, partial bowel obstruction, etc., should be ruled out. Supportive measures should include the following as clinically indicated:

- Dietary modifications (e.g., small, frequent meals, low fiber, and lactose-avoidance)

- Maintain hydration with clear liquids or IV fluids as needed

- Loperamide and/or oral antibiotics

Dose modification may also be required (refer to Table 3 – General Dose Modification Guidelines).
5.8.2 Dose Modification for General Toxicities

General guidelines regarding management and dose reduction for adverse events that are considered by the investigator to be related to study treatment and for which specific guidelines do not apply are provided in Table 3. These guidelines are intended primarily for non-hematological toxicities not easily managed with routine supportive care. For example, alopecia is not an indication for dose modification, nor is grade 2 nausea and vomiting that can be easily managed with anti-emetics.

These are general guidelines and investigators should use always use clinical judgment in determining dose adjustments for any individual patient. Some toxicities may require hospitalization for stabilization, additional work-up, and consultation with a specialist before treatment can be restarted. Specific adverse events and recommended management include:

- **Renal insufficiency** – close monitoring of serum creatinine, treatment of associated pyrexia (see Table 4 - Management and dose modification guidelines for pyrexia), and treatment interruption for increased serum creatinine >2 mg/dl (or >0.5 mg/dl above baseline). Nephrology consultation should also be obtained if no obvious cause for persistent creatinine elevation (e.g. volume depletion).

- **Pneumonitis** – initial work-up should include high-resolution CT scan, ruling out infection, and pulse oximetry. Pulmonary function testing, bronchoscopy and/or bronchoalveolar lavage, and empiric steroids may be indicated for more severe cases. Pulmonary consultation is recommended. For Grade 2 to 3 (if no recovery to grade ≤1 within 4 weeks) and grade 4 pneumonitis, permanently discontinue trametinib. Treatment with dabrafenib may continue.

- **Rash** – For mild rash, follow Grade 1 general dose modification guidelines (Table 3). For moderate (Grade 2), reduction of dose is allowed by at least one dose level, however, dose interruption may be required until resolution to Grade 1. If toxicity resolves, can consider re-escalation to initial dose level. For Grade 3, if event resolves to Grade 1 or less, suggest to also consider restarting at a reduced dose. If Grade 2 or 3 rash does not resolve or worsens after 2 weeks of dose modification/interruption and clinical treatment, discontinue trametinib. Treatment with dabrafenib may continue.

- **Pancreatitis** – In the event of abdominal pain or suspected pancreatitis, amylase and lipase laboratory samples should be collected for confirmation of the diagnosis.

Investigators should always err on the side of caution in these settings if treatment-related toxicity is a possibility. Note that guidelines for management of hepatobiliary adverse events are provided separately in Section 5.9.

General dose modification guidelines are provided in Table 3 below. Dose levels referred to in Table 2 are as follows:
Table 2  Dose Levels

<table>
<thead>
<tr>
<th></th>
<th>Dabrafenib/placebo</th>
<th>Trametinib/placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting dose</td>
<td>150 mg BID</td>
<td>2 mg once daily</td>
</tr>
<tr>
<td>L-1 (1st level dose reduction)</td>
<td>100 mg BID</td>
<td>1.5 mg once daily</td>
</tr>
<tr>
<td>L-2 (2nd level dose reduction)</td>
<td>75 mg BID</td>
<td>1 mg once daily</td>
</tr>
</tbody>
</table>

Table 3  Dose Modification Guidelines - General

<table>
<thead>
<tr>
<th>CTCAE Grade</th>
<th>Action and Dose Modification(^a,b,c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 or Grade 2 (tolerable)</td>
<td>Continue study treatments at same dose level (no dose modification)</td>
</tr>
<tr>
<td>Grade 2 (Intolerable)</td>
<td></td>
</tr>
<tr>
<td>1st or 2nd occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at same dose level</td>
</tr>
<tr>
<td>3rd or occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at next lower dose level</td>
</tr>
<tr>
<td>4th or greater occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at two dose levels lower than the starting dose or discontinue treatments per investigator discretion</td>
</tr>
<tr>
<td>Grade 3</td>
<td></td>
</tr>
<tr>
<td>1st occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at next lower dose level</td>
</tr>
<tr>
<td>2nd occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at two dose levels lower than the starting dose</td>
</tr>
<tr>
<td>3rd occurrence</td>
<td>Discontinue treatments.</td>
</tr>
<tr>
<td>Grade 4</td>
<td></td>
</tr>
<tr>
<td>1st occurrence</td>
<td>Discontinue treatments.</td>
</tr>
</tbody>
</table>

a. Treatments should be discontinued if more than 2 dose reductions are required
b. Approval from the Novartis Medical Lead is required to restart study treatments after ≥21 days interruption
c. These guidelines are intended for non-hematological toxicities not easily managed with routine supportive care (see above).

5.8.3  Dose Modification Guidelines - Adverse Events of Special Interest

5.8.3.1  Pyrexia

Pyrexia has been observed in subjects receiving dabrafenib, either as monotherapy or in combination with trametinib. In a minority of cases pyrexia was accompanied by symptoms such as severe chills, dehydration, hypotension, dizziness or weakness and required hospitalization.
Subjects should be instructed on the importance of immediately reporting febrile episodes. In the event of a fever, the subject should be instructed to take non-steroidal anti-pyretics (e.g. ibuprofen) as appropriate to control fever. In subjects experiencing pyrexia associated with rigors, severe chills, dehydration, or hypotension, renal function should be monitored carefully and oral corticosteroids should be started after the event resolves (see Table 4).

Pyrexia accompanied by hypotension, dehydration requiring IV fluids, renal insufficiency, or severe rigors/chills in the absence of an obvious infectious cause should be reported as an SAE (Section 7.3.2.2).

Guidelines regarding management and dose reduction for pyrexia considered to be related to dabrafenib are provided in Table 4. Pyrexia is defined as a body temperature equal to or above 38.0 °Celsius or 100.4 °Fahrenheit.

Trametinib dose modification is not required for pyrexia.
Table 4  Management and Dose Modification Guidelines for Pyrexia\textsuperscript{a,b}  

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Any               | • Clinical evaluation for infection and hypersensitivity\textsuperscript{c}  
|                   | • Laboratory work-up\textsuperscript{c}  
|                   | • Hydration as required\textsuperscript{d}  
|                   | • Blood sample for cytokine analysis\textsuperscript{e}  
| 1\textsuperscript{st} Event\textsuperscript{f} | • Administer anti-pyretic treatment if clinically indicated\textsuperscript{f}  
|                   | • Interrupt dabrafenib/placebo  
|                   | • Continue trametinib or placebo  
|                   | • Once pyrexia resolves to baseline, restart dabrafenib/placebo at the same dose level  
|                   | • If fever was associated with dehydration, hypotension, or renal insufficiency, reduce dabrafenib/placebo by one dose level and begin oral corticosteroids (prednisone 10 mg or equivalent) for at least 5 days or as clinically indicated\textsuperscript{g}  
| 2\textsuperscript{nd} Event\textsuperscript{g} | • Same as for 1\textsuperscript{st} event, and  
|                   | • Consider oral corticosteroids (i.e., prednisone 10 mg) for at least 5 days or as clinically indicated\textsuperscript{g}  
| Subsequent Events: | • Interrupt dabrafenib/placebo  
|                   | • Continue trametinib or placebo  
|                   | • Once pyrexia resolves to baseline, restart \textsuperscript{d} dabrafenib/placebo (consider dose reduction by one level)  
|                   | • Optimize oral corticosteroid dose as clinically indicated for recalcitrant pyrexia\textsuperscript{a}  
|                   | • If corticosteroids have been tapered and pyrexia recurs, restart steroids  
|                   | • If corticosteroids cannot be tapered or escalating doses are required, consult Medical Lead  

BUN = blood urea nitrogen; CRP = C-reactive protein

\textsuperscript{a}  Pyrexia is defined as a body temperature equal to or above 38.0\textdegree Celsius or 100.4\textdegree Fahrenheit.

\textsuperscript{b}  For subjects experiencing pyrexia complicated by severe rigors/chills, etc., a clinical evaluation and laboratory work-up is mandatory for each event; anti-pyretic treatment should be started immediately at the first occurrence and prophylactic oral corticosteroids are recommended when restarting dabrafenib.

\textsuperscript{c}  Thorough clinical examination for signs and symptoms of infection or hypersensitivity is required; laboratory work-up should include full-blood-count, electrolytes, creatinine, BUN, CRP, liver-function tests, blood culture, and urine culture.

\textsuperscript{d}  Oral hydration should be encouraged in subjects without evidence of dehydration. Intravenous hydration is recommended in subjects experiencing pyrexia complicated by dehydration/hypotension.
e. Blood sample for cytokine analysis must be sent to the central laboratory

f. Anti-pyretic treatment may include acetaminophen (paracetamol), ibuprofen, or suitable anti-pyretic medication according to institutional standards. Ibuprofen is preferred and the maximum recommended daily dose of acetaminophen should not be exceeded to reduce risk of liver toxicity. Pophylactic anti-pyretic treatment may be discontinued after three days in the absence of pyrexia

g. In subjects experiencing pyrexia complicated by severe rigors/chills, etc., which cannot be controlled with anti-pyretic medication, oral corticosteroids should be started after the 1st event and doses should be gradually increased for subsequent events.

h. Dabrafenib/placebo should be reduced by one dose level at discretion of the investigator if pyrexia is accompanied by severe recurring rigors which cannot be managed by best supportive care, including increasing doses of oral steroids. Re-escalation of dabrafenib is allowed if no episode of pyrexia is observed in the 4 weeks subsequent to dose reduction.

5.8.3.2 Visual changes

Episodes of visual changes have been observed in subjects receiving trametinib. The causal relationship between a change in vision and the study treatment should be carefully explored and an ophthalmologist should be consulted. Special attention should be given to retinal (e.g., CSR) or retinal vein abnormalities (e.g., RVO). For events of visual changes regardless of severity, a blood sample for PK analysis must be drawn as close as possible to the time of the event.

Guidelines regarding management and dose reduction for visual changes considered to be related to study treatment are provided in Table 5.

<table>
<thead>
<tr>
<th>CTCAE Grade</th>
<th>Management and Dose Modification Guidelines for Visual Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Adverse Event Management</td>
</tr>
<tr>
<td></td>
<td>• Consult ophthalmologist within 7 days of onset</td>
</tr>
<tr>
<td></td>
<td>• Exclude CSR or RVO</td>
</tr>
<tr>
<td></td>
<td>• Consult retinal specialist if available in case of CSR or RVO</td>
</tr>
<tr>
<td></td>
<td>• Continue follow up examination(s) (by retinal specialist if available) for CSR and RVO</td>
</tr>
<tr>
<td></td>
<td>Action and Dose Modification</td>
</tr>
<tr>
<td></td>
<td>• Continue trametinib/placebo at the same dose level until ophthalmologic examination can be conductedb</td>
</tr>
<tr>
<td></td>
<td>• If ophthalmologic examination cannot be performed within 7 days of onset, interrupt trametinib/placebo until CSR and RVO can be excluded and symptoms resolve</td>
</tr>
<tr>
<td></td>
<td>• If CSR and RVO excluded restart trametinib/placebo at same dose level</td>
</tr>
<tr>
<td></td>
<td>• CSR: interrupt trametinib/placebo until symptoms resolve and exam (by retinal specialist if available) shows resolution; report as SAE</td>
</tr>
<tr>
<td></td>
<td>• If CSR resolves restart with trametinib/placebo reduced by one dose level</td>
</tr>
<tr>
<td>CTCAE Grade</td>
<td>Adverse Event Management</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------</td>
</tr>
</tbody>
</table>
| Grade 2 and Grade 3 | • Consult ophthalmologist immediately  
• Exclude CSR and RVO  
• Consult retinal specialist if available in case of RVO or CSR for follow-up exam  
• Continue follow up examination(s) (by retinal specialist if available) for CSR and RVO | • Interrupt trametinib/placebo until signs and symptoms have resolved to baseline  
• If CSR and RVO excluded and symptoms resolved to baseline restart trametinib/placebo reduced by one dose level  
• CSR: Interrupt trametinib/placebo until symptoms resolve and exam (by retinal specialist if available) shows resolution; report as SAE  
• If CSR resolves restart trametinib/placebo reduced by one dose level  
• RVO: Permanently discontinue study treatments and report as SAE |
| Grade 4 | • Consult ophthalmologist immediately  
• Exclude CSR and RVO  
• Continue follow up examination(s) (by retinal specialist if available) for CSR and RVO | • Permanently discontinue trametinib/placebo  
• If CSR or RVO then report as SAE |

Abbreviations: CSR = central serous retinopathy; CTCAE = Common Terminology Criteria for Adverse Events; RVO = retinal vein occlusion; SAE = serious adverse event
a. Refers to CTCAE Version 4.0 ‘Eye disorders – Other, specify’
b. If visual changes are clearly unrelated to study treatment (e.g., allergic conjunctivitis), monitor closely but ophthalmic examination is not required.

5.8.3.3 Cardiovascular toxicity
Cardiovascular adverse events have been seen in subjects receiving trametinib and dabrafenib, either as monotherapy or in combination. Dose modification of either agent may be required for decreased LVEF, hypertension or QTc prolongation.
5.8.3.3.1 Decreased Left Ventricular Ejection Fraction (LVEF)
Decreases of the left-ventricular-ejection-fraction (LVEF) have been observed in subjects receiving trametinib monotherapy and with trametinib in combination with dabrafenib. Therefore, ECHOs must be performed to assess cardiac ejection fraction at regular intervals as outlined in the Time and Events Table (Table 10). All ECHOs will be collected; instructions are provided in the Study Procedures Manual (SPM). Dose modification guidance and stopping criteria for LVEF decrease are provided in Table 6.

<table>
<thead>
<tr>
<th>Clinic</th>
<th>LVEF-drop (%) or CTCAE grade</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Asymptomatic | Absolute decrease of >10% in LVEF compared to baseline and ejection fraction below the institution’s low LLN | • Interrupt study treatments and repeat ECHO within 2 weeks<sup>a</sup>  
• If the LVEF recovers within 4 weeks (defined as LVEF ≥LLN and absolute decrease ≤10% compared to baseline)  
  ○ Consult with the Novartis Medical Lead and request approval for restart  
  ○ Restart with trametinib/placebo reduced by one dose level  
  ○ Restart dabrafenib/placebo at previous dose level  
  ○ Repeat ECHO 2, 4, 8 and 12 weeks after restart; continue in intervals of 12 weeks thereafter  
• If repeat LVEF does not recover within 4 weeks  
  ○ Consult with cardiologist  
  ○ Permanently discontinue trametinib/placebo  
  ○ Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution  
  ○ Consult with Novartis Medical Lead<sup>c</sup> |
| Symptomatic<sup>b</sup> | Grade 3: resting LVEF 39-20% or >20% absolute reduction from baseline  
Grade 4: resting LVEF <20% | • Permanently discontinue trametinib/placebo.  
• Consult with cardiologist  
• Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution |

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; ECHO = echocardiogram; LLN = lower limit of normal; LVEF = left ventricular ejection fraction;

- If ECHO does not show LVEF recovery after 2 weeks, repeat ECHO 2 weeks later.
- Symptoms may include: dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.
- Once LVEF recovers, restarting dabrafenib monotherapy can be considered in consultation with Novartis Medical Lead.
5.8.3.3.2 Hypertension

Any level of hypertension should be actively managed. Trametinib does not need to be interrupted while mild hypertension is brought under control; however treatment interruption and dose-reduction are recommended for more severe or symptomatic hypertension (e.g. persistent systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg despite antihypertensive treatment).

5.8.3.3.3 QTc prolongation

Guidelines for dose modification and stopping criteria due to QTc-prolongation are provided in Table 7 below:

Table 7 Withholding and Stopping Criteria for QTc-Prolongation

<table>
<thead>
<tr>
<th>QTc-Prolongation</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>QTcB ≥501 msec</td>
<td>Interrupt all study treatments until QTcB prolongation resolves to grade 1 or baseline</td>
</tr>
<tr>
<td></td>
<td>○ Recommend Testing serum potassium, calcium, phosphorus and magnesium. If abnormal, correct</td>
</tr>
<tr>
<td></td>
<td>per routine clinical practice to within normal limits.</td>
</tr>
<tr>
<td></td>
<td>○ Review concomitant medication usage for a prolonged QTc.</td>
</tr>
<tr>
<td></td>
<td>Restart at current dose levelb</td>
</tr>
<tr>
<td></td>
<td>If event recurs, permanently discontinue study treatments</td>
</tr>
</tbody>
</table>

Abbreviations: msec = millisecond; QTcB = QT interval on electrocardiogram corrected using the Bazett's formula

a. Based on average QTc value of triplicate ECGs. For example, if an ECG demonstrates a prolonged QT interval, obtain two or more ECGs over a brief period, and then use the averaged QTc values of the three ECGs to determine if study treatments should be interrupted or discontinued.

b. If the QTc prolongation resolves to grade 1 or baseline, the subject may resume study treatment if the investigator and Novartis Medical Lead agree that the subject will benefit from further treatment.

5.8.3.3.4 Valvular Toxicity

- Subjects who have an asymptomatic, moderate regurgitation or stenosis by ECHO (Grade 2 mitral/tricuspid/aortic valvular toxicity per NCI CTCAE v4.0) should temporarily discontinue dabrafenib/placebo and have a repeat evaluation by ECHO within 1 week. ECHO should be repeated every 1-2 weeks for 4 weeks or until valve recovery to baseline.
  - If the valve recovers to baseline any time during the next 4 weeks, after consultation and approval of the Novartis Medical Lead, the subject may be restarted on dabrafenib/placebo at a reduced dose(s). For such subjects, monitoring of the valve via ECHO will then be performed 2 and 4 weeks after rechallenge, and every 4 weeks thereafter for 12 weeks and then per protocol.
  - If repeat ECHO does not reveal valve recovery to baseline within 4 weeks, then the subject should permanently discontinue dabrafenib/placebo. The
valve should continue to be monitored via ECHO every 4 weeks for 16 weeks or until resolution.

- Subjects with a Grade 3 or 4 (symptomatic, severe regurgitation/stenosis by imaging, with symptoms controlled by medical intervention) valvular toxicity must discontinue dabrafenib/placebo. Valvular toxicity should continue to be monitored every 4 weeks for 16 weeks or until resolution. If recovery occurs (return to baseline via imaging AND symptom resolution) within 4 weeks, the subject may restart dabrafenib/placebo at a reduced dose after consultation and approval of the Novartis Medical Lead. For such subjects, monitoring of the valve via ECHO will then be performed 2 and 4 weeks after rechallenge, and every 4 weeks thereafter for 12 weeks and then per protocol.

ECHO must be performed at baseline and at follow-up visit(s). Copies of all ECHO(s) and cardiology consultations performed on subjects who experience a valvular toxicity will be required by Novartis for possible review.

5.8.3.4 Cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma (KA)

Both cuSCC and KA have been observed in subjects treated with dabrafenib and the combination of dabrafenib and trametinib [GlaxoSmithKline Document Number 2011N126811_00, GlaxoSmithKline Document Number 2012N136095_00 and GlaxoSmithKline Document Number HM2009/00151/02]. These should be surgically removed according to institutional practices. Dose modification or interruption of study treatment is not required for cuSCC or KA, however they should be reported as an SAE (refer to Section 7.3.2.2). In addition, a biopsy of the lesion should be taken, wherever possible, and submitted for further analyses as described in the SPM.

5.9 Monitoring, Interruption, and Stopping Criteria for Hepatobiliary Events

NOTE: if serum bilirubin fractionation is not immediately available, if ALT ≥ 3xULN and bilirubin ≥ 2xULN, discontinue subject from study treatment. Serum bilirubin fractionation should be performed if testing is available. If testing is unavailable, record presence of detectable urinary bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.

5.9.1 Liver chemistry stopping criteria

These liver chemistry stopping and follow up criteria have been designed to assure subject safety and evaluate liver event etiology in alignment with the FDA Guidance for Industry – Drug-Induced Liver Injury: Premarketing Clinical Evaluation (July 2009, www.fda.gov).

Liver chemistry stopping criteria 1-5 are defined as follows:

1. ALT ≥3xULN and bilirubin ≥2xULN (>35% direct bilirubin) (or ALT≥3xULN and INR>1.5, if INR measured)

   NOTE: If serum bilirubin fractionation is not immediately available and if ALT ≥ 3xULN and bilirubin ≥ 2xULN, subject should be discontinued from study treatments. Serum bilirubin fractionation should be performed if testing is
available. If testing is unavailable, record presence of detectable urinary bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.

2. ALT ≥ 8xULN
3. ALT ≥ 5xULN but <8 xULN persists for ≥2 weeks
4. ALT ≥ 3xULN if associated with symptoms (new or worsening) believed to be related to hepatitis (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, or jaundice) or hypersensitivity (such as fever, rash or eosinophilia).
5. ALT ≥ 5xULN but <8 xULN and cannot be monitored weekly for ≥2 weeks.

When any of the liver chemistry stopping criteria 1 - 5 is met, do the following:

- **Immediately discontinue subject from** study treatment
- Report the event to Novartis **within 24 hours** of learning its occurrence
- Complete the liver event eCRF and SAE data collection tool if the event also meets the criteria for an SAE
  - All events of ALT ≥ 3xULN and bilirubin ≥ 2xULN (>35% direct bilirubin) (or ALT≥3xULN and INR>1.5, if INR measured; INR measurement is not required and the threshold value stated will not apply to subjects receiving anticoagulants), termed ‘Hy’s Law’, must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis).
  - NOTE: if serum bilirubin fractionation is not immediately available, and if ALT ≥ 3xULN and bilirubin ≥ 2xULN discontinue subject from study treatment. Serum bilirubin fractionation should be performed if testing is available. If testing is unavailable, **record presence of detectable urinary bilirubin on dipstick**, indicating direct bilirubin elevations and suggesting liver injury
- Complete the liver imaging and/or liver biopsy eCRFs if these tests are performed
- Perform liver event follow up assessments, and monitor the subject until liver chemistries resolve, stabilize, or return to baseline values as described below
- Withdraw the subject from the study after completion of the liver chemistry monitoring (unless further safety follow up is required or Novartis Medical Governance approval of drug restart is granted, as described in Section 5.9.1.3).
  - Follow-up for overall survival or disease recurrence is required following discontinuation from study treatment
- Do not restart investigational product unless written approval is granted by Novartis Medical Governance (details for restarting investigational product are described in Section 5.9.1.3), whereupon the subject continues in the study after completion of the liver chemistry monitoring described in Section 5.9.1.2).
- Subjects meeting criterion 5 should be monitored as frequently as possible.
In addition, for subjects meeting liver stopping criterion 1:

- Make every reasonable attempt to have subjects return to clinic **within 24 hours** for repeat liver chemistries, liver event follow up assessments (refer to Section 5.9.1.1), and close monitoring

- A specialist or hepatology consultation is recommended

- Monitor subjects twice weekly until liver chemistries (ALT, AST, alkaline phosphatase, bilirubin) resolve, stabilize or return to within baseline values.

For subjects meeting any of the liver stopping criteria 2 – 5:

- Make every reasonable attempt to have subjects return to clinic **within 24-72 hrs** for repeat liver chemistries and liver event follow up assessments (refer to Section 5.9.1.1)

- Monitor subjects weekly until liver chemistries (ALT, AST, alkaline phosphatase, bilirubin) resolve, stabilize or return to within baseline values;
  - Subjects meeting criterion 5 should be monitored as frequently as possible.

### 5.9.1.1 Liver Event Follow Up Assessments

For subjects meeting any of the liver chemistry stopping criteria 1 – 5, make every attempt to carry out the liver event follow-up assessments described below:

Viral hepatitis serology including:

- Hepatitis A IgM antibody
- Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM)
- Hepatitis C RNA
- Cytomegalovirus IgM antibody
- Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile antibody or monospot testing)
- Hepatitis E IgM antibody.

- Blood sample for pharmacokinetic (PK) analysis, obtained within 10 days of last dose. Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the subject’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in the SPM.

- Serum creatinine phosphokinase (CPK) and lactate dehydrogenase (LDH).
- Fractionate bilirubin, if total bilirubin ≥2xULN.
- Obtain complete blood count with differential to assess eosinophilia.
- Record the appearance or worsening of clinical symptoms of hepatitis, or hypersensitivity, such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or eosinophilia as relevant on the AEs form. Please note that
treatment with trametinib often associates with rash which is usually acneiform and affects the scalp, face, neck, chest, and upper back. Discuss with Medical Lead as needed.

- Record use of concomitant medications such as acetaminophen (paracetamol), herbal remedies, other over the counter medications, or putative hepatotoxins, on the concomitant medications form.

- Record alcohol use on the liver event alcohol intake form.

The following assessments are required for subjects with ALT ≥3xULN and bilirubin ≥2xULN (>35% direct) but are optional for other abnormal liver chemistries:

- Anti-nuclear antibody, anti-smooth muscle antibody, Type 1 anti-liver kidney microsomal antibodies, and quantitative total immunoglobulin G (IgG or gamma globulins).

- Liver imaging (ultrasound, magnetic resonance, or computerized tomography) to evaluate liver disease.

- Serum acetaminophen adduct assay (quantifies potential acetaminophen contribution to liver injury, detectable by high performance liquid chromatography (HPLC) assay more than 1 week following acetaminophen use).

- Only in those with underlying chronic hepatitis B at study entry (identified by positive hepatitis B surface antigen): quantitative hepatitis B DNA and hepatitis delta antibody. NOTE: if hepatitis delta antibody assay cannot be performed, it can be replaced with a polymerase chain reaction (PCR) of hepatitis D RNA virus (where needed) – as outlined in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1153793/

5.9.1.2 Liver Chemistry Monitoring Criteria

For subjects with ALT ≥3xULN but <8xULN which exhibit a decrease to ALT ≥3xULN, but <5xULN and bilirubin <2xULN, without hepatitis symptoms or rash and who can be monitored weekly for 4 weeks, the following actions should be taken:

- Notify the Novartis Medical Lead within 24 hours of learning of the abnormality to discuss subject safety

- Continue study treatment

- Return weekly for repeat liver chemistries (ALT, AST, alkaline phosphatase, bilirubin) until they resolve, stabilize or return to within baseline values

- If at any time the subject meets any of the liver chemistry stopping criteria 1–5, proceed as described above

- If, after 4 weeks of monitoring, ALT <3xULN and bilirubin <2xULN, monitor subjects twice monthly until liver chemistries normalize or return to within baseline values.

Refer to Appendix 7 for algorithm of liver chemistry monitoring, stopping and follow up criteria.
5.9.1.3 Restoring Investigational Product

5.9.1.3.1 Drug Restart/Rechallenge Following Liver Events that are Possibly Related to Study Treatment

Appointment by Novartis for study treatment restart can be considered where:
The subject is receiving compelling benefit, benefit of drug restart exceeds risk, and no effective alternative therapy is available. Ethics Committee or Institutional Review Board approval of drug restart/rechallenge must be obtained, as required.
If the restart/rechallenge is approved by Novartis in writing, the subject must be provided with a clear description of the possible benefits and risks of drug administration, including the possibility of recurrent, more severe liver injury or death.
The subject must also provide signed informed consent specifically for the investigational product (IP) restart/rechallenge. Documentation of informed consent must be recorded in the study chart.
Study treatment must be administered at the dose specified by Novartis.
Subjects approved by Novartis for restart/rechallenge of IP must return to the clinic twice a week for liver chemistry tests until stable, liver chemistries have been demonstrated and then laboratory monitoring may resume as per protocol.

5.9.1.3.2 Drug Restart Following Transient Resolving Liver Events Not Related to Study Treatment

Appointment by Novartis for drug restart can be considered where:
- Liver chemistries have a clear underlying cause (e.g., biliary obstruction, hypotension and liver chemistries have improved to normal or are within 1.5 x baseline and ALT <3xULN). Ethics Committee or Institutional Review Board approval of drug restart/rechallenge must be obtained, as required.
- If restart of drug is approved by Novartis in writing, the subject must be provided with a clear description of the possible benefits and risks of drug administration, including the possibility of recurrent, more severe liver injury or death.
- The subject must also provide signed informed consent specifically for the restart. Documentation of informed consent must be recorded in the study chart.
- Study treatment must be administered at the dose specified by Novartis.
- Subjects approved by Novartis for restarting IP must return to the clinic once a week for liver chemistry tests until stable, liver chemistries have been demonstrated and then laboratory monitoring may resume as per protocol. If protocol defined stopping criteria for liver chemistry elevations are met, study drug must be stopped.
6 CONCOMITANT MEDICATIONS AND NON-DRUG THERAPIES

6.1 Permitted Medications and Non-Drug Therapies

The investigator must be informed as soon as possible about any medication taken from the time of screening until 30 days after the last dose of study treatment. Any concomitant medication(s), including dietary supplements, taken during the study will be recorded in the eCRF. The minimum requirement is that drug name, dose, and the dates of administration are to be recorded. Additionally, a complete list of all prior surgical procedures will be recorded in the eCRF.

Subjects should receive full supportive care during the study, including transfusions of blood and blood products, and treatment with antibiotics, anti-emetics, anti-diarrheals, and analgesics, and other care as deemed appropriate, and in accordance with their institutional guidelines. Use of anticoagulants such as warfarin is permitted provided that INR is monitored in accordance with local institutional practice. Flu shots are recommended for enrolled subjects.

6.2 Prohibited Medications and Non-Drug Therapies

The use of certain medications and illicit drugs within 28 days or 5 half lives, whichever is shorter, prior to randomization and for the duration of the study will not be allowed. The following medications or non-drug therapies are also prohibited while on treatment in this study:

- Other anti-cancer therapies;
- Other investigational drugs;
- Antiretroviral drugs (Note: Subjects with known HIV are ineligible for study participation);
- Herbal remedies (e.g., St. John’s wort);
- Dabrafenib is metabolized primarily by Cytochrome P450 (CYP) 2C8 and CYP3A4. Co-administration of dabrafenib with ketoconazole, a CYP3A4 inhibitor, or with gemfibrozil, a CYP2C8 inhibitor, resulted in increases in dabrafenib AUC of 71% and 47%, respectively. Drugs that are strong inhibitors or inducers of CYP3A and CYP2C8 (for examples see Table 8) may only be used under special circumstances (e.g. as a single use for a procedure) while treatment with study drug is interrupted as they may alter dabrafenib concentrations; consider therapeutic substitutions for these medications. Approval of the Novartis MedicalLead is required in these situations. A partial list of these medications is provided in Table 8. The list may be modified based on emerging data. Refer to the SPM for the most current list.
Table 8  Prohibited Medications

<p>| PROHIBITED – Strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib may be decreased |</p>
<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>Drugs/Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>Rifamycin class agents (e.g., rifampin, rifabutin, rifapentine),</td>
</tr>
<tr>
<td>Anticonvulsant</td>
<td>Carbamazepine, oxcarbazepine phenobarbital, phenytoin, s-mephénytoïn</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>bosentan, St. John’s wort</td>
</tr>
</tbody>
</table>

<p>| PROHIBITED – Strong inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib may be increased |</p>
<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>Drugs/Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>Clarithromycin, telithromycin, troleandomycin</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>Nefazodone</td>
</tr>
<tr>
<td>Antifungals</td>
<td>Itraconazole, ketoconazole, posaconazole, voriconazole</td>
</tr>
<tr>
<td>Antiretroviral</td>
<td>Ritonavir, saquinavir, atazanavir</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>Gemfibrozil</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Conivaptan</td>
</tr>
</tbody>
</table>

6.3  Medications to be Used with Caution

The following medications should be used with caution as their concentrations may be altered by dabrafenib or they may alter dabrafenib concentrations:

- Drugs that are moderate inhibitors or inducers of CYP3A and CYP2C8 as they may alter concentrations of dabrafenib.

- Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam (CYP3A4 substrate) and S-warfarin (CYP2C9 substrate). Dabrafenib is an in vitro inducer of CYP2B6 and other enzymes such as CYP2C8, CYP2C19, UDP-glucuronyl transferases and transporters may also be affected. Co-administration of dabrafenib and medications which are affected by the induction of these enzymes (including warfarin) and transporters may result in loss of efficacy. If co-administration of these medications is necessary, investigators should consider substitutions of these medications. A partial list of these medications is provided in Table 9. The list may be modified based on emerging data. Refer to the SPM for the most current list.

- Therapeutic level dosing of warfarin can be used with approval by the Novartis Medical Lead and close monitoring of PT/INR by the site. Exposure decreased by 37% due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR. Consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate. Prophylactic low dose warfarin may be given to maintain central catheter patency.

- Dabrafenib solubility is pH-dependent with decreased solubility at higher pH. Drugs such as proton pump inhibitors that inhibit gastric acid secretion to elevate gastric pH may decrease the solubility of dabrafenib and reduce its
bioavailability. No clinical study has been conducted to evaluate the effect of pH on dabrafenib pharmacokinetics. In an ad-hoc analysis, no differences in $C_{\text{max}}$ and AUC were noted between subjects who reported taking pH-elevating products relative to other subjects. Due to the theoretical risk that pH-elevating agents may decrease oral bioavailability and exposure to dabrafenib, these medicinal products that increase gastric pH should be used with caution when administered with dabrafenib.

### Table 9  Medications to be used with Caution

<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>Moderate CYP3A and CYP2C8 Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmics</td>
<td>Diltiazem, verapamil</td>
</tr>
<tr>
<td>Antibiotic</td>
<td>Erythromycin</td>
</tr>
<tr>
<td>Antifungal</td>
<td>Fluconazole</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Aprepitant</td>
</tr>
</tbody>
</table>

**USE WITH CAUTION:** Moderate inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib may be increased.

<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or Transporter Substrates that May Be Affected by Induction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Alfentanil, buprenorphine, celecoxib, codeine, fentanyl, methadone, oxycodone</td>
</tr>
<tr>
<td>Antiarhythmics</td>
<td>Disopyramide, dronedarone, mexiletine, propafenone, quinidine</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>Chloramphenicol, doxycycline, erythromycin, moxifloxacin</td>
</tr>
<tr>
<td>Anticoagulants/ Antiplatelets</td>
<td>Cilostazole, warfarin</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Divalproex, lamotrigine, valproate, zonisamide</td>
</tr>
<tr>
<td>Antidepressants and Antipsychotics</td>
<td>Aripiprazole, bupropion, buspirone, desipramine, haloperidol mirtazapine, pimozide, quetiapine, trazodone, amitryptiline, clomipramine, imipramine</td>
</tr>
<tr>
<td>Antidiabetics</td>
<td>Glyburide, saxagliptin, tolbutamide, nateglinide, pioglitazone, repaglinide, rosiglitazone</td>
</tr>
<tr>
<td>Antifungals</td>
<td>Caspofungin, fluconazole, terbinafine</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Astemizole, chlorpheniramine, ebastine</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>Amlodipine, diltiazem, felodipine, nifedipine, nilvadipine, nisoldipine, verapamil</td>
</tr>
<tr>
<td>Antimigraine Agents</td>
<td>Diergotamine, eletriptan, ergotamine</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Dexamethasone, methylprednisolone, oral budesonide</td>
</tr>
<tr>
<td>Erectile Dysfunction Agents</td>
<td>Sildenafil, tadalfil, vardenafil</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>Atorvastatin, lovastatin, simvastatin, rosuvastatin, pravastatin</td>
</tr>
<tr>
<td>Hypnotics and Sedatives</td>
<td>Alprazolam, brotizolam, diazepam, estazolam, midazolam, trazolam, zolpidem, zopiclone</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>Everolimus, sirolimus, tacrolimus</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Aprepitant, cisapride, darifenac, disopyramide, leflunomide methohexital, oral contraceptives, quinine, ranitidine, solifenacin, sulfasalazine, tramadol, tolvaptan, chloroquine, zopiclone</td>
</tr>
<tr>
<td>Selective Aldosterone Blockers</td>
<td>Eplerenone</td>
</tr>
</tbody>
</table>

**USE WITH CAUTION:** Co-administration of drugs that increase gastric pH should be used with caution when administered with dabrafenib.
6.4 Treatment after Discontinuation of Study Treatment or Withdrawal from/Completion of Study

The investigator is responsible for ensuring that consideration has been given for the post-study care of the patient’s medical condition whether or not Novartis is providing specific post-study treatment.

Treatment after relapse or study discontinuation will not be provided as part of the protocol. Upon relapse or study discontinuation, subjects may receive additional (non protocol) anti-cancer therapy at the discretion of the treating physician which may include inhibitors of the MAP-kinase pathway. If treatment occurs after relapse the new anti-cancer therapy and the subject’s best response to treatment should be documented in the eCRF. Every effort should be made to complete the required follow up evaluations (refer to Table 11 for follow-up assessments and procedures). At a minimum subjects should be followed for survival even if other assessments are not performed.

Refer to Section 4.2 for follow-up assessment of subjects who are to be followed up for disease recurrence and/or survival after permanently discontinuing from study treatment.

6.5 Treatment of Study Treatment Overdose

In the event of a dabrafenib overdose, defined as administration of more than 300 mg as a single dose or 600 mg per day (the highest dose tested in clinical studies to date), and/or a trametinib overdose, defined as administration of more than 3.0 mg once daily (the maximum tolerated dose defined in the MEK11054 Study), the investigator should contact the Novartis Medical Lead immediately and closely monitor the subject for AEs/SAEs and laboratory abnormalities. Novartis does not recommend specific treatment. The investigator will use clinical judgment to treat any overdose.

Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the Novartis Medical Lead based on the clinical evaluation of the subject.

A plasma sample for PK analysis may be requested by the Novartis Medical Lead on a case-by-case basis. This plasma sample should be collected as soon as possible, but within 10 days from the date of the last dose of on-study dosing.

Information regarding the quantity of the excess dose as well as the duration of the overdosing should be documented in the eCRF.
7 STUDY ASSESSMENTS AND PROCEDURES

A signed, written informed consent form must be obtained from the subject prior to any study-specific procedures or assessments. Refer to the Time and Events Tables for the timing of all assessments (Table 10 and Table 11). Details on efficacy and safety assessments are presented in Section 7.2 and Section 7.3, respectively. Details on health outcomes, PK, and pharmacogenetics (PGx) are presented in Section 7.4, Section 7.5, and Section 7.6, respectively. Further details of study procedures and assessments can be found in the study procedures manual (SPM).

Procedures conducted as part of the subject’s routine clinical management (e.g., imaging, pelvic/rectal exam, eye exams, ECG, ECHO) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided the procedure meets the protocol-defined criteria and has been performed in the timeframe specified in the protocol. Central laboratory results for BRAF testing, coagulation, hematology, clinical chemistry, and serum pregnancy are required for eligibility.

Investigators may be requested to perform additional safety tests during the course of the study based on newly available data to ensure appropriate safety monitoring. Appropriate local regulatory and ethical approvals should be obtained before any additional testing is performed.
<table>
<thead>
<tr>
<th>Study Assessments</th>
<th>Screening</th>
<th>Day 1</th>
<th>Month 1</th>
<th>Month 2</th>
<th>Month 3</th>
<th>Month 4</th>
<th>Month 5</th>
<th>Month 6</th>
<th>Month 7</th>
<th>Month 8</th>
<th>Month 9</th>
<th>Month 10</th>
<th>Month 11</th>
<th>Month 12</th>
<th>Treatment Discontinued (only if)</th>
<th>Unscheduled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Window (Days)</td>
<td>≤28 days</td>
<td>N/A</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>± 3 days</td>
<td>N/A</td>
</tr>
<tr>
<td>Informed consent</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>± 30 days from last dose</td>
<td>N/A</td>
</tr>
<tr>
<td>Tumor tissue sample for BRAF V600E/K mutation and biomarker testing</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Inclusion / exclusion criteria</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Demographic data</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>Serum</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>X</td>
<td>urine</td>
</tr>
<tr>
<td>Coagulation</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Central labs (Hematology &amp; Chemistry)</td>
<td>×</td>
<td></td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Medical history</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Tobacco and alcohol consumption</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Randomization</td>
<td>×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Study Assessments&lt;sup&gt;1&lt;/sup&gt;</td>
<td>SCREENING</td>
<td>TREATMENT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>≤28 days except where noted&lt;sup&gt;2,4&lt;/sup&gt;</td>
<td>N/A</td>
<td>± 3 days</td>
<td>± 30 days from last dose</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense Oral study treatment and Assess compliance&lt;sup&gt;12&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Performance status (ECOG)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ECG&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHO&lt;sup&gt;14&lt;/sup&gt;</td>
<td>X</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic examination&lt;sup&gt;15&lt;/sup&gt;</td>
<td>X</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatologic skin assessment&lt;sup&gt;16&lt;/sup&gt;</td>
<td>X</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination&lt;sup&gt;17&lt;/sup&gt;</td>
<td>X Complete</td>
<td>X Brief</td>
<td>X Brief</td>
<td>X Brief</td>
<td>X Brief</td>
<td>X Brief</td>
<td>X Brief</td>
<td>X Complete</td>
<td>X Complete</td>
<td>X Brief</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest, abdomen and pelvic CT scans&lt;sup&gt;18&lt;/sup&gt;</td>
<td>X</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X±7 days</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain CT/MRI&lt;sup&gt;19&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of Life Assessment&lt;sup&gt;19&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> Study Assessments may vary based on protocol and patient status.
<sup>2</sup> Visit window is ≤28 days unless noted.
<sup>3</sup> Discontinued only if necessary.
<sup>4</sup> Specific assessment intervals may vary.
<sup>5</sup> Treatment refers to the administration of medication or therapy.
<sup>6</sup> ECG is Electrocardiogram.
<sup>12</sup> ECHO is Echocardiogram.
<sup>13</sup> Ophthalmic examination includes visual acuity and intraocular pressure.
<sup>14</sup> Dermatologic skin assessment includes skin fold thickness, body mass index, and skin condition.
<sup>15</sup> Physical examination includes vital signs, weight, and physical examination.
<sup>16</sup> Chest, abdomen and pelvic CT scans include computed tomography of the chest, abdomen, and pelvis.
<sup>17</sup> Quality of Life Assessment includes patient-reported outcomes and health-related quality of life measures.
<table>
<thead>
<tr>
<th>Study Assessments¹</th>
<th>Screening</th>
<th>Day 1</th>
<th>Month 1</th>
<th>Month 2</th>
<th>Month 3</th>
<th>Month 4</th>
<th>Month 5</th>
<th>Month 6</th>
<th>Month 7</th>
<th>Month 8</th>
<th>Month 9</th>
<th>Month 10</th>
<th>Month 11</th>
<th>Month 12</th>
<th>Treatment Discont.² (only if Unsched)</th>
<th>Unsched</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Window (Days)</td>
<td>≤28 days except where noted²,⁴</td>
<td>N/A</td>
<td>±3 days</td>
<td>N/A</td>
<td>±30 days from last dose</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications²³</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>N/A</td>
</tr>
<tr>
<td>Blood products and blood supportive care products</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse events²¹</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood sample for PGx²²</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for cfDNA and other biomarker testing²³</td>
<td>X(All)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
</tr>
<tr>
<td>Blood sample for cytokine and markers of pyrexia testing²⁷</td>
<td>X(All)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
<td>X (subset)</td>
</tr>
<tr>
<td>PK Sampling²⁴</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Assessments¹</td>
<td>SCREENING</td>
<td>TREATMENT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>≤28 days except where noted²,⁴</td>
<td>N/A</td>
<td>± 3 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor tissue sample for biomarker research⁸</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

At the time of disease recurrence only

Abbreviations: CAF = cytokines and angiogenic factors; cfDNA = circulating cell-free DNA; CT = computed tomography; ECG = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic Case Report Form; EQ-5D = EuroQol-5D; LLN = lower limit of normal; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; PGx = pharmacogenetics; PK = pharmacokinetics; SPM = Study Procedures Manual.

1. All assessments mandated throughout the study must be performed on a calendar schedule; delays in treatment administration will not delay performance of assessments. For monthly visits (i.e. Month 1, 2, 3, etc.) subjects should return to the clinic approximately every 4 weeks. A post baseline study visit window of ±3 days is allowed for visits during treatment. A window of ±7 days is permitted for some post baseline assessments, where noted in Table 10.

2. Screening procedures may be performed up to 28 days prior to randomization, unless otherwise noted in the table. Screening visits with a different window are noted in parentheses.

3. Informed consent may be given at any time prior to the performance of any study-related procedures. Informed consent for PGx research is to be obtained before any PGx-related procedures. Only subjects consented for the main clinical study are eligible for consent for PGx.

4. Tumor tissue must be collected to assess the BRAF V600E/K mutation status via central lab testing (See Section 7.7.1 and SPM for details.). A positive BRAF result from the central lab need not be repeated if randomization falls outside the 28-day screening window.

5. Only subjects who meet all inclusion and exclusion criteria will be eligible to enter into the study.

6. Record date of birth, race, ethnicity, and gender.
7. For all women of childbearing potential a serum pregnancy test will be required within 7 days prior to randomization; preferably, as close to the first dose as possible. Subsequent tests may be urine tests, and should be performed at Months 3, 6, 9, and 12 or discontinuation if discontinuation occurs prior to Month 12. Additionally if study treatment is interrupted for more than 7 days, regardless of the reason for the disruption, a urine test must be performed to confirm the subject is not pregnant prior to re-starting study treatment.

8. Coagulation sample to be obtained at screening only and analyzed by a central laboratory.

9. Analysis of clinical chemistry and hematology samples including those at screening will be performed by a central laboratory. Screening labs must be performed within 28 days prior to randomization.

10. Record date of diagnosis, primary tumor type, histology, stage, and other disease characteristics as indicated in the eCRF.

11. Record past and current medical conditions, surgical procedures and cardiovascular family history.

12. Dosing instructions must be provided to the subject. Subjects should start treatment as soon as possible after randomization but no later than 72 hours post-randomization. Study treatment will be dispensed at randomization and monthly. Site must call IVRS to register each study visit. Compliance will be assessed at all visits after Day 1 (Randomization). To assess compliance subjects should be instructed to return study drug at each visit; compliance will be assessed by querying the subject and counting tablets/capsules. Dose reductions, dose interruptions/delays, and/or dose escalations must be recorded in the eCRF.

13. ECG must be performed at Screening, Months 1, 3, 6, 9, and 12 or discontinuation if discontinuation occurs prior to Month 12, unless clinically indicated sooner. For subjects that discontinue study treatment before Month 12 an ECG must be performed at the discontinuation visit within 30 days of the last dose. A single 12-lead ECG will be performed by qualified site personnel after the subject has rested in a semi-recumbent or supine position for at least 5 minutes. Two copies of the ECG tracing should be obtained at the time of the ECG; the first copy will be kept in the subject’s medical chart and the second copy will be kept in the study file for retrospective collection by the Sponsor if necessary. ECGs should be done in triplicate when the initial test is abnormal.

14. ECHO must be performed at the Screening, Months 1, 3, 6, 9, and 12 or discontinuation if discontinuation occurs prior to Month 12, unless clinically indicated sooner. For subjects that discontinue study treatment before Month 12 an ECHO must be performed at the discontinuation visit within 30 days of the last dose. While on treatment, subjects who have asymptomatic, absolute decrease in LVEF of >10% compared to screening AND whose ejection fraction is below the institution’s LLN, must be followed according to LVEF guidelines for study drug management and requirements for subsequent ECHO.

15. An ophthalmic examination must be performed by an ophthalmologist at Screening, Months 1, 3, 6, and 12, or at discontinuation if discontinuation occurs prior to Month 12. Additional ophthalmic exams will be performed only as symptomatically warranted.

16. A thorough dermatologic exam should be performed by the Investigator at Screening, and Months 2, 4, 6, 8, 10, and 12 or at discontinuation if discontinuation occurs prior to Month 12. Refer to Table 11 for the schedule of assessments during follow-up. This may be referred to a dermatologist at the discretion of the investigator. If possible, the same physician should perform each exam for the duration of the study (i.e. if the subject is referred to a dermatologist for the screening exam, the dermatologist should do all follow up dermatologic assessments) to ensure consistency between evaluations. These visits should include periodic patient counseling on primary and secondary melanoma prevention measures including self-examination.

17. All physical exams will include the measurement of height (screening only) and weight using the metric scale, collection of vital signs including blood pressure, body temperature, pulse rate, and respirations. In addition a complete physical exam including a thorough genitourinary (pelvic) examination, inspection of the head and neck region, and digital rectal examination for both male and female subjects must be performed at Screening, and Month 12 or discontinuation if discontinuation occurs prior to
Month 12. For female subjects the genitourinary exam must include a PAP smear. If the subject has had a genitourinary and rectal exam within 6 months of randomization these do not need to be repeated at screening. Brief physical examinations will be performed at all other timepoints as indicated. Refer to protocol Section 7.3.7 for additional detail on these examinations.

18. Diagnostic quality, contrast enhanced CT scan of the chest, abdomen and pelvis must be performed at all visits indicated in the table. Intravenous contrast should be used, for the CT scans, and preferably with oral contrast as well. CT contrast of the chest, with contrast-enhanced MRI of the abdomen and pelvis should be substituted for full CT scanning if the CT scanning frequency is not permitted per country or ethics requirements or if CT contrast is contraindicated. If MRI scanning is not possible, and CT intravenous contrast is contraindicated, CT without contrast is allowed, but it is the least preferable option. Method of imaging should be consistent throughout the study (i.e. if CT is done at screening, CT must be done at all future timepoints). For scanning during follow-up prior to disease recurrence refer to Table 11.

19. Quality of life assessments will consist of the EQ-5D.

20. All medications taken by the subject during the study from the time of screening until 30 days after the last dose of study treatment will be recorded; any new anti-cancer therapy, if taken after study treatment discontinuation will be recorded as detailed in Table 11, Footnotes 7 & 10.

21. Adverse events will be recorded from the time the first dose of study treatment is administered until 30 days after discontinuation of study treatment. Serious adverse events (SAEs) will be collected over the same time period as AEs except SAEs assessed as related to study participation (e.g., protocol-mandated procedures, invasive tests, or change in existing therapy), study treatment, concomitant medication which must be recorded from the time a subject consents to participate in the study up to and including any follow-up contact.

22. Blood sample for PGx to be obtained only if the informed consent for PGx research has been obtained. Sample can be collected at any timepoint during the study; however collection at the first opportunity following randomization is preferred.

23. A blood sample for analysis of cDNA, cytokines and angiogenic factors (CAF) and other biomarkers is mandatory at Day 1 pre-dose and at the time of disease recurrence for all subjects and will be collected in a subset of subjects at selected sites at Month 3, 6, 9, 12 (or discontinuation if treatment is permanently discontinued before Month 12). Please refer to protocol Section 7.7 for a description of potential biomarkers to be analyzed.

24. Blood samples will be collected for PK analysis in a subset of subjects while on treatment. Subjects with morning clinic visit will be asked to withhold their morning dose and have a predose sample obtained within 8 to 14 hours after the previous dose. Subjects with afternoon clinic visit will take their dose as usual in the morning and have a sample obtained during their visit. Date and time of both sample collection and dose of both drugs/or placebos will be recorded on the eCRF.

25. If treatment discontinuation occurs prior to Month 12 the treatment discontinuation visit should be performed within 30 days of the subject’s last dose. Laboratory assessments and other required assessments do not need to be repeated at the discontinuation visit if they were performed within 30 days of the discontinuation visit. Follow-up should occur until death or study completion according to the follow-up assessment schedule in the table unless the subject withdraws from the study.

26. Baseline MRI (preferred) or CT (only if MRI contraindicated or unavailable) of the brain must be performed on all subjects. Post-baseline scans should be performed as clinically indicated.

27. Blood sample for cytokine testing (and other potential markers of pyrexia) to be collected for all subjects prior to administration of the first dose of study drugs, in a subset of subjects at intervals during treatment and where possible in any subject that experiences adverse event(s) of pyrexia at the time of the event during the treatment period. If a subject experiences pyrexia requiring hospitalization a sample should be drawn upon admission, where possible.

28. Wherever possible a tumor tissue sample should be collected at the time of disease recurrence for biomarker research.
## Table 11  Time and Events Table – Follow-Up Assessments

<table>
<thead>
<tr>
<th>Study Assessments¹</th>
<th>FOLLOW-UP¹⁰</th>
<th>STUDY COMPLETION¹²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BEFORE RECURRANCE</td>
<td>AFTER RECURRANCE¹³</td>
</tr>
<tr>
<td>Study Assessments¹</td>
<td>Uns ch</td>
<td>Every 3 Months (M3-M12)¹⁴</td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>N/A</td>
<td>(± 14 days)</td>
</tr>
<tr>
<td>Central Labs² (Hematology &amp; Chemistry)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Performance status (ECOG)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Dermatologic skin assessment¹</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical examination*</td>
<td>X (Brief)</td>
<td>X (Brief)</td>
</tr>
<tr>
<td>Chest, abdomen and pelvic CT scans²</td>
<td>X¹⁰</td>
<td>X</td>
</tr>
<tr>
<td>Quality of Life Assessment⁶</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Concomitant medications⁷</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>BEFORE RECURRENCE</td>
<td>AFTER RECURRENCE</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Study Assessments&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Unsch</td>
<td>Every 3 Months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(M3-M12)&lt;sup&gt;14&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Month 15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Every 3 Months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(M18-M24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(± 14 days)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(± 14 days)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(± 14 days)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>N/A</td>
<td>(± 14 days)</td>
</tr>
<tr>
<td>Adverse events&lt;sup&gt;2&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood sample for biomarker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>testing&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up contact, anti-cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>therapies and best response&lt;sup&gt;10&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor tissue sample for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>biomarker research&lt;sup&gt;11&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subject completion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death record</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Abbreviations: CT = computed tomography; ECG = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group; EQ-5D = EuroQol-5D; LLN = lower limit of normal; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; PGx = pharmacogenetics; PK = pharmacokinetics; SPM = Study Procedures Manual.

1. All assessments mandated throughout the study must be performed on a calendar schedule. A study visit window of ±14 days is allowed for all follow-up visits.

2. Analysis of clinical chemistry and hematology samples will be performed by a central laboratory. Labs should be drawn at Month 18 then annually thereafter during follow-up prior to disease recurrence and at the time of disease recurrence.

3. A thorough dermatologic exam should be performed every three months Month 3-24 and every six months after month 24 during the follow up period prior to disease recurrence. This may be referred to a dermatologist at the discretion of the investigator. If possible, the same physician should perform each exam for the duration of the study (i.e. if the subject is referred to a dermatologist for the screening exam, the dermatologist should do all follow up dermatologic assessments) to ensure consistency between evaluations. These visits should include periodic patient counseling on primary and secondary melanoma prevention measures including self-examination.

4. All physical exams will include the measurement of height (screening only) and weight using the metric scale, collection of vital signs including blood pressure, body temperature, pulse rate, and respirations. In addition a complete physical exam including a thorough genitourinary (pelvic) examination, inspection of the head and neck region, and digital rectal examination for both male and female subjects must be performed at Month 18. For female subjects the genitourinary exam must include a PAP smear. Brief physical examinations will be performed at all other timepoints as indicated. Refer to protocol Section 7.3.7 for additional detail on these examinations.

5. Diagnostic quality, contrast enhanced CT scan of the chest, abdomen and pelvis must be performed at all visits indicated in the table. Intravenous contrast should be used, for the CT scans, and preferably with oral contrast as well. CT contrast of the chest, with contrast-enhanced MRI of the abdomen and pelvis should be substituted for full CT scanning if the CT scanning frequency is not permitted per country or ethics requirements or if CT contrast is contraindicated. If MRI scanning is not possible, and CT intravenous contrast is contraindicated, CT without contrast is allowed, but it is the least preferable option. Method of imaging should be consistent throughout the study (i.e. if CT is done at screening, CT must be done at all future timepoints). MRI (preferred) or CT (only if MRI contraindicated or unavailable) of the brain should be performed as clinically indicated.

6. Quality of life assessments will consist of the EQ-5D. Once subject is in follow-up after recurrence QOL questionnaire may be sent by mail to the subject for completion, this will maintain the integrity of the assessment as there is no visual analog scale.

7. All medications taken by the subject during the study from the time of screening until 30 days after the last dose of study treatment will be recorded; any new anti-cancer therapy, if taken after study treatment discontinuation will be recorded as detailed in Footnote 10.

8. Adverse events will be recorded from the time the first dose of study treatment is administered until 30 days after discontinuation of study treatment. Serious adverse events (SAEs) will be collected over the same time period as AEs except SAEs assessed as related to study participation (e.g., protocol-mandated procedures, invasive tests, or change in existing therapy), study treatment, concomitant medication which must be recorded from the time a subject consents to participate in the study up to and including any follow-up contact.

9. A blood sample for analysis of biomarkers is mandatory at the time of disease recurrence. Refer to protocol Section 7.7 for a descriptions of potential biomarkers to be analyzed.

10. Follow-up will start once treatment is complete and continue through the end of the study even if disease recurs. Follow-up contact prior to disease recurrence will include clinic visits. Follow-up after disease recurrence should follow the schedule as noted in Table 11; however the information collected will be limited to: quality of life information, any radiotherapy, surgical procedure or new anti-cancer therapy initiated until study completion; withdrawal or death; best response to any follow-up treatment and survival data.
11. Wherever possible a tumor tissue sample should be collected at the time of disease recurrence for biomarker research.
12. To be completed if the subject permanently withdraws from the study (i.e. death, withdrawal of consent, lost to follow-up).
13. For subjects that experience disease recurrence prior to Month 12 the discontinuation visit should be performed and follow-up assessments should start at the next 3 month interval following the recurrence and continue every 3 months thereafter until study completion, withdrawal or death. For example, if a subject experiences disease recurrence at Month 2, the discontinuation visit should be performed according to Table 10 and the follow-up assessments would start at Month 3 and continue every 3 months thereafter according to Table 11 until study completion, withdrawal or death.
14. For subjects that discontinue study treatment prior to Month 12 with no evidence of disease recurrence follow-up visits should start at the next 3 month interval following treatment discontinuation. For example, if a subject discontinues treatment at Month 1, the discontinuation visit should be performed according to Table 10 and the follow-up visits would start at Month 3 and continue every 3 months thereafter according to Table 11. At the time of disease recurrence follow-up assessments should start at the next 3 month interval after the recurrence and continue every 3 months thereafter according to Table 11 until study completion, withdrawal or death.
15. Chest, abdomen and pelvic CT scans do not need to be repeated at the first follow-up visit if they have been performed within 6 weeks of the first follow-up visit.
16. Subjects that discontinue study treatments due to disease recurrence should be monitored every 3 months for six months following discontinuation of the study treatments or until the initiation of another anti-cancer therapy.
7.1 Critical Baseline Assessments
Efficacy assessments conducted at baseline are described in Section 7.2, tumor tissue and biomarker assessments are described in Section 7.7, and HRQOL assessments are described in Section 7.4. Safety assessments conducted at baseline and during treatment are described in Section 7.3. Cardiovascular medical history/risk factors will be assessed at baseline.

7.1.1 Baseline Confirmation of BRAF Mutation-positive Melanoma
Subjects with completely resected histologically confirmed high-risk (Stage IIIa [LN metastasis >1 mm], IIIb or IIIc) cutaneous melanoma will be screened for eligibility after signing the informed consent form. Subjects will be screened prior to treatment to determine whether their tumor sample has a BRAF V600E or V600K mutation, indicating their eligibility for the study. Tumor BRAF mutation testing will be conducted using the bioMerieux BRAF THxID IUO assay (IDE: G120011), and testing will be performed in a central reference laboratory. Details related to BRAF mutation testing are provided in Section 7.7.1 and in the SPM.

7.2 Efficacy

7.2.1 Efficacy Endpoints

7.2.1.1 Primary Endpoint
The primary efficacy endpoint of this study is relapse free survival (RFS) which is defined as the time from randomization to disease recurrence or death from any cause. Recurrence of or death from the same cancer and all deaths from other causes are events. Treatment emergent malignancies (excluding second melanomas) will not be considered as events, and loss to follow-up is censored.

- Types of recurrence to be considered as an event include loco-regional, distant metastases and second primary melanoma.

- Any death occurring without prior documentation of tumor recurrence will be considered as an event (and will not be censored in the statistical analysis).

- If no event has occurred by the time of the analysis, then the time to event will be censored as the date of the last adequate assessment of the patient in question.

- Any new primary cancer at another site, squamous cell carcinoma, or keratoacanthoma, will not be considered as a recurrence and should be reported as a SAE (See Section 7.3.2.2). A second primary melanoma will be considered as a recurrence. Tumor tissue samples of any new primary cancers (including melanoma) should also be submitted for biomarker characterization (See Section 7.7.2).
7.2.1.2 Secondary Endpoints

The secondary efficacy endpoints of this study are:

- Overall Survival (OS) defined as the interval from randomization to the date of death, irrespective of the cause of death; patients still alive will be censored at the date of the last contact.

- Distant metastasis-free survival (DMFS), defined as the interval from randomization to the date of first distant metastasis or date of death, whichever occurs first. Patients alive and without distant metastasis are censored at the date of last assessment.

- Freedom from relapse (FFR), defined as interval from randomization to local or distant recurrence with censoring of patients dying from causes other than melanoma or treatment-related toxicity at the date of death. Incidence of non-melanoma malignancy will not be considered as an event. Patients alive without recurrence or with second primary cancers will be censored at the date of last assessment.

7.2.1.3 Efficacy Assessment

See the Time and Events Tables (Table 10, Table 11) for the schedule of efficacy assessments. Assessments must be performed on a calendar schedule and should not be affected by dose interruptions/delays. For post-baseline efficacy assessments Month 1 through Month 12, a window of ±3 days (physical exam) or ±7 days (CT scans, dermatologic skin assessment) is permitted to allow for flexible scheduling. After Month 12 a post-baseline assessment window of ±14 days is permitted.

The following are required for efficacy assessment:

- Clinical examination

- Diagnostic quality, contrast-enhanced CT scan of the chest, abdomen and pelvis should be performed at baseline and subsequent timepoints as indicated in the Time and Events Tables (Table 10 and Table 11). Intravenous contrast should be used for the CT scans preferably with oral contrast as well. CT contrast of the chest, with contrast-enhanced MRI of the abdomen and pelvis should be substituted for full CT scanning if the CT frequency prescribed in the Time and Events Table is not permitted per country or ethics requirements or if CT contrast is contraindicated. The method of imaging should be consistent throughout the study (i.e. if CT is done at screening, CT will be done at all future timepoints). All CTs/MRIs will be collected; instructions are provided in the Study Procedures Manual (SPM).

- A baseline MRI of the brain is required for all subjects. CT may be performed only if MRI contraindicated or unavailable. Subsequent brain scans should only be performed as clinically indicated (e.g. symptoms suggestive of CNS recurrence). MRI/CT of the brain will be collected; instructions are provided in the Study Procedures Manual (SPM).

- Biopsy of suspected recurrences is strongly recommended, both to confirm the diagnosis and to obtain tissue for exploratory analyses (Section 7.7.2).
7.2.1.4 Assessment Guidelines

Please note the following:

- The same diagnostic method, including use of contrast, when applicable, must be used throughout the study. Contrast agents must be used in accordance with the Image Acquisition Guidelines presented in the SPM, where not contraindicated.

- Ultrasound is not a suitable modality of disease assessment for distant metastases. If new lesions are identified by ultrasound, confirmation by CT or MRI is required.

- Fluorodeoxyglucose positron emission tomography (FDG)-PET can be useful in confirming new sites of disease where a positive FDG-PET scan correlates with the new site of disease present on CT/MRI or when a baseline FDG-PET was previously negative for the site of the new lesion.

- If PET/CT is performed then the CT component can only be used for standard disease assessments if performed to diagnostic quality, which includes the required anatomical coverage and prescribed use of contrast. The method of assessment should be noted as CT on the CRF.

**Clinical examination:** New lesions detected by clinical examination must be biopsied, where possible, to confirm disease recurrence. If a biopsy cannot be obtained then CT/MRI must be done to confirm disease recurrence.

**CT and MRI:** **Contrast enhanced CT with 5mm contiguous slices is recommended.** MRI is acceptable (refer to Section 7.2.1.3), but when used, the technical specification of the scanning sequences should be optimized for the evaluation of the type of disease. Whenever possible the same scanner should be used.

**Brain Scan:** For the baseline brain scan and any post-baseline brain scans, contrast enhanced MRI is preferable to contrast enhanced CT.

7.2.1.5 Follow-up Assessments for Subjects Permanently Discontinued from Study Treatment prior to protocol treatment period (12 months)

Refer to Section 4.2 Permanent Discontinuation from Study Treatment and the Time and Events Schedule (Table 11) for follow-up assessment of subjects for disease recurrence and survival after permanently discontinuing from study treatment.

7.2.1.6 Assessment of Subject Completion

If a subject withdraws from the study during Months 1 through Month 24, the last radiographic assessment was more than 3 months prior to withdrawal from study and disease recurrence has not been documented, a disease assessment should be obtained at the time of withdrawal from study.

If a subject withdraws from the study after Month 24, the last radiographic assessment was more than 6 months prior to withdrawal from study and disease recurrence has not been documented, a disease assessment should be obtained at the time of withdrawal from study.
7.3 Safety

7.3.1 Safety Endpoints
The secondary objectives of the study include characterizing the safety of dabrafenib and trametinib combination therapy. As a consequence, clinical assessments including vital signs and physical examinations, 12-lead ECG, ECHO, eye exams, chemistry and hematology laboratory values, and AEs will be monitored and evaluated.

7.3.2 Adverse Events
The investigator or site staff will be responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE as outlined in Section 7.3.2.1 and Section 7.3.2.2, respectively.

7.3.2.1 Definition of an AE
Any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits, abuse, or misuse. Examples of events meeting the definition of an AE include:

- Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or grade of the condition
- New conditions detected or diagnosed after study treatment administration even though it may have been present prior to the start of the study
- Signs, symptoms, or the clinical sequelae of a suspected interaction
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication (overdose per se will not be reported as an AE/SAE) unless this is an intentional overdose taken with possible suicidal/self-harming intent. This should be reported regardless of sequelae.

“Lack of efficacy” or “failure of expected pharmacological action” per se is not to be reported as an AE or SAE. However, any signs and symptoms and/or clinical sequelae resulting from “lack of efficacy” will be reported as an AE or SAE, if they fulfill the definition of an AE or SAE.

Events that do not meet the definition of an AE include:

- Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE.
- Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.
• The disease/disorder being studied, or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject’s condition.

7.3.2.2 Definition of an SAE
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose:

a. Results in death

b. Is life-threatening

NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c. Requires hospitalization or prolongation of existing hospitalization

NOTE: In general, hospitalization signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-subject setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious.

Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.

d. Results in disability/incapacity, or

NOTE: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

e. Is a congenital anomaly/birth defect.

f. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

g. Protocol-Specific SAEs:

• All events of possible drug-induced liver injury with hyperbilirubinaemia defined as ALT ≥3xULN and bilirubin ≥ 2xULN (>35% direct) (or ALT ≥ 3xULN and INR>1.5, if INR measured) or termed ‘Hy’s Law’ events (INR
measurement is not required and the threshold value stated will not apply to patients receiving anticoagulants).

NOTE: bilirubin fractionation is performed if testing is available. If testing is unavailable, record presence of detectable urinary bilirubin on dipstick indicating direct bilirubin elevations and suggesting liver injury. If testing is unavailable and a subject meets the criterion of total bilirubin ≥ 2xULN, then the event is still reported as an SAE. If INR is obtained, include values on the SAE form. INR elevations >1.5 suggest severe liver injury.

- Any new primary cancers and treatment emergent malignancies (including squamous cell carcinoma, keratoacanthoma and second primary melanoma) with the exception of basal cell carcinoma (BCC). BCC should be reported as an AE or SAE based on the discretion of the investigator.
- Laboratory abnormalities as referenced in Section 7.3.2.3
- LVEF that meets stopping criteria Section 5.8.3.3.1.
- Central serous retinopathy (CSR) or retinal vein occlusion (RVO)
- Pyrexia accompanied by hypotension, dehydration requiring IV fluids, renal insufficiency, and/or severe rigors/chills in the absence of an obvious infectious cause.

7.3.2.3 Laboratory and Other Safety Assessment Abnormalities Reported as AEs and SAEs

Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis), or other safety assessments (e.g., ECGs, radiological scans, vital signs measurements) including those that worsen from baseline, and events felt to be clinically significant in the medical and scientific judgment of the investigator are to be recorded as an AE or SAE, in accordance with the definitions provided.

In addition, an associated AE or SAE is to be recorded for any laboratory test result or other safety assessment that led to an intervention, including permanent discontinuation of study treatment, dose reduction, and/or dose interruption/delay.

However, any clinically significant safety assessments that are associated with the underlying disease, unless judged by the investigator to be more severe than expected for the subject's condition, are not to be reported as AEs or SAEs.

7.3.2.4 Disease-Related Outcomes Not Qualifying as SAEs

An event which is part of the natural course of the disease under study (i.e., disease recurrence or hospitalization due to disease recurrence) does not need to be reported as an SAE. Death due to disease under study is to be recorded on the Death CRF form. However, if the underlying disease (i.e., recurrence) is greater than that which would normally be expected for the subject, or if the investigator considers that there was a causal relationship between treatment with GSK1120212 and GSK2118436 or protocol design/procedures and the disease recurrence, then this must be reported as an SAE. Local or distant relapse is the primary efficacy endpoint of the study and should not be reported as an SAE.
7.3.2.5 Time Period and Frequency of Detecting AEs and SAEs

The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE.

From the time a subject consents to participate in and completes the study (see Section 4.2.1), all SAEs assessed as related to study participation (e.g., protocol-mandated procedures, invasive tests, or change in existing therapy), will be reported promptly to Novartis, as indicated in Table 12. SAEs will be collected over the same time period as stated above for AEs. In addition, any new malignancy (defined in Section 7.3.2.2) or any SAE assessed as related to study participation (e.g., protocol-mandated procedures, invasive tests, or change in existing therapy), study treatment or Novartis concomitant medication must be recorded from the time a subject consents to participate in the study up to and including any follow-up contact. All SAEs will be reported to Novartis within 24 hours, as indicated in Section 7.3.2.6. For any new malignancy, every effort should be made to identify the RAS mutation status; the mutation test should be performed locally and reported within 12 weeks of diagnosis. Additional genetic analysis may be performed depending on the tumor types, and the results reported at the discretion of the investigator.

After discontinuation of study treatment, the investigator will monitor all AEs/SAEs that are ongoing until resolution or stabilization of the event or until the subject is lost to follow-up. At any time after 30 days from the last dose of study treatment the investigator may report any adverse event that they believe is possibly related to study treatment. Treatment emergent malignancies should be reported regardless of the time from treatment discontinuation to occurrence of the event.

7.3.2.6 Prompt Reporting of SAEs and Other Events to Novartis

SAEs, pregnancies, and liver function abnormalities meeting pre-defined criteria will be reported promptly by the investigator to Novartis as described in the following table once the investigator determines the event meets the protocol definition for that event.

Table 12: Time Frames for Reporting SAEs and Other Events

<table>
<thead>
<tr>
<th>Type of Event</th>
<th>Initial Reports</th>
<th>Follow-up Information on a Previous Report</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Time Frame</td>
<td>Documents</td>
</tr>
<tr>
<td>All SAEs</td>
<td>24 hours</td>
<td>SAE data collection tool</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>24 hours</td>
<td>Pregnancy Notification Form</td>
</tr>
<tr>
<td>Liver chemistry abnormalities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT ≥ 3xULN PLUS Bilirubin ≥ 2xULN (≥ 35% direct) (or ALT ≥ 3xULN and INR ≥ 1.5, if INR measured)</td>
<td>24 hours¹</td>
<td>SAE data collection tool. Liver Event CRF and liver imaging and/or biopsy CRFs if applicable²</td>
</tr>
<tr>
<td>Type of Event</td>
<td>Initial Reports</td>
<td>Follow-up Information on a Previous Report</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>ALT $\geq 8x$ULN; ALT $\geq 3x$ULN with hepatitis or rash or $\geq 3x$ULN and $&lt;5x$ULN that persists $\geq 4$ weeks</td>
<td>24 hours¹</td>
<td>Liver event CRF²</td>
</tr>
<tr>
<td>ALT $\geq 5x$ULN plus bilirubin $&lt;2x$ULN</td>
<td>24 hours¹</td>
<td>Liver event CRF does not need completing unless elevations persist for 2 weeks or subject cannot be monitored weekly for 2 weeks²</td>
</tr>
<tr>
<td>ALT $\geq 5x$ULN and bilirubin $&lt;2x$ULN that persists $\geq 2$ weeks</td>
<td>24 hours¹</td>
<td>Liver event CRF²</td>
</tr>
<tr>
<td>ALT $\geq 3x$ULN and $&lt;5x$ULN and bilirubin $&lt;2x$ULN</td>
<td>24 hours¹</td>
<td>Liver event CRF does not need completing unless elevations persist for 4 weeks or subject cannot be monitored weekly for 4 weeks²</td>
</tr>
</tbody>
</table>

1. Novartis to be notified at onset of liver chemistry elevations to discuss subject safety.
2. Liver Event Documents (i.e., "Liver Event CRF" and "Liver Imaging CRF" and/or "Liver Biopsy CRF", as applicable) should be completed as soon as possible.
3. INR measurement is not required; if measured, the threshold value stated will not apply to subjects receiving anticoagulants.

Liver chemistry stopping, follow-up, and monitoring criteria are provided in Section 5.9. Methods for detecting, recording, evaluating, and following up on AEs and SAEs and procedures for completing and transmitting SAE reports to Novartis are provided in the SPM. Procedures for post-study AEs and SAEs are provided in the SPM.

7.3.2.7 Regulatory reporting requirements for SAEs
Prompt notification of SAEs by the investigator to Novartis is essential so that legal obligations and ethical responsibilities towards the safety of subjects are met. Novartis has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation. Novartis
will comply with country specific regulatory requirements relating to safety reporting to the regulatory authority, IRB/IEC and investigators. Investigator safety reports are prepared for suspected unexpected serious adverse reactions according to local regulatory requirements and Novartis policy and are forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE(s) or other specific safety information (e.g., summary or listing of SAEs) from Novartis will file it with the IRB and will notify the IRB/IEC, if appropriate according to local requirements.

7.3.3 Pregnancy Testing, Prevention and Reporting

7.3.3.1 Pregnancy Test and Prevention

The need for a screening pregnancy test depends on whether a female subject is of childbearing potential or non-childbearing potential.

A female of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) is defined as any female who has had a hysterectomy, bilateral oophorectomy (ovariectomy) or bilateral tubal ligation, or is post-menopausal.

A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile, e.g., age appropriate, >45 years in the absence of hormone replacement therapy (HRT). In questionable cases, the subject must have a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value < 40 pg/mL (<140 pmol/L).

A female of child-bearing potential is defined as any female who does not meet the criteria of non-childbearing potential as described in the previous paragraph.

If a female subject is of childbearing potential, she must have a serum β-hCG pregnancy test performed within 7 days prior to randomization. Subjects with positive pregnancy test result must be excluded from the study. Subjects with negative pregnancy test result must agree to use an effective contraception method as described below during the study until 4 months following the last dose of study treatment.

Novartis acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:

- An intrauterine device with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject’s entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days prior to first dose of study treatment, through the dosing period, and for at least 4 months after the last dose of study treatment.

Note: Abstinence is acceptable only when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

- Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository).

Note: Hormonal-based methods (e.g., oral contraceptives) are not recommended due to potential drug-drug interactions with dabrafenib.
Female subjects who are lactating must discontinue nursing prior to the first dose of study treatment and must refrain from nursing throughout the treatment period and for 4 months following the last dose of study treatment.

If a subject becomes pregnant during the treatment period of the study, the study treatments should be stopped immediately.

7.3.3.2 Pregnancy Reporting

Any pregnancy that occurs during study participation must be reported using a clinical trial pregnancy form. To ensure subject safety, each pregnancy must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy must be followed up to determine outcome (including premature termination) and status of mother and child. Pregnancy complications and elective terminations for medical reasons must be reported as an AE or SAE. Spontaneous abortions must be reported as an SAE.

Any SAE occurring in association with a pregnancy brought to the investigator’s attention after the subject has completed the study and considered by the investigator as possibly related to the study treatment, must be promptly reported to Novartis.

In addition, the investigator must attempt to collect pregnancy information on any female partners of male study subjects who become pregnant while the subject is enrolled in the study. Pregnancy information must be reported to Novartis as described above.

7.3.4 Laboratory Assessments

All protocol required laboratory assessments, as defined in Table 10 and Table 11 should be performed by the central laboratory. Laboratory assessments must be conducted in accordance with the Central Laboratory Manual and Protocol Time and Events Schedule in Table 10 and Table 11). Laboratory requisition forms must be completed and samples must be clearly labeled with the subject number, protocol number, site/centre number, and visit date. Details for the preparation and shipment of samples will be provided by the central laboratory. Reference ranges for all safety parameters will be provided to the site by the central laboratory.

If any additional non-protocol specified laboratory assessments are performed at the institution’s local laboratory and result in a change in patient management or are considered clinical significant by the investigator (for example SAE or AE or dose modification) the results must be recorded in the subject’s eCRF. Refer to the SPM for appropriate processing and handling of samples to avoid duplication and/or additional blood draws.

Clinical chemistry and hematology parameters to be tested are listed in Table 13. Female subjects will have a serum pregnancy test at Screening; urine pregnancy testing will be done during study treatment at the visits indicated in the Time and Events Tables (Table 10 and Table 11). Post-baseline urine pregnancy testing may be done by local laboratory.
### Table 13  Clinical Chemistry and Hematology Parameters

<table>
<thead>
<tr>
<th>Clinical Chemistry Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
</tr>
<tr>
<td>Alanine Transaminase (ALT) or Serum Glutamic Pyruvic Transaminase (SGPT)</td>
</tr>
<tr>
<td>Aspartate Aminotransferase (AST) or Serum Glutamic Oxaloacetic Transaminase (SGOT)</td>
</tr>
<tr>
<td>Bicarbonate</td>
</tr>
<tr>
<td>Blood Urea Nitrogen (BUN) or urea</td>
</tr>
<tr>
<td>Calcium</td>
</tr>
<tr>
<td>Chloride</td>
</tr>
<tr>
<td>Creatinine</td>
</tr>
<tr>
<td>Glucose (random)</td>
</tr>
<tr>
<td>Lactate Dehydrogenase (LDH)</td>
</tr>
<tr>
<td>Phosphate</td>
</tr>
<tr>
<td>Potassium</td>
</tr>
<tr>
<td>Sodium</td>
</tr>
<tr>
<td>Total Bilirubinün</td>
</tr>
<tr>
<td>Total Protein</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hematology Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>White Blood Cell (WBC) Count</td>
</tr>
<tr>
<td>Hemoglobin</td>
</tr>
<tr>
<td>International Normalized Ratio (INR; at Screening only) a</td>
</tr>
<tr>
<td>Platelet Count</td>
</tr>
<tr>
<td>Prothrombin Time (PT; at Screening only) b</td>
</tr>
<tr>
<td>Partial Thromboplastin Time (PTT; at Screening only) b</td>
</tr>
<tr>
<td>Automated WBC Differential (expressed as %):</td>
</tr>
<tr>
<td>Basophils</td>
</tr>
<tr>
<td>Eosinophils</td>
</tr>
<tr>
<td>Lymphocytes</td>
</tr>
<tr>
<td>Monocytes</td>
</tr>
<tr>
<td>Neutrophils</td>
</tr>
</tbody>
</table>

---

a. Coagulation panel to be done at Screening only.
b. Bilirubin fractionation is recommended if total bilirubin is > 2 x the upper limit of normal (ULN).
c. If serum creatinine is > 1.5 mg/dL, creatinine clearance should be calculated using the standard Cockcroft-Gault formula (Appendix 4).

For subjects with a history of chronic HBV and/or HCV, the following tests will be performed at Screening:

- Viral hepatitis serology;
- Hepatitis B surface antigen and Hepatitis B core antibody (IgM), and/or
- Hepatitis C RNA.

### 7.3.5 Ophthalmic Examination

Subjects are required to have a standard ophthalmic examination performed by an ophthalmologist at Screening, Months 1, 3, 6, and 12 or at discontinuation if discontinuation occurs prior to Month 12. Additional ophthalmic exams will be performed only as symptomatically warranted. The exam will include a fundoscopic examination (direct or indirect), visual acuity (with correction), visual field examination, and tonometry with special attention to retinal abnormalities that are predisposing factors for RVO or CSR.
In subjects with clinical suspicion of RVO or CSR, fluorescein angiography and/or optical coherence tomography are highly recommended.

### 7.3.6 Vital Signs

Vital sign measurements will include systolic and diastolic blood pressure, body temperature, pulse rate, body weight, and height (only at Screening). Body temperature, weight and height measurements should be recorded in the metric scale.

All blood pressure assessments should be performed under optimal conditions i.e. after (i) subject has been seated with back support, ensuring that legs are uncrossed and flat on the floor, (ii) subject is relaxed comfortably for at least 5 minutes, (iii) preparatory steps including removal of any restrictive clothing over the cuff area and selection of the right cuff size have been ensured, (iii) the arm is supported so that the middle of the cuff is at the heart level, and (iv) the subject remains quiet during the measurement. In subjects with an initial blood pressure reading within the hypertensive range, a second reading should be taken at least 1 minute later, with the 2 readings averaged to obtain a final blood pressure measurement. Only the averaged value should be entered in the eCRF.

### 7.3.7 Physical Examinations

All physical exams (brief and complete) will include the measurement of height (screening only) and weight using the metric scale, collection of vital signs including blood pressure, body temperature, pulse rate, and respirations as well as assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A complete physical exam will also include a thorough genitourinary (pelvic) examination, inspection of the head and neck region, and digital rectal examination for both male and female subjects. For female subjects the genitourinary exam must include a PAP smear. Complete physical exams must be performed at Screening, Month 12 or discontinuation if discontinuation occurs prior to Month 12 and Month 18. If the subject has had a genitourinary and rectal exam within 6 months of randomization these do not need to be repeated at screening. Brief physical examinations will be performed at all other timepoints as indicated in the Time and Events Tables (Table 10 and Table 11). Refer to the SPM for additional detail regarding the exam requirements for the inspection of the head and neck region.

### 7.3.8 Dermatologic Examination

Dermatologic exams are required at Screening, Month 2, Month 4, Month 6, Month 8, Month 10 and Month 12 (or discontinuation if subject discontinues prior to Month 12), every three months from Month 12 until Month 24, and every 6 months after Month 24. Exams may be performed by the investigator or may be referred to a dermatologist, at the discretion of the investigator. If possible, the same physician should perform each exam for the duration of the study (i.e. if the subject is referred to a dermatologist for the screening exam, the dermatologist should do all follow up dermatologic assessments) to ensure consistency between evaluations. Refer to the SPM for additional detail regarding the dermatologic examination including exam requirements and required training for investigators that will be performing the exam.
7.3.9 **Electrocardiograms (ECG)**

Twelve (12)-lead ECGs will be obtained using an ECG machine that automatically calculates heart rate and measures PR, QRS, QT, RR and QTcB intervals. At each assessment, a single 12-lead ECG will be performed by qualified site personnel after the subject has rested in a semi-recumbent or supine position for at least 5 minutes. Two copies of the ECG tracing should be obtained at the time of the ECG; the first copy will be kept in the subject's medical chart and the second copy will be kept in the study file for retrospective collection by the Sponsor if necessary. See Section 5.8.3.3.3 for instructions if QTc withholding criteria are met.

7.3.10 **Echocardiograms (ECHO)**

Echocardiograms (ECHO) will be performed to assess cardiac ejection fraction and cardiac valve morphology. The echocardiographer’s evaluation should include an evaluation for left ventricular ejection fraction and both right and left-sided valvular lesions. Copies of all ECHO scans may be collected by the sponsor for possible future central/independent review. Collection details and Image Acquisition Guidelines (IAG) will be provided in the SPM.

7.4 **Health Outcomes**

7.4.1 **Health Outcomes Endpoints**

As part of the exploratory objectives of this study, changes in HRQOL from baseline will be assessed and compared between treatment groups using the EuroQol-5D (EQ-5D) questionnaire.

7.4.2 **Health Outcomes Assessments**

The Euro Qol, (EQ-5D) questionnaire is a 2-page, generic preference-based QOL measure comprised of a 5-item health status measure and a visual analogue scale (VAS) [Kind, 1996; Rabin, 2001] and used to generate 2 scores. The EQ-5D utility score, used for computation of health valuations (utilities) for application in economic modeling, is based on answers to 5 questions that evaluate mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Answers range from 1 to 3, depending on whether the patients perceives no problems (= 1), some problems (= 2), or significant problems (= 3) in that aspect of their health. The EQ-5D VAS generates a single health status index in which patients are asked to rate their current health by drawing a line from a box marked, “Your health state today” to the appropriate point on a 20-cm visual analog scale ranging from 100 (best imaginable health state) to 0 (worst imaginable health state). Subjects in both treatment groups will complete the EQ-5D at baseline and at various time points throughout the study (see Table 10 and Table 11 for Time and Events schedules).
7.5 Pharmacokinetics

7.5.1 Pharmacokinetic Endpoints
As part of the exploratory objectives of this study, the following population PK endpoints will be included for dabrafenib, dabrafenib metabolites and trametinib:

- Apparent clearance following oral dosing (CL/F); and
- Volume of distribution (V/F);

The results of the population PK analysis will be reported separately from the clinical study report.

7.5.2 Blood Sample Collection for Pharmacokinetics
Blood samples for PK analyses of dabrafenib, trametinib, and metabolites of dabrafenib will be collected in a subset of approximately 100 subjects at selected sites at the time points indicated in the Time and Events Table (Table 10). The actual date and time of each blood sample collection will be recorded. No more than 25 mL of blood will be collected over the duration of the study for PK blood sample collection, including any extra assessments that may be required.

Details of PK blood sample collection (including volume to be collected), processing, storage, and shipping procedures will be provided in the SPM.

7.5.3 Pharmacokinetic Sample Analysis
Plasma analysis will be performed under the management of PK Sciences, Novartis.
Plasma concentrations of trametinib and of dabrafenib and its metabolites (hydroxy-, and desmethyl dabrafenib; carboxy-dabrafenib may be assayed as needed) will be determined using the currently approved analytical methodology. Raw data will be stored in the Good Laboratory Practice (GLP) Archives at Novartis.

7.5.4 Meals and Dietary Restrictions
Subjects should be fasted for at least one hour prior to dosing through at least two hour after dosing due to the effect of food on dabrafenib absorption. If a subject vomits after taking study medication, the subject should be instructed not to retake the dose and should take the next scheduled dose.

Subjects shall abstain from ingestion of any food or drink containing grapefruit and grapefruit juice, Seville oranges or pomellos within 24 hours prior to the first dose of dabrafenib until the end of the study, as these have been shown to inhibit CYP3A4 activity.
7.6 Pharmacogenetics
Information regarding pharmacogenetic (PGx) research is included in Appendix 9.

7.7 Translational Research
After completion of the clinical trial, investigations will be performed on samples collected during the course of the trial to detect factors or profiles that correlate with other measures of response to treatment with dabrafenib and trametinib or with disease status. The results gained may also be of application for medically related conditions. Unless stated otherwise, these investigations may be performed irrespective of clinical outcome.

Comparative examination of pre-dosing profiles of participants may uncover known or novel candidate biomarkers/profiles which could be used to predict response to treatment with dabrafenib and trametinib combination therapy or provide new insights into melanoma and medically related conditions. Comparative examination of post-dosing profiles in conjunction with pre-dosing profiles may yield known and novel candidate biomarkers/profiles and new insights which relate to the action of dabrafenib and trametinib combination therapy.

All samples may be retained for a maximum of 15 years after the last subject completes the trial.

Novel candidate biomarkers and subsequently discovered biomarkers of the biological response associated with melanoma or medically related conditions and/or the action of dabrafenib and trametinib in combination may be identified by application of:

- DNA/gene and protein analysis of tumor tissue and/or blood/plasma.
- BRAF mutation assay
- Circulating cell-free DNA analysis of blood/plasma.
- CAF analysis of plasma.
- Cytokine analysis of plasma for safety events (e.g. Pyrexia)
- RNA analysis of tumor immune response gene signature

7.7.1 BRAF mutation assay
To determine BRAF V600E/K status, tumor tissue will be assessed from all subjects at Screening. The tissue will be tested for the BRAFV600E or V600K mutations using the bioMerieux THxID BRAF assay performed in a CLIA certified central reference laboratory. Tissue from either the primary tumor or metastatic lymph nodes is acceptable, however the most recently obtained tumor tissue (either archived material or fresh biopsy) is preferred.

The tissue requirements for the BRAF mutation assay evaluating patient eligibility for the study are provided in the SPM.

Additional biomarkers related to the activity of dabrafenib and trametinib may also be analyzed as described in Section 7.7.2.

7.7.2 Biopsy at Screening & Recurrence for Biomarker Research
The exploratory research objectives of this study include further characterization of the subject population through analysis of tumor DNA, RNA, and protein, or other
aberrations from tumor tissue, and to determine whether these are associated with clinical outcome in response to therapy. Mutations in BRAF, MEK1, MEK2, PTEN, N-RAS and other pathway and cancer-related genes may be assessed. Other biomarkers (e.g., expression of genes and proteins) related to the activity of dabrafenib and/or trametinib may also be measured. These analyses may be performed on the mandatory sample collected at screening and on samples from new tumor lesions that may present at relapse depending on feasibility of obtaining a sample of the recurrence. Analyses may also be performed on tumor tissue samples of any new primary cancers (including melanoma). RNA analysis may be performed on the tumor tissues to evaluate gene signature indicative of immune response. Further details on tissue requirements will be provided in the SPM.

7.7.3 Circulating cell-free DNA (cfDNA) Analysis
Tumor-specific circulating nucleic acid (cfDNA) levels detected in plasma or serum have been found to correlate with increasing tumor burden and decline following therapy. Furthermore, cfDNA in cancer subjects can harbor many genetic alterations (mutations, microsatellite alterations, aberrant methylation), which are generally consistent with the tumor. Thus, tumor-specific circulating cell-free DNA has the potential to be a useful biomarker of therapeutic response as well as serving as an early predictor of disease recurrence or distant metastasis.

cfDNA blood/plasma samples will be collected at baseline and at the time of disease recurrence on all subjects for assessment of cfDNA levels as a marker for reappearance of tumor burden (refer to the Time and Events Tables, Table 10 and Table 11). cfDNA blood/plasma samples will also be collected in a subset of approximately 100 subjects at selected sites at intervals on-treatment (refer to the Time and Events Table, Table 10). The cfDNA samples may also be explored to determine whether mutations in the cfDNA, including but not limited to BRAF V600, also correlate to mutations in tumor tissue from which it is derived wherever feasible. The cfDNA burden and mutation analysis results may be correlated to patient clinical endpoints. Further details on blood requirements are provided in the SPM.

7.7.4 CAF analysis
Clusters of markers (e.g. cytokine and angiogenic factors) circulating in the plasma have been found to correlate with tumor pathway activation. In addition, increased levels of circulating proteins such as VEGF and IFN-γ have been associated with disease metastasis in certain melanoma. Blood-based markers have the important advantage that specimens are readily available, simple to prepare and store, and can be taken prior to and during treatment. This allows for the assessment of predictive markers based on the baseline evaluation as well as markers of activity and resistance based on changes that occur during treatment. To characterize immune markers that may impact efficacy of BRAF/MEK targeted agents or predict response, serum samples may be explored to assess levels of circulating proteins such as VEGF, IFN-γ and other cytokines and angiogenic factors. Therefore, a broad panel of cytokines and angiogenic factors (CAF) will be evaluated in plasma. The samples may also be explored to assess markers of systemic immune response and inflammation. The above finding will be correlated with clinical outcome.
7.7.5 Cytokine analysis

Cytokine analysis (such as IL-1, IL-6, IL-8, IL-10, PD1, gamma interferon and TNF-alpha) and analysis of other markers of interest (e.g. PERK) will be conducted to evaluate events of pyrexia. Blood/plasma samples will be collected at baseline all subjects for assessment of cytokine levels and other markers of interest. In addition blood samples will be collected for any subject that has an event of pyrexia at the time of the event, where possible. Blood/plasma samples will also be collected in a subset of approximately 100 subjects at selected sites at intervals on-treatment (refer to the Time and Events Table, Table 10).

8 DATA MANAGEMENT

For this study subject data will be entered into Novartis defined electronic case report forms (eCRFs), transmitted electronically to Novartis or designee and combined with data provided from other sources in a validated data system.

Management of clinical data will be performed in accordance with applicable Novartis standards and data cleaning procedures to ensure the integrity of the data, e.g., removing errors and inconsistencies in the data. Adverse events and concomitant medications terms will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and custom drug dictionary. The eCRFs (including queries and audit trails) will be retained by Novartis, and copies will be sent to the investigator to maintain as the investigator copy.

9 DATA ANALYSIS AND STATISTICAL CONSIDERATIONS

9.1 Hypotheses

The primary objective of this two-arm study is to evaluate the efficacy of dabrafenib/trametinib combination therapy compared to placebos with respect to Relapse-Free Survival (RFS) for subjects with Stage III, resected BRAF V600E/K mutation-positive melanoma.

The study is designed to provide evidence with respect to RFS to either support the null hypothesis, $H_0: \lambda = 1$ or reject it in favor of the alternative hypothesis, $H_A: \lambda \neq 1$, where $\lambda$ is the hazard ratio (HR) of combination therapy relative to two placebos.

As per the initial protocol design (i.e. before Amendment 7), with 467 RFS events the study would have 95.3% power to detect $HR=0.7143$ (corresponding to median RFS of 15 and 21 months in the placebo arm and the combination therapy arm, respectively)

Final RFS analysis (as per Protocol Amendment 7):

The cutoff date for the final RFS analysis will be 30-June-2017 and the actual number of RFS events observed by that date will be used. At the time of Amendment 7, it is predicted to observe approximately 410 RFS events by the analysis cutoff date and this will provide more than 90% power to detect the originally targeted HR.
9.2 Study Design Considerations

9.2.1 Sample Size Assumptions

As per the initial protocol design (i.e. before Amendment 7), the following assumptions were made in the estimation of the required sample size:

- Exponential survival distributions;
- A HR of 0.7143 (median RFS times of 15 and 21 months in the placebo arm and the combination therapy arm, respectively);
- A 1:1 randomization scheme;
- An overall 5%, two-sided risk of erroneously claiming superiority of the combination therapy in the presence of no true underlying difference (i.e., overall Type I error);
  - A 95% chance of successfully claiming superiority of the combination therapy in the presence of a true underlying difference (i.e., power or 1-Type II error);
- An accrual rate of 42 subjects per month over 20.3 months; and
- A dropout rate of 5% for the placebo group and 15% for the combination group.

To enable the observation of 467 total events, an estimated total of 852 subjects (i.e., 426 subjects in each of the arms) would need to be enrolled, leading to implementation of final analyses at approximately 32 months after the start of the study.

As per Protocol Amendment 7, the final primary RFS analysis will be performed at the pre-defined cut-off date, by which time it is expected that approximately 410 RFS events will have been accrued. The study power would be approximately 92% assuming 410 RFS events are observed by the data-cut and assuming originally targeted treatment effect represented by a hazard ratio equal to 0.7143. The choice of final RFS analysis timing is independent of the underlying treatment effect which is unknown. With the amended design, the type I error in this study is therefore preserved.

Secondary Endpoint: Overall Survival

At the time of the primary analysis of RFS, all secondary endpoints will also be summarized. If the primary efficacy analysis of RFS is statistically significant, statistical analyses of secondary endpoints will be performed to supplement the primary analysis and facilitate a comprehensive description of the efficacy results. All statistical tests, unless otherwise specified, will be stratified for treatment and stratification factors.

Detailed information on the statistical methods will be provided in the Reporting and Analysis Plan (RAP).

OS is identified as the key secondary endpoint. A hierarchical approach will be taken to control for the overall type-I error rate for testing of multiple endpoints. Therefore OS will be formally statistically tested only if the primary efficacy endpoint RFS is statistically significant. As per the initial protocol design (before Amendment 7), the first potential time point for OS analysis will be at the time of the RFS final analysis when 467 RFS events will be observed:

1. If RFS is significant, an interim analysis for OS will be performed:
a. If OS is not significant at this stage, based on O'Brien-Fleming adjustments detailed below, the final OS analysis will be performed when 70% of the total number of randomized subjects have died (i.e. 597 deaths).

b. If OS is significant, no further formal analysis will be performed.

2. If RFS is not significant, OS will not be formally statistically tested.

As per the initial protocol design (before Amendment 7), the type I error rate will be controlled by using a group-sequential design for testing OS at multiple time points. Specifically, Lan-DeMets method [Lan, 1983] with O'Brien-Fleming type stopping boundary (as in EAST 5.3) will be used to maintain the cumulative type-I error rate at 2.5% (one-sided). The exact nominal p-values that will be needed to be observed to declare statistical significance at the time of these analyses for OS will depend on the number of OS events that have been observed at the time of these analyses.

Following the Protocol Amendment 7, the first OS interim analysis will be performed at the same time as the revised final RFS analysis; an additional 2nd OS interim analysis will be performed when approximately 299 OS events have occurred; the final OS analysis remains to be conducted at approximately 597 events. Approximately 150 OS events are projected to be observed by the new proposed data cut-off date of primary RFS analysis (~25% of the originally targeted number of OS events). The proposed additional OS interim analysis will be performed at approximately 299 events which represents ~50% of the originally targeted number.

O’Brien-Fleming type stopping boundary will be used for all OS tests planned in the Amendment 7 to maintain the cumulative type-I error rate at 2.5% (one-sided). With O’Brien-Fleming boundaries (as in EAST 6), the interim thresholds for claiming statistical significance are HR=0.493 (at 1st interim analysis assuming that exactly 150 OS events) and HR=0.710 (at 2nd interim assuming exactly 299 OS events) and the final threshold for claiming statistical significance is HR=0.851 (at final OS analysis assuming exactly 597 OS events). If any of the OS interim analyses is significant, no further formal analysis will be performed.

The study will be double blinded with randomization stratified for:

- Mutation type (V600E or V600K);
- Disease stage (IIIa, IIIb, IIIc)

Randomization to the Stage IIIa strata will be capped at 40% of the total number of subjects. Randomization to the Stage IIIb and IIIc strata will not be capped. All randomized subjects will be included in the analyses to test the hypotheses of interest regardless of length of follow-up or whether or not study treatment was administered (i.e., subjects will not be replaced).

**9.2.2 Sample Size Sensitivity**

As per the initial protocol design (before Amendment 7), Table 14 shows the various power scenarios at the time of the RFS analysis under the assumed risk reduction (29%) and for scenarios where percent improvement and underlying medians vary assuming 467 events (relapses and all-cause deaths) have accrued.
Table 14  Statistical Power Scenario for RFS Analysis

<table>
<thead>
<tr>
<th>Placebos</th>
<th>Combination Therapy</th>
<th>% Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 months</td>
<td>20 months</td>
<td>42.8%</td>
<td>0.7</td>
<td>96.9%</td>
</tr>
<tr>
<td>15 months</td>
<td>21 months</td>
<td>40%</td>
<td>0.714</td>
<td>95%</td>
</tr>
<tr>
<td>16 months</td>
<td>21 months</td>
<td>31.3%</td>
<td>0.762</td>
<td>83.1%</td>
</tr>
<tr>
<td>16 months</td>
<td>22 months</td>
<td>37.5%</td>
<td>0.727</td>
<td>92.7%</td>
</tr>
</tbody>
</table>

The final OS analysis will be performed when 597 deaths are observed. Table 15 shows the power to detect various treatment effects. For example with 597 deaths, the study would have 80% power to detect a hazard ratio of 0.793.

Table 15  Statistical Power Scenario for OS Analysis

<table>
<thead>
<tr>
<th>Median OS</th>
<th>Placebo</th>
<th>Combination Therapy</th>
<th>% Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>48 months</td>
<td>60.5 months</td>
<td>26.0%</td>
<td>0.793</td>
<td>80%</td>
<td></td>
</tr>
<tr>
<td>47 months</td>
<td>59 months</td>
<td>25.5%</td>
<td>0.797</td>
<td>79%</td>
<td></td>
</tr>
<tr>
<td>48 months</td>
<td>60 months</td>
<td>25.0%</td>
<td>0.8</td>
<td>77%</td>
<td></td>
</tr>
<tr>
<td>48 months</td>
<td>58 months</td>
<td>20.8%</td>
<td>0.828</td>
<td>63%</td>
<td></td>
</tr>
<tr>
<td>49 months</td>
<td>60 months</td>
<td>22.4%</td>
<td>0.817</td>
<td>69%</td>
<td></td>
</tr>
<tr>
<td>49 months</td>
<td>61 months</td>
<td>24.5%</td>
<td>0.803</td>
<td>76%</td>
<td></td>
</tr>
</tbody>
</table>

9.2.3  Sample Size Re-estimation
There will be no sample size re-estimation.

9.3  Data Analysis Considerations

9.3.1  Analysis Populations
The Intent-to-Treat Population (ITT) will consist of all randomized subjects whether or not randomized treatment was administered. This population will be based on the treatment to which the subject was randomized and will be the primary population for the analysis of efficacy data. Any subject who receives a treatment randomization number will be considered to have been randomized.
The Safety Population will consist of all subjects who received at least one dose of randomized treatment and will be based on the actual treatment received. This population will be used for the analysis of clinical safety data.

The Pharmacokinetics (PK) Population will consist of all subjects included in the Safety population for whom a PK sample is obtained and analyzed.

The cfDNA Population will consist of all subjects from the ITT population for whom samples for cfDNA have been obtained and analyzed.

9.3.2 Analysis Data Sets

The primary dataset for efficacy (RFS, OS, DMFS, FFR) will be comprised of the ITT population as defined in Section 9.3.1.

The primary dataset for assessing safety will be the Safety Population as defined in Section 9.3.1.

The primary objective will be supported by the test for superiority of combination therapy over placebo in relation to RFS (refer to Section 9.1) using the ITT population.

The cutoff date for the final RFS analysis will be the actual number of RFS events observed by that date will be used. Subjects will continue to be followed for OS until approximately 70 percent of the total number of randomized subjects has died (i.e. 597 deaths).

Details on the handling of missing data are provided in the RAP.

9.3.3 Treatment Comparisons

9.3.3.1 Primary Comparisons of Interest

The primary treatment comparison will be between the combination therapy arm and the placebo arm, with respect to RFS within the ITT population.

9.3.3.2 Other Comparisons of Interest

Treatment comparisons for secondary efficacy (including subgroup analyses) and safety endpoints will be between the combination therapy arm and the placebo arm.

Overall survival (OS) is a key secondary comparison of interest. At the time of the primary RFS analysis, OS will be estimated for each group and compared. At the end of study, OS will be tested provided the initial RFS analysis was statistically significant, hence the testing will be treated hierarchically and no adjustments for multiplicity are planned. At the time of the primary RFS analysis, DMFS and FFR will be estimated for each group and compared. As these are supportive analyses, no adjustments for multiplicity are planned. P-values will be used to provide guidance on the weight or the evidence of any observed effect.

9.3.4 Interim Analysis & IDMC

No interim analyses will be performed for efficacy or futility for the primary endpoint RFS unless otherwise requested by the independent data monitoring committee (IDMC). Following the Protocol Amendment 7, the first OS interim analysis will be performed at the same time as the revised final RFS analysis (i.e. at the cutoff date); an additional OS interim analysis will be performed when approximately 299 OS events have occurred; the final OS analysis remains to be conducted at approximately 597 events.
An IDMC will be chartered to review accumulating safety data to provide an opportunity to terminate the study early if there are concerns regarding safety. The IDMC will be convened after approximately 100 subjects have been randomized, and will review safety data at intervals specified in the IDMC Charter. The recommendations of the IDMC will be communicated and in the event of a recommendation to halt the trial early due to safety concerns to the appropriate regulatory agencies.

The IDMC responsibilities, review schedules and mechanism for communicating recommendations will be outlined in an IDMC charter.

9.3.5 Key Elements of Analysis Plan

Data will be listed and summarized according to reporting standards, where applicable. Complete details will be documented in the reporting and analysis plan (RAP). Any deviations from, or additions to, the original analysis plan described in this protocol will be documented in the RAP and final study report.

As it is anticipated that accrual will be spread thinly across centers and summaries of data by center would be unlikely to be informative, data from all participating centers will be pooled prior to analysis.

All data up to the time of study completion/withdrawal from study will be included in the analysis, regardless of duration of treatment.

As the duration of treatment for a given subject will depend on efficacy and tolerability, the duration of follow-up will vary between subjects. Consequently there will be no imputation for missing data.

Demographic and baseline characteristics will be summarized.

For the analysis of overall survival, the last date of known contact will be used for those subjects who have not died at the time of analysis; such subjects will be considered censored.

As noted in Section 9.3.3.2 there will be no adjustments for multiplicity.

All significance tests, unless otherwise noted, will be stratified by mutation type (V600E or V600K), and disease stage (IIIA, IIIB, IIIC) for a total of 6 strata.

Additional details on efficacy analyses are provided in Section 9.3.5.1. Similarly additional details on safety analyses are provided in Section 9.3.5.2.

9.3.5.1 Efficacy Analyses

9.3.5.1.1 Primary Analysis

If a subject has neither relapsed or died or started new anti-cancer therapy, then RFS will be censored at the date of last adequate assessment. If no post-baseline disease assessments exist, the subject will be censored at the date of randomization. In the primary analysis if a non-protocol anti-cancer therapy is started before the occurrence of a RFS event, then RFS will be censored at the last adequate assessment prior to the start of such therapy. Definition of “adequate assessment” and censoring rules will be detailed in the RAP.

RFS will be summarized using Kaplan-Meier estimates and compared between treatment arms using a stratified log-rank test. The Pike estimator [Bernstein, 1981, Berry, 1991] of the treatment hazard ratios (HR) will be provided, together with a 95% confidence
interval (CI). The Pike estimator, which is a nonparametric estimator of the HR, has been specifically developed for survival data and is used as a measure of the relative survival experience of two groups. Within the range of values of the ratio of the hazard rates of interest in clinical trials, Pike estimator is more efficient in terms of mean square error than the Cox proportional hazard method [Bernstein, 1981]. Median times to RFS, first and third quartiles will be presented, along with 95% CI if there are a sufficient number of relapses or deaths. A graph of RFS curves and a listing of RFS times will also be provided.

Following the final analysis of RFS, the study will remain open for further follow-up to collect additional survival and safety data. Updated safety and efficacy analyses may be performed at the close of the study.

**Sensitivity Analyses for RFS:**

Sensitivity analyses using the ITT population will be conducted in order to confirm the results of the primary analysis. Some key sensitivity analyses are provided below.

Additional sensitivity analyses will be defined in the RAP.

The following sensitivity analyses will be performed for RFS and will be detailed in the RAP:

- **RFS** regardless of start of new anticancer therapy prior to documented relapse. Namely, all RFS events will be included regardless of whether or not subsequent anticancer therapy was initiated prior to the event.

- **Cox** Regression analysis including baseline prognostic factors as covariates will be performed. Factors included in the model will be pre-specified in the RAP.

- **RFS Analysis ignoring new melanoma as an event.**

9.3.5.1.2 Secondary Analyses

OS will be estimated using the Kaplan Meier method and treatment comparisons, when performed, will be made using a stratified log-rank test (based on the two stratification factors defined in Section 9.2). All cause mortality will be used and censoring will be performed using the date of last known contact for those who are alive at the time of analysis. The hazard ratio along with 95% confidence intervals will be provided.

DMFS will be estimated using the Kaplan Meier method and treatment comparisons will be made using a log-rank test. The first appearance of distant metastasis or all cause mortality will be used as events. Censoring will be performed using the date of last assessment for those who are alive without distant metastasis at the time of analysis. The hazard ratio along with 95% confidence intervals will be provided.

FFR will be estimated using the Kaplan Meier method and treatment comparisons will be made using a log-rank test. The first appearance of local/distant metastasis or mortality due to disease recurrence or toxicity will be used as events. Censoring will be performed using the date of last assessment for those who are alive without local/distant metastasis or new primary melanoma at the time of analysis. FFR will be censored if patients died from causes other than melanoma or treatment-related toxicity at the date of death. The hazard ratio along with 95% confidence intervals will be provided.
Other efficacy analyses will be detailed in the RAP.

9.3.5.2 Safety Analyses

Safety endpoints are described in Section 2 and Section 7.3.

The Safety population will be used for the analysis of safety data. Complete details of the safety analyses will be provided in the RAP.

9.3.5.2.1 Extent of Exposure

The number of subjects administered study treatment will be summarized according to the duration of therapy.

9.3.5.2.2 Adverse Events

Adverse events (AEs) will be coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and grouped by system organ class. AEs will be graded by the investigator according to the NCI-CTCAE (version 4.0).

Events will be summarized by frequency and proportion of total subjects by system organ class and preferred term. Separate summaries will be given for all AEs, drug-related AEs, serious AEs and AEs leading to discontinuation of study treatment.

If the AE is listed in the NCI CTCAE (version 4.0) table, the maximum grade will be summarized.

Characteristics (e.g., number of occurrences, action taken, grade, etc.) of AEs of special interest (including SCC and other proliferative lesions) will be summarized separately as detailed in the RAP.

The incidence of deaths and the primary cause of death will be summarized.

9.3.5.2.3 Clinical Laboratory Evaluations

Hematology and clinical chemistry data will be summarized at each scheduled assessment according to NCI CTCAE grade (version 4.0). The proportion of values lying outside the reference range will also be presented for laboratory tests that are not graded because there are no associated NCI CTCAE criteria. Summaries will include data from scheduled assessments only, and all data will be reported according to the nominal visit date for which it was recorded (i.e., no visit windows will be applied). Unscheduled data will be included in “overall” and “any post-screening” summaries which will capture a worst case across all scheduled and unscheduled visits post first dose of study treatment. Further details will be provided in the RAP.

9.3.5.2.4 Other Safety Measures

The results of scheduled assessments of vital signs, ECOG performance status, 12-lead ECG, and ECHO will be summarized. Summaries will include data from scheduled assessments only. All data will be reported according to the nominal visit date for which it was recorded (i.e., no visit windows will be applied). Unscheduled data will be included in ‘worse case’ summaries which will capture a worst case across all scheduled and unscheduled visits after the first dose of study treatment. All data will be listed. Further details will be provided in the RAP.
9.3.5.3 Health Outcomes Analyses

Quality of life (QOL) will be assessed using the EQ-5D (Appendix 8). Changes in QOL from baseline as measured by the EQ-5D will be evaluated and compared between treatment groups using a repeated measures analysis of covariance. Analyses will be based on the ITT population.

The two scores from the EQ-5D will be estimated – the utility score calculated from the 5 domains using a scoring algorithm and the VAS score based on the 0-100 feeling thermometer. Changes from baseline will be summarized and, at specified time points of interest, differences between treatment groups for each defined score will be analyzed.

The calculation of scores and methods to deal with missing data will be handled according to the questionnaire’s standard scoring guidelines. Full details of all the health outcomes analyses will be provided in a separate RAP.

9.3.5.4 Pharmacokinetic Analyses

Concentrations of dabrafenib, its metabolites (hydroxy-, and desmethyl-dabrafenib; carboxy-dabrafenib may be assayed as needed), and trametinib will be summarized by cohort and nominal times (morning vs. afternoon sample).

The PK of dabrafenib and trametinib will be determined in the PK population using a non-linear mixed effects modeling approach. Population PK parameters including CL/F and V/F will be estimated along with relevant covariates that may influence exposure based on the existing population PK models. Depending on the final structure of the PK model, additional PK parameters may also be estimated. Prior population PK models for dabrafenib or trametinib will be used, at least as a starting point, to analyze concentration data from this study.

Population PK modeling will be performed using the non-linear mixed effects software NONMEM (Globomax LLC; Hanover, MD). Further details of population PK analyses will be described under a separate RAP. Results of the population PK analysis may be included in a report separate from the clinical study report.

9.3.5.5 Pharmacokinetic/Pharmacodynamic Analyses

If data warrant, exploratory analyses will be performed to examine the potential relationship between exposure and clinical endpoints such as RFS and other clinical/safety measures. Further details of pharmacokinetic/pharmacodynamic analyses will be described in a separate RAP.

9.3.5.6 Translational Research Analyses

The results of translational research investigations will be reported separately from the main clinical study report. All endpoints of interest from all comparisons will be descriptively and/or graphically summarized as appropriate to the data.

As data warrant, analyses will be performed to further characterize the subject population through analysis of tumor DNA, RNA, and protein, or other aberrations from tumor tissue, and to determine whether or not these are associated with clinical outcome in response to therapy.

Further details on the translational research analyses will be addressed in the RAP.
9.3.5.7 Pharmacogenetic Analyses

Further details on PGx analyses will be addressed in Appendix 9 and the RAP.

10 STUDY CONDUCT CONSIDERATIONS

10.1 Posting of Information on Publicly Available Clinical Trial Registers

Study information from this protocol will be posted on publicly available clinical trial registers before enrolment of subjects begins.

10.2 Regulatory and Ethical Considerations, Including the Informed Consent Process

Prior to initiation of a study site, the sponsor will obtain favorable opinion/approval from the appropriate regulatory agency to conduct the study in accordance with ICH Good Clinical Practice (GCP) and applicable country-specific regulatory requirements. The study will be conducted in accordance with all applicable regulatory requirements. The study will be conducted in accordance with ICH Good Clinical Practice (GCP), all applicable subject privacy requirements, and the ethical principles that are outlined in the Declaration of Helsinki 2008, including, but not limited to:

- Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and favorable opinion/approval of study protocol and any subsequent amendments.
- Subject informed consent.
- Investigator reporting requirements.

[Redacted] will provide full details of the above procedures, either verbally, in writing, or both.

Written informed consent must be obtained from each subject prior to participation in the study.

In approving the clinical protocol the IEC/IRB and, where required, the applicable regulatory agency are also approving the optional assessments e.g., PGx assessments described in Appendix 9, unless otherwise indicated. Where permitted by regulatory authorities, approval of the optional assessments can occur after approval is obtained for the rest of the study. If so, then the written approval will clearly indicate approval of the optional assessments is being deferred and the study, except for the optional assessments, can be initiated. When the optional assessments are not approved, then the approval for the rest of the study will clearly indicate this and therefore, the optional assessments will not be conducted.

10.3 Quality Control (Study Monitoring)

In accordance with applicable regulations, GCP, and [Redacted] procedures, [Redacted] personnel (or designated Clinical Research Organization [CRO]) will contact the site prior to the start of the study to review with the site staff the protocol, study requirements, and their responsibilities to satisfy regulatory, ethical, and [Redacted] requirements. When reviewing data collection procedures, the discussion will include identification,
agreement and documentation of data items for which the CRF will serve as the source document.

The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents and to allocate their time and the time to their staff to monitor to discuss findings and any issues. Monitoring visits will be conducted in a manner to ensure that the:

- Data are authentic, accurate, and complete.
- Safety and rights of subjects are being protected.
- Study is conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

10.4 Quality Assurance
To ensure compliance with GCP and all applicable regulatory requirements, [redacted] may conduct a quality assurance assessment and/or audit of the site records, and the regulatory agencies may conduct a regulatory inspection at any time during or after completion of the study. In the event of an assessment, audit or inspection, the investigator (and institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and to allocate their time and the time of their staff to discuss the conduct of the study, any findings/relevant issues and to implement any corrective and/or preventative actions to address any findings/issues identified.

10.5 Study and Site Closure
The study will be considered complete when approximately 70 percent of the total number of randomized subjects have died or are otherwise lost to follow-up, at which time an OS analysis will be performed.

Upon completion or termination of the study, the monitor will conduct site closure activities with the investigator or site staff (as appropriate), in accordance with applicable regulations, ICH GCP, and [redacted] Standard Operating Procedures. [redacted] reserves the right to temporarily suspend or terminate the study at any time for reasons including (but not limited to) safety issues, ethical issues, or severe noncompliance. If [redacted] determines that such action is required, [redacted] will discuss the reasons for taking such action with the investigator or head of the medical institution (where applicable). When feasible, [redacted] will provide advance notice to the investigator or head of the medical institution of the impending action.

If a study is suspended or terminated for safety reasons, [redacted] will promptly inform all investigators, heads of the medical institutions (where applicable), and/or institutions conducting the study. [redacted] will also promptly inform the relevant regulatory authorities of the suspension/termination along with the reasons for such action. Where required by applicable regulations, the investigator or head of the medical institution must inform the IRB/TEC promptly and provide the reason(s) for the suspension/termination.
10.6 Records Retention

Following closure of the study, the investigator or head of the medical institution (where applicable) must maintain all site study records (except for those required by local regulations to be maintained elsewhere) in a safe and secure location. The records must be easily accessible when needed (e.g., for an audit or regulatory inspection) and must be available for review in conjunction with assessment of the facility, supporting systems, and relevant site staff.

Where permitted by local laws/regulations or institutional policy, some or all of the records may be maintained in a format other than hard copy (e.g., microfiche, scanned, electronic); however, caution must be exercised before such action is taken. The investigator must ensure that all reproductions are legible and are a true and accurate copy of the original. In addition, they must meet accessibility and retrieval standards, including regeneration of a hard copy, if required. The investigator must also ensure that an acceptable back-up of the reproductions exists and that there is an acceptable quality control procedure in place for creating the reproductions.

Essential documents (written and electronic) should be retained for a period of not less than fifteen (15) years from the completion of the Clinical Trial unless the Sponsor provides written permission to dispose of them or, requires their retention for an additional period of time because of applicable laws, regulations and/or guidelines. The investigator must notify [REDACTED] of any changes in the archival arrangements, including, but not limited to archival of records at an off-site facility or transfer of ownership of the records in the event that the investigator is no longer associated with the site.

10.7 Provision of Study Results to Investigators, Posting of Information on Publicly Available Clinical Trials Registers and Publication

Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the clinical study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results at a site or other mutually-agreeable location.

[REDACTED] will also provide the investigator with the full summary of the study results. The investigator is encouraged to share the summary results with the study subjects, as appropriate.

[REDACTED] will provide the investigator with the randomization codes for their site only after completion of the full statistical analysis.

[REDACTED] aims to post a results summary to [REDACTED] other publicly available registers no later than twelve (12) months after the last subject’s last visit (LSLV). In addition, upon study completion and finalization of study report [REDACTED] aims to submit results of the study for publication.
10.8 Independent Data Monitoring Committee

An Independent Data Monitoring Committee (IDMC) will be utilized in this study to ensure external objective medical and/or statistical review of safety and/or efficacy issues in order to protect the ethical and safety interests of subjects and to protect the scientific validity of the study. The schedule and the analysis plan for IDMC review are described in the charter.
11 REFERENCES


Clinicaltrials.gov. EORTC18991, EORTC18071, DERMA, EORTC18552, ECOG1690, AVAST-M, GO27826. 25 May 2012.


# APPENDICES

## 12.1 Appendix 1: Melanoma of the Skin Staging

![Melanoma of the Skin Staging](image)

### Definitions

**Primary Tumor (T)**
- **TX**: Primary tumor cannot be assessed (for example, coregaged or severely regressed melanoma)
- **T0**: No evidence of primary tumor
- **Tis**: Melanoma in situ
- **T1**: Melanomas 1.0 mm or less in thickness
- **T2**: Melanomas 1.01–2.0 mm
- **T3**: Melanomas 2.01–4.0 mm
- **T4**: Melanomas more than 4.0 mm

**Regional Lymph Nodes (N)**

- **N0**: No regional metastases detected
- **N1**: Regional metastases detected based on the number of metastatic nodes and presence or absence of distant metastases.

**Distant Metastasis (M)**

- **M0**: No detectable evidence of distant metastases
- **M1a**: Metastases to skin, subcutaneous, and/or distant lymph nodes
- **M1b**: Metastases to lung
- **M1c**: Metastases to other visceral sites or distant metastases to any site combined with an elevated serum LDH

### Staging System

**ANATOMIC STAGE/PROGNOSTIC GROUPS**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical Staging</th>
<th>Pathologic Staging</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1a N0 M0</td>
<td>IA T1a N0 M0</td>
</tr>
<tr>
<td>IB</td>
<td>T1b N0 M0</td>
<td>IB T1b N0 M0</td>
</tr>
<tr>
<td>IIA</td>
<td>T1b N0 M1a</td>
<td>IIA T1b N0 M1a</td>
</tr>
<tr>
<td>IIB</td>
<td>T1b N0 M1b L0</td>
<td>IIB T1b N0 M1b L0</td>
</tr>
<tr>
<td>IIC</td>
<td>T1b N0 M1c</td>
<td>IIc T1b N0 M1c</td>
</tr>
<tr>
<td>III</td>
<td>Any T N0 M1</td>
<td>III Any T N0 M1</td>
</tr>
<tr>
<td>IV</td>
<td>Any T Any N M1</td>
<td>IV Any T Any N M1</td>
</tr>
</tbody>
</table>

### Notes

1. Microstaging is defined as the smallest lymph node in a lymph node dissection that contains metastases.
2. All other measurable nodes are considered to be involved with metastases.
3. Clinical staging includes microstaging of the primary melanoma and Dukesesonomic staging for metastases. By convention, this should be used for cases with no involvement of nodes.
4. Pathologic staging includes microstaging of the primary melanoma and Dukesesonomic staging for metastases. By convention, this should be used for complete or partial cases with no involvement of nodes.

12.2 Appendix 2: Surgical Guidelines

Management of the primary

Wide excision with a minimal 1 cm margin surrounding the primary lesion or biopsy scar will be required. For lesions with Breslow’s thickness >2 mm, a 2 cm margin is preferred only when anatomically feasible (i.e., for lesions of the trunk and proximal extremities). On other sites narrower margins are recommended to avoid mutilation. For subungual melanoma, a distal interphalangeal amputation with histologically negative margins constitutes an adequately wide excision. The specimen should be excised to include skin and all subcutaneous tissue down to the muscular fascia. Inclusion of the fascia is not recommended, but fascia may be included at the discretion of the operating surgeon. Closure of the defect may be via primary closure, split thickness skin graft, or rotation flap at the discretion of the surgeon.

Completion Lymph node dissection (CLND)

Patients should have a complete lymphadenectomy with no clinical or radiographic evidence of regional node disease remaining.

Specific considerations apply to the following drainage areas [Garbe, 2008]:

Head and Neck
- Radical or modified radical neck dissection is required
- Parietal/frontal regions (excluding chin and neck) – include superficial parotoidectomy
- Dorsal regions – include retroauricular and occipital lymph nodes

Axilla
- Level I and II lymph nodes
- Level III lymph nodes medial to lesser pectoralis (note: muscle may need to be removed if lymph nodes are extensively involved)

Inguinal
- Dissection should extend from femoral triangle and lower abdominal rectus from the pubic tubercle to the anterior iliac crest (including saphenous foramen and inguinal ligament and removal of saphenous vein if no contraindications)
- Include iliac lymph nodes if clinically positive (including Cloquet’s node) to level of iliac bifurcation, along with obturator lymph nodes

Reference:
### Appendix 3: Eastern Cooperative Oncology Group (ECOG) Performance Status

<table>
<thead>
<tr>
<th>Activity Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction.</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.</td>
</tr>
<tr>
<td>5</td>
<td>Dead.</td>
</tr>
</tbody>
</table>

Reference:
12.4 Appendix 4: Cockcroft-Gault Formula

To determine eligibility for the study, investigators should calculate a subject’s creatinine clearance by the Cockcroft-Gault formula as follows [Cockcroft, 1976]:

\[
\text{CrCl for males (mL/min)} = \frac{(140 - \text{age [years]}) \times \text{(weight [kg])}}{72 \times \text{(serum creatinine [mg/dL])}}
\]

\[
\text{CrCL for females (mL/min)} = \frac{0.85 \times (140 - \text{age [years]}) \times \text{(weight [kg])}}{72 \times \text{(serum creatinine [mg/dL])}}
\]

For SI units:

\[
\text{CrCl for males (mL/min)} = \frac{(140 - \text{age [years]}) \times \text{(weight [kg])} \times 1.23}{\text{(serum creatinine [\mu mol/L])}}
\]

\[
\text{CrCL for females (mL/min)} = \frac{(140 - \text{age [years]}) \times \text{(weight [kg])} \times 1.05}{\text{(serum creatinine [\mu mol/L])}}
\]

CrCl = creatinine clearance; SI = Système International d’Unités.

Reference:

12.5 Appendix 5: QT interval on electrocardiogram corrected using the Bazett’s formula (QTcB)

Bazett's formula used to correct QT interval for heart rate is:

\[ QTcB = \frac{QT}{\sqrt{RR}} \]

where QTcB is the QT interval corrected for heart rate, RR is the interval from the onset of one QRS complex to the onset of the next QRS complex, measured in seconds, often derived from the heart rate (HR) as 60/HR, and QT is the QT interval measured in milliseconds.

Reference:
### 12.6 Appendix 6: New York Heart Association (NYHA) Guidelines

The New York Heart Association Functional Classification provides a simple way of classifying the extent of heart failure [The Criteria Committee of the New York Heart Association, 1994]. It places subjects in 1 of 4 categories based on the level of limitation experienced during physical activity:

<table>
<thead>
<tr>
<th>Functional Capacity</th>
<th>Objective Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class I:</strong> Subjects with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.</td>
<td><strong>A:</strong> No objective evidence of cardiovascular disease.</td>
</tr>
<tr>
<td><strong>Class II:</strong> Subjects with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.</td>
<td><strong>B:</strong> Objective evidence of minimal cardiovascular disease.</td>
</tr>
<tr>
<td><strong>Class III:</strong> Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.</td>
<td><strong>C:</strong> Objective evidence of moderately severe cardiovascular disease.</td>
</tr>
<tr>
<td><strong>Class IV:</strong> Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</td>
<td><strong>D:</strong> Objective evidence of severe cardiovascular disease.</td>
</tr>
</tbody>
</table>

**Reference:**

12.7 Appendix 7: Liver Chemistry Monitoring, Interruption Stopping and Follow-up Criteria

### Phase III-IV Liver Safety Algorithms

- **ALT > 3xULN**: Continue IP. Obtain twice monthly liver chemistries until normalised or back to baseline values.
- **ALT < 3xULN + bilirubin < 2xULN after ≤ 4 wks?**
  - Yes: Notify NVS within 24h to discuss subject safety. Continue IP. Check liver chemistry weekly for 4 weeks. Able to monitor weekly for 4 weeks?
    - Yes: Able to monitor weekly for 4 weeks.
    - No: Notify NVS within 24h to discuss subject safety. Continue IP. Check liver chemistry weekly for 4 weeks.
  - No: ALT > 3xULN but ≤ 5xULN or hepatocellular symptoms or rash?
    - Yes: Continue IP. Check liver chemistry weekly for 4 weeks. Able to monitor weekly for 4 weeks?
      - Yes: Able to monitor weekly for 4 weeks.
      - No: Notify NVS within 24h to discuss subject safety. Continue IP. Check liver chemistry weekly for 4 weeks.
    - No: ALT > 3xULN but > 5xULN or bilirubin < 5xULN or no symptoms.
      - Yes: INR value not applicable to patients on anticoagulants. INR value not applicable to patients on anticoagulants.
      - No: INR value not applicable to patients on anticoagulants.

- **ALP > 2xULN**
  - Yes: Notify NVS within 24h to discuss subject safety. Continue IP. Check liver chemistry weekly for 4 weeks. Able to monitor weekly for 4 weeks?
    - Yes: Able to monitor weekly for 4 weeks.
    - No: Notify NVS within 24h to discuss subject safety. Continue IP. Check liver chemistry weekly for 4 weeks.
  - No: ALT > 3xULN but ≤ 5xULN or hepatocellular symptoms or rash?
    - Yes: Continue IP. Check liver chemistry weekly for 4 weeks. Able to monitor weekly for 4 weeks?
      - Yes: Able to monitor weekly for 4 weeks.
      - No: Notify NVS within 24h to discuss subject safety. Continue IP. Check liver chemistry weekly for 4 weeks.
    - No: ALT > 3xULN but > 5xULN or bilirubin < 5xULN or no symptoms.
      - Yes: INR value not applicable to patients on anticoagulants. INR value not applicable to patients on anticoagulants.
      - No: INR value not applicable to patients on anticoagulants.

- **INR**
  - Yes: INR value not applicable to patients on anticoagulants.
  - No: INR value not applicable to patients on anticoagulants.

**IP may be re-challenged if protocol provides this option.**
12.8 Appendix 8: Health-related Quality of Life (HRQoL) Questionnaire

EQ-5D-3L Health Questionnaire

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

**Mobility**

- I have no problems in walking about
- I have some problems in walking about
- I am confined to bed

**Self-Care**

- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself

**Usual Activities** (e.g. work, study, housework, family or leisure activities)

- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities

**Pain/Discomfort**

- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort

**Anxiety/Depression**

- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed

US (English) © 1998 EuroQol Group. EQ-5D is a trade mark of the EuroQol Group
US (English) © 1998 EuroQol Group. EQ-5D is a trade mark of the EuroQol Group
To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.
12.9 Appendix 9: Pharmacogenetic Research

**PHARMACOGENETICS – BACKGROUND**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Function</th>
<th>Impact on Drug Response</th>
<th>Example Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C19</td>
<td>Metabolizing enzyme</td>
<td>Increased metabolite formation</td>
<td>Clopidogrel</td>
</tr>
<tr>
<td>VKORC1</td>
<td>Coagulation factor</td>
<td>Reduced warfarin sensitivity</td>
<td>Warfarin</td>
</tr>
<tr>
<td>HLA-B*5701</td>
<td>Drug transporter</td>
<td>Increased risk of Stevens-Johnson syndrome</td>
<td>lamotrigine</td>
</tr>
</tbody>
</table>

*Note: This table is a simplified representation of pharmacogenetic relevance.*
12.10 Appendix 10: Country Specific Requirements

Not Applicable.
12.11 Appendix 11: Protocol Changes for Amendment 01

AMENDMENT NUMBER 01
This amendment is applicable to all investigational study sites in all countries.

ADMINISTRATIVE REVISIONS AS FOLLOWS:
Corrected the numbering of the exclusion criteria.
Replaced “Ouellet, Danielle” as an author with “Stuttle, Ben”.

SECTION 2 OBJECTIVES AND ENDPOINTS

Previous:
Relapse Free Survival (RFS), defined as the time from randomization to disease recurrence or death from any cause. Recurrence of or death from the same cancer and all deaths from other causes are events. Treatment emergent malignancy(ies) other than second melanomas will not be considered as events, and loss to follow-up is censored. Patients without RFS events will be censored at the last assessment.

Revised:
Relapse Free Survival (RFS), defined as the time from randomization to disease recurrence or death from any cause. Recurrence of or death from the same cancer and all deaths from other causes are events. Treatment emergent malignancy(ies) other than second melanomas will not be considered as events, and loss to follow-up is censored. Patients without RFS events will be censored at the last adequate assessment.

DEFINITION OF STUDY COMPLETION AND TIMING FOR FINAL OS ANALYSIS THROUGOUT THE DOCUMENT

Previous:
The study will be considered complete, and the final OS analysis will be conducted when approximately 70% of the total number of randomized subjects have died or are otherwise lost to follow-up.

Revised:
The study will be considered complete, and the final OS analysis will be conducted when approximately 70% of the total number of randomized subjects have died (i.e. 597 deaths).

SECTION 4.1.2 INCLUSION CRITERIA

Previous:
3. Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis >1 mm), IIIb or IIIc; refer to Appendix 1 for Staging Guidelines] cutaneous melanoma determined to be V600E/K mutation positive using the bioMerieux (bMX) investigational use only (IUO) THxID BRAF Assay (ID: G120011). The testing will be conducted by a central reference laboratory.

Revised:
3. Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis >1 mm), IIIb or IIIc; refer to Appendix 1 for Staging Guidelines] cutaneous melanoma determined to be V600E/K mutation positive using the bioMerieux (bMX) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The testing will be conducted by a central reference laboratory. **Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.**

**Reason for change:** Provide further clarity on eligible patient population.

**Previous:**

10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in Section 7.3.3 from **14 days prior to randomization**, throughout the treatment period and for **6 months** after the last dose of study treatment.

**Revised:**

10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in Section 7.3.3 from the **day of randomization**, throughout the treatment period and for **16 weeks** after the last dose of study treatment.

**Reason for change:** Updated to reflect current safety requirements for the combination and align with other combination studies.

**SECTION 4.1.3 EXCLUSION CRITERIA**

**Previous:**

12. History of another malignancy or a concurrent malignancy including prior malignant melanoma.

**Revised:**

12. History of another malignancy including melanoma or a concurrent malignancy except as noted below.

**Reason for change:** Provide additional clarity.

**SECTION 5.2 DOSAGE AND ADMINISTRATION**

**Previous:**

Subjects should abstain from ingestion of any food or drink containing grapefruit and grapefruit juice, Seville oranges, or pommelos within **7 days** prior to randomization until treatment discontinuation, as these have been shown to inhibit CYP3A4 activity.

**Revised:**

Subjects should abstain from ingestion of any food or drink containing grapefruit and grapefruit juice, Seville oranges, or pommelos within **24 hours** prior to randomization until treatment discontinuation, as these have been shown to inhibit CYP3A4 activity.

**Reason for change:** Updated as per new information.

**SECTION 5.8.2 DOSE MODIFICATION FOR GENERAL TOXICITIES**

**Previous:**

General guidelines regarding management and dose reduction for adverse events that are considered by the investigator to be related to study treatment and for which specific
guidelines do not apply are provided in Table 3. These guidelines are intended primarily for toxicities not easily managed with routine supportive care. For example, alopecia is not an indication for dose modification, nor is grade 2 nausea and vomiting that can be easily managed with anti-emetics.

Revised:
General guidelines regarding management and dose reduction for adverse events that are considered by the investigator to be related to study treatment and for which specific guidelines do not apply are provided in Table 3. These guidelines are intended primarily for non-hematological toxicities not easily managed with routine supportive care. For example, alopecia is not an indication for dose modification, nor is grade 2 nausea and vomiting that can be easily managed with anti-emetics.
SECTION 5.8.2 DOSE MODIFICATION FOR GENERAL TOXICITIES

Previous:

TABLE 3 DOSE MODIFICATION GUIDELINES - GENERAL

<table>
<thead>
<tr>
<th>CTCAE Grade</th>
<th>Action and Dose Modification(^a)(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 or Grade 2 (tolerable)</td>
<td>Continue study treatments at same dose level (no dose modification)</td>
</tr>
<tr>
<td>Grade 2 (Intolerable)</td>
<td></td>
</tr>
<tr>
<td>1(^{st}) or 2(^{nd}) occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at same dose level</td>
</tr>
<tr>
<td>3(^{rd}) or occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at next lower dose level</td>
</tr>
<tr>
<td>4(^{th}) or greater occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at two dose levels lower than the starting dose or discontinue treatments per investigator discretion</td>
</tr>
<tr>
<td>Grade 3</td>
<td></td>
</tr>
<tr>
<td>1(^{st}) occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at same dose level</td>
</tr>
<tr>
<td>2(^{nd}) occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at next lower dose level</td>
</tr>
<tr>
<td>3(^{rd}) occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at two dose levels lower than the starting dose</td>
</tr>
<tr>
<td>4(^{th}) occurrence</td>
<td>Discontinue treatments</td>
</tr>
<tr>
<td>Grade 4</td>
<td></td>
</tr>
<tr>
<td>1(^{st}) occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at next lower dose level or discontinue at discretion of investigator</td>
</tr>
<tr>
<td>2(^{nd}) occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at two dose levels lower than the starting dose or discontinue at discretion of investigator and after discussion with the medical monitor.</td>
</tr>
<tr>
<td>3(^{rd}) occurrence</td>
<td>Discontinue treatments</td>
</tr>
</tbody>
</table>

\(^a\) Treatments should be discontinued if more than 2 dose reductions are required

\(^b\) Approval from the Medical Monitor is required to restart study treatments after ≥21 days interruption
**TABLE 3 DOSE MODIFICATION GUIDELINES - GENERAL**

<table>
<thead>
<tr>
<th>CTCAE Grade</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 or Grade 2 (tolerable)</td>
<td>Continue study treatments at same dose level (no dose modification)</td>
</tr>
<tr>
<td>Grade 2 (Intolerable)</td>
<td></td>
</tr>
<tr>
<td>1st or 2nd occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at same dose level</td>
</tr>
<tr>
<td>3rd or occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at next lower dose level</td>
</tr>
<tr>
<td>4th or greater occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 then restart at two dose levels lower than the starting dose or discontinue treatments per investigator discretion</td>
</tr>
<tr>
<td>Grade 3</td>
<td></td>
</tr>
<tr>
<td>1st occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at next lower dose level</td>
</tr>
<tr>
<td>2nd occurrence</td>
<td>Interrupt study treatments until toxicity resolves to ≤ grade 1 or baseline then restart at two dose levels lower than the starting dose.</td>
</tr>
<tr>
<td>3rd occurrence</td>
<td>Discontinue treatments</td>
</tr>
<tr>
<td>Grade 4</td>
<td></td>
</tr>
<tr>
<td>1st occurrence</td>
<td>Discontinue treatments</td>
</tr>
</tbody>
</table>

a. Treatments should be discontinued if more than 2 dose reductions are required
b. Approval from the Medical Monitor is required to restart study treatments after ≥21 days interruption
c. These guidelines are intended for non-hematological toxicities not easily managed with routine supportive care (see above).

---

**SECTION 5.8.3.1 PYREXIA**

*Previous:*
Pyrexia has been observed in subjects receiving dabrafenib, either as monotherapy or in combination with trametinib. In a minority of cases pyrexia was accompanied by symptoms such as severe chills, dehydration, hypotension, dizziness or weakness and required hospitalization.

Subjects should be instructed on the importance of immediately reporting febrile episodes. In the event of a fever, the subject should be instructed to take non-steroidal anti-pyretics as appropriate to control fever. In subjects experiencing pyrexia associated with rigors, severe chills, dehydration, hypotension, renal function should be monitored carefully (see Section 5.8.2).
Pyrexia accompanied by hypotension, dehydration requiring IV fluids, or severe rigors/chills should be reported as an SAE (Section 7.3.2.2).

Guidelines regarding management and dose reduction for pyrexia considered to be related to dabrafenib are provided in Table 4. Pyrexia is defined as a body temperature equal to or above 38.5°C Celsius or 101.3°F Fahrenheit. Trametinib dose modification is not required.

**TABLE 4 MANAGEMENT AND DOSE MODIFICATION GUIDELINES FOR PYREXIA**

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Any            | Clinical evaluation for infection and hypersensitivity\(\text{a}\)  
Laboratory work-up\(\text{c}\)  
Hydration as required\(\text{d}\)  
Blood sample for cytokine analysis\(\text{a}\) |
| 1\textsuperscript{st} Event\(\text{b}\) | Administer anti-pyretic treatment if clinically indicated\(\text{d}\)  
**Interrupt dabrafenib**  
Continue trametinib or placebo  
Once pyrexia resolves to baseline, restart dabrafenib at the same dose level  
• If fever was associated with dehydration, hypotension, or renal insufficiency, reduce dabrafenib by one dose level |
| 2\textsuperscript{nd} Event\(\text{b}\) | Same as for 1\textsuperscript{st} event, and  
• Consider oral corticosteroids (i.e., prednisone 10 mg) for at least 5 days or as clinically indicated\(\text{d}\) |
| Subsequent Events: | **Interrupt dabrafenib**  
Continue trametinib or placebo  
• Once pyrexia resolves to baseline, **restart dabrafenib (consider dose reduction by one level)**\(\text{b}\) Optimize oral corticosteroid dose as clinically indicated for recalcitrant pyrexia\(\text{a}\)  
• If corticosteroids have been tapered and pyrexia recurs, restart steroids  
• If corticosteroids cannot be tapered or escalating doses are required, consult medical monitor |

BUN = blood urea nitrogen; CRP = C-reactive protein

\[\begin{align*}
\text{a.} & \text{ Pyrexia is defined as a body temperature equal to or above } 38.5^\circ \text{Celsius or } 101.3^\circ \text{Fahrenheit.} \\
\text{b.} & \text{ For subjects experiencing pyrexia complicated by rigors, severe chills, etc., a clinical evaluation and laboratory work-up is mandatory for each event; anti-pyretic treatment should be started immediately at the first occurrence and prophylactic anti-pyretic treatment is recommended when restarting after an interruption.} \\
\text{c.} & \text{ Thorough clinical examination for signs and symptoms of infection or hypersensitivity is required; laboratory work-up should include full-blood-count, electrolytes, creatinine, BUN, CRP, liver-function tests, blood culture, and urine culture.} \\
\text{d.} & \text{ Oral hydration should be encouraged in subjects without evidence of dehydration. Intravenous hydration is recommended in subjects experiencing pyrexia complicated by dehydration/hypotension.} \\
\text{e.} & \text{ Blood sample for cytokine analysis must be sent to the central laboratory.}
\end{align*}\]
f. Anti-pyretic treatment may include acetaminophen (paracetamol), ibuprofen, or suitable anti-pyretic medication according to institutional standards. Prophylactic anti-pyretic treatment may be discontinued after three days in the absence of pyrexia.

g. In subjects experiencing pyrexia complicated by rigors, severe chills, etc., which cannot be controlled with anti-pyretic medication, oral corticosteroids should be started at the 2nd event and doses should be gradually increased for subsequent events.

h. Dabrafenib should be reduced by one dose level at discretion of the investigator if pyrexia is accompanied by severe recurring rigors which cannot be managed by best supportive care, including increasing doses of oral steroids. Re-escalation of dabrafenib is allowed if no episode of pyrexia is observed in the 4 weeks subsequent to dose reduction.

Revised:

Pyrexia has been observed in subjects receiving dabrafenib, either as monotherapy or in combination with trametinib. In a minority of cases pyrexia was accompanied by symptoms such as severe chills, dehydration, hypotension, dizziness or weakness and required hospitalization.

Subjects should be instructed on the importance of immediately reporting febrile episodes. In the event of a fever, the subject should be instructed to take non-steroidal anti-pyretics (e.g. ibuprofen) as appropriate to control fever. Subjects experiencing pyrexia associated with rigors, severe rigors/chills, dehydration, hypotension, or renal function should be monitored carefully and oral corticosteroids should be started after the event resolves (see Table 4).

Pyrexia accompanied by hypotension, dehydration requiring IV fluids, renal insufficiency, or severe rigors/chills in the absence of an obvious infectious cause should be reported as an SAE (Section 7.3.2.2).

Guidelines regarding management and dose reduction for pyrexia considered to be related to dabrafenib are provided in Table 4. Pyrexia is defined as a body temperature equal to or above 38.0°C Celsius or 100.4°F Fahrenheit.

Trametinib dose modification is not required for pyrexia.
# TABLE 4 MANAGEMENT AND DOSE MODIFICATION GUIDELINES FOR PYREXIA\textsuperscript{A,B}

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Any        | Clinical evaluation for infection and hypersensitivity\textsuperscript{c}  
Laboratory work-up\textsuperscript{e}  
Hydration as required\textsuperscript{d}  
Blood sample for cytokine analysis\textsuperscript{g} |
| 1\textsuperscript{st} Event\textsuperscript{f} | Administer anti-pyretic treatment if clinically indicated\textsuperscript{i}  
Interrupt dabrafenib  
Continue trametinib or placebo  
Once pyrexia resolves to baseline, restart dabrafenib at the same dose level  
- If fever was associated with dehydration, hypotension, or renal insufficiency, reduce dabrafenib by one dose level and begin oral corticosteroids (prednisone 10 mg or equivalent) for at least 5 days or as clinically indicated\textsuperscript{e} |
| 2\textsuperscript{nd} Event\textsuperscript{g} | Same as for 1\textsuperscript{st} event, and  
- Consider oral corticosteroids (i.e., prednisone 10 mg) for at least 5 days or as clinically indicated\textsuperscript{i} |
| Subsequent Events: | Interrupt dabrafenib  
Continue trametinib or placebo  
- Once pyrexia resolves to baseline, restart dabrafenib (consider dose reduction by one level)\textsuperscript{h}  
Optimize oral corticosteroid dose as clinically indicated for recalcitrant pyrexia\textsuperscript{d}  
- If corticosteroids have been tapered and pyrexia recurs, restart steroids  
- If corticosteroids cannot be tapered or escalating doses are required, consult medical monitor |

BUN = blood urea nitrogen; CRP = C-reactive protein

a. Pyrexia is defined as a body temperature equal to or above 38.0\textdegree Celsius or 100.4\textdegree Fahrenheit.
b. For subjects experiencing pyrexia complicated by severe rigors/chills, etc., a clinical evaluation and laboratory work-up is mandatory for each event; anti-pyretic treatment should be started immediately at the first occurrence and prophylactic oral corticosteroids are recommended when restarting dabrafenib.
c. Thorough clinical examination for signs and symptoms of infection or hypersensitivity is required; laboratory work-up should include full-blood-count, electrolytes, creatinine, BUN, CRP, liver-function tests, blood culture, and urine culture.
d. Oral hydration should be encouraged in subjects without evidence of dehydration. Intravenous hydration is recommended in subjects experiencing pyrexia complicated by dehydration/hypotension.
e. Blood sample for cytokine analysis must be sent to the central laboratory.
f. Anti-pyretic treatment may include acetaminophen (paracetamol), ibuprofen, or suitable anti-pyretic medication according to institutional standards. Ibuprofen is preferred and the maximum recommended daily dose of acetaminophen should not be exceeded to reduce risk of liver toxicity. Prophylactic anti-pyretic treatment may be discontinued after three days in the absence of pyrexia.
g. In subjects experiencing pyrexia complicated by severe rigors/chills, etc., which cannot be controlled with anti-pyretic medication, oral corticosteroids should be started after the 1\textsuperscript{st} event and doses should be gradually increased for subsequent events.
h. Dabrafenib should be reduced by one dose level at discretion of the investigator if pyrexia is accompanied by severe recurring rigors which cannot be managed by best supportive care, including increasing doses of oral steroids. Re-escalation of dabrafenib is allowed if no episode of pyrexia is observed in the 4 weeks subsequent to dose reduction.

**REASON FOR CHANGE: REVISED TO INCLUDE CORTICOSTEROID AND IBUPROFEN GUIDANCE. SECTION 5.8.3.2 VISUAL CHANGES**

**Previous:**
Disorders associated with visual disturbances, including Central Serous Retinopathy (CSR) and Retinal Vein Occlusion (RVO) have been observed with trametinib. Symptoms such as blurry vision, decreased acuity, and other visual phenomena have been reported in the clinical trials with trametinib. Adequate ophthalmologic evaluations should be performed according to the Time and Events Table (Table 9). Additional ophthalmic exams will be performed only as symptomatically warranted. If patients report visual disturbances at any time while on trametinib therapy, additional ophthalmologic evaluation should be undertaken. If a retinal abnormality is diagnosed, follow the dose modification schedule in Table 5. In patients who experience retinal vein occlusion, treatment with trametinib should be permanently discontinued.

**TABLE 5 MANAGEMENT AND DOSE MODIFICATION GUIDELINES FOR VISUAL CHANGES**

<table>
<thead>
<tr>
<th>Gradea</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Grade</td>
<td>Blood sample for pharmacokinetics analysis must be drawn as close as possible to the time of the event.</td>
</tr>
<tr>
<td>Grade 1 or Grade 2 (Tolerable)</td>
<td>Continue treatment and monitor as clinically indicated</td>
</tr>
<tr>
<td>Grade 2 (Intolerable) or Grade 3</td>
<td><strong>Interrupt trametinib until toxicity is Grade 0-1 and reduce trametinib by one dose level when resuming therapy.</strong></td>
</tr>
<tr>
<td>Grade 4</td>
<td>Trametinib must be permanently discontinued.</td>
</tr>
</tbody>
</table>

a. Refer to NCI-CTCAE v 4.0 for grading of visual changes.

**Revised:**
Disorders associated with visual disturbances, including Central Serous Retinopathy (CSR) and Retinal Vein Occlusion (RVO) have been observed with trametinib. Symptoms such as blurry vision, decreased acuity, and other visual phenomena have been reported in the clinical trials with trametinib. Adequate ophthalmologic evaluations should be performed according to the Time and Events Table (Table 10). Additional ophthalmic exams must be performed if patients report visual disturbances at any time while on trametinib therapy. If a retinal abnormality is diagnosed, follow the dose modification schedule in Table 5. In patients who experience retinal vein occlusion, treatment with trametinib should be permanently discontinued.
TABLE 5 MANAGEMENT AND DOSE MODIFICATION GUIDELINES FOR VISUAL CHANGES

<table>
<thead>
<tr>
<th>Grade*</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Grade</td>
<td>Blood sample for pharmacokinetics analysis must be drawn as close as possible to the time of the event.</td>
</tr>
<tr>
<td>Grade 1</td>
<td>Continue treatment and monitor as clinically indicated</td>
</tr>
<tr>
<td>Grade 2 or Grade 3</td>
<td>Interrupt trametinib. Refer subject for ophthalmologic evaluation. Once toxicity is Grade 0-1 reduce trametinib by one dose level when resuming therapy.</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Trametinib must be permanently discontinued.</td>
</tr>
</tbody>
</table>

a. Refer to NCI-CTCAE v 4.0 for grading of visual changes.

SECTION 5.8.3.3.1 DECREASED LEFT VENTRICULAR EJECTION FRACTION (LVEF)

Previous:
Trametinib should be interrupted if an absolute decrease of >10% from baseline occurs and the ejection fraction is below the institutional LLN and these subjects should have a repeat evaluation of LVEF within 2 weeks. Trametinib can be restarted at a reduced dose if LVEF recovers (defined as ≥LLN and absolute decrease ≤ 10% compared to baseline) within 4 weeks after consultation and approval of the GSK medical monitor. For such subjects, monitoring of LVEF will then be performed 2 and 4 weeks after restarting treatment with trametinib, then every 4 weeks thereafter for 12 weeks and then every 3 months thereafter. Trametinib should be permanently discontinued and cardiac consultation obtained if LVEF does not recover within 4 weeks or if the patient is symptomatic. Ejection fraction should continue to be monitored at 2 weeks, at 4 weeks, then every 4 weeks for 16 weeks or until resolution. Subjects with a CTCAE Grade 3 or 4 left ventricular cardiac dysfunction must permanently discontinue treatment with trametinib. Evaluation by a cardiologist should be considered. Ejection fraction should continue to be monitored at 2 weeks, at 4 weeks, then every 4 weeks for 16 weeks or until resolution. Similar precautions should be followed for dabrafenib if LVEF remains depressed despite discontinuation of trametinib, and discussion with the medical monitor is recommended.
Revised:
Decreases of the left-ventricular-ejection-fraction (LVEF) have been observed in subjects receiving trametinib monotherapy and with trametinib in combination with dabrafenib. Therefore, ECHOs must be performed to assess cardiac ejection fraction at regular intervals as outlined in the Time and Events Table (Table 10). All ECHOs will be collected; instructions are provided in the Study Procedures Manual (SPM). Dose modification guidance and stopping criteria for LVEF decrease are provided in Table 6.

**TABLE 6  DOSE MODIFICATION GUIDELINES AND STOPPING CRITERIA FOR LVEF DECREASE**

<table>
<thead>
<tr>
<th>Clinic</th>
<th>LVEF-drop (%) or CTCAE grade</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic</td>
<td>Absolute decrease of &gt;10% in LVEF compared to baseline and ejection fraction below the institution’s low LLN</td>
<td>• Interrupt study treatment and repeat ECHO within 2 weeks&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• If the LVEF recovers within 4 weeks (defined as LVEF ≥ LLN and absolute decrease ≤ 10% compared to baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Consult with the GSK medical monitor and request approval for restart</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Restart with trametinib reduced by one dose level</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Restart dabrafenib at previous dose level</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Repeat ECHO 2, 4, 8 and 12 weeks after re-start; continue in intervals of 12 weeks thereafter</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• If repeat LVEF does not recover within 4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Consult with cardiologist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Permanently discontinue trametinib</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Consult with medical monitor</td>
</tr>
<tr>
<td>Symptomatic</td>
<td>Grade 3: resting LVEF 39-20% or &gt;20% absolute reduction from baseline</td>
<td>• Permanently discontinue study treatment.</td>
</tr>
<tr>
<td></td>
<td>Grade 4: resting LVEF &lt;20%</td>
<td>• Consult with cardiologist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution</td>
</tr>
</tbody>
</table>

CTCAE = Common Terminology Criteria for Adverse Events; ECHO = echocardiogram; LLN = lower limit of normal; LVEF = left ventricular ejection fraction;
<sup>a</sup> If ECHO does not show LVEF recovery after 2 weeks, repeat ECHO 2 weeks later.
<sup>b</sup> Symptoms may include: dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.
<sup>c</sup> Once LVEF recovers, restarting dabrafenib monotherapy can be considered in consultation with GSK medical monitor.
Reason for change: Revised to maintain consistency with other dabrafenib and trametinib combination therapy protocols.

SECTION 5.9.1.2 LIVER CHEMISTRY MONITORING CRITERIA

Previous:
For subjects with ALT □3xULN but <8xULN which exhibit a decrease to ALT □3xULN, but <5xULN and bilirubin <2xULN, without hepatitis symptoms or rash, and who can be monitored weekly for 4 weeks, the following actions should be taken:

Revised:
For subjects with ALT ≥3xULN but <8xULN which exhibit a decrease to ALT ≥3xULN, but <5xULN and bilirubin <2xULN, without hepatitis symptoms or rash, and who can be monitored weekly for 4 weeks, the following actions should be taken:

Reason for change: Typographical correction to include the appropriate symbol.

TABLE 10 (FORMERLY TABLE 9) TIME AND EVENTS TABLE – SCREENING AND TREATMENT

Changes and Reason for Change:
Visit window of ±7 days for Month 1 to Month 12 visits changed to ±3 days to accommodate drug supply dispensing. This change was made, where applicable, throughout the document.

Added PK sample in a subset of subjects at Month 1 to align with cytokine and biomarkers of pyrexia sample collection. Added the following instruction to Footnote 24 to provide additional clarity on timing of predose PK sample: “within 8 to 14 hours after the previous dose”.

Added a line and corresponding footnote (footnote # 28) for tumor tissue sample for biomarker research collection at the time of disease recurrence to accommodate relapses during the treatment phase.

Footnote #1: Changed monthly visit definition from approximately every 4-5 weeks ±7 days to approximately every 4 weeks ±3 days to accommodate drug supply dispensing.

Footnote #15: Replaced “a qualified professional” with “an ophthalmologist” per FDA’s request.

Footnote #18: Updated text to allow for substitution of MRI of chest, abdomen and pelvis in place of full CT scanning if CT scanning frequency not permitted per country or ethics requirements or if CT contrast is contraindicated.

Footnote #20: Typographical correction. “All medications taken by the subject during the study from the time of screening until 90 days…” changed to “All medications taken by the subject during the study from the time of screening until 30 days…” to be consistent with Section 6.1 of the protocol.

Footnote #23: Changed collection of blood sample for cfDNA, CAF and other biomarkers from all subjects at Day 1 pre-dose, Months 3, 6, 9, and 12 (or discontinuation if treatment is permanently discontinued before Month 12) and disease recurrence to all subjects at Day 1 pre-dose and disease recurrence, and a subset of subjects at selected sites for Months 3, 6, 9, 12 (or discontinuation if treatment is permanently discontinued before Month 12).
Footnote #27: Changed collection of blood sample for cytokine testing (and other potential markers of pyrexia) from all subjects at Screening, Months 3, 6, 9, and 12 (or discontinuation if treatment is permanently discontinued before Month 12) and disease recurrence to all subjects at Day 1 pre-dose, and a subset of subjects at selected sites for Months 3, 6, 9, 12 (or discontinuation if treatment is permanently discontinued before Month 12). Also clarified that a sample is to be collected in any subject that experiences pyrexia at the time of the event, where possible.

Re-labeled as Table 10 due to addition of LVEF Table 6 in Section 5.8.3.3.1.

**TABLE 11 (FORMERLY TABLE 10) TIME AND EVENTS TABLE – FOLLOW-UP ASSESSMENTS**

*Changes and Reasons for Change:*

Typographical errors: Deleted the “X” in “Unsch” visit for Central labs. Deleted “X” in Month 15 for concomitant medications and adverse events. Footnote #7 and #8, changed “90 days” to “30 days” to be consistent with the rest of the protocol.

Table and Footnote #2: Added a note that central labs should be drawn at the Month 18 visit and then annually during follow-up and at the time of disease recurrence to clarify the lab schedule.

Footnote #5: Updated text to allow for substitution of MRI of chest, abdomen and pelvis in place of full CT scanning if CT scanning frequency not permitted per country or ethics requirements or if CT contrast is contraindicated.

Removed the Month 21 CT scan to reduce study budget.

Re-labeled the Time and Events Table for Follow-up Assessments as Table 11 due to addition of LVEF Table 6 in Section 5.8.3.3.1.
SECTION 7.2.1.1 PRIMARY ENDPOINT

Previous:
- If no event has occurred by the time of the analysis, then the time to event will be censored as the date of the last assessment of the patient in question.

Revised:
- If no event has occurred by the time of the analysis, then the time to event will be censored as the date of the last adequate assessment of the patient in question.

SECTION 7.2.1.2 SECONDARY ENDPOINTS

Previous:
The secondary efficacy endpoints of this study are:
Overall Survival (OS) defined as the interval from randomization to the date of death, irrespective of the cause of death; patients still alive will be censored at the date of the last assessment.

Revised:
The secondary efficacy endpoints of this study are:
- Overall Survival (OS) defined as the interval from randomization to the date of death, irrespective of the cause of death; patients still alive will be censored at the date of the last contact.

Reason for change: Clarification

SECTION 7.2.1.3 EFFICACY ASSESSMENT

Previous text:
- Diagnostic quality, contrast-enhanced CT for Chest/Abdomen/Pelvis should be performed at baseline and subsequent timepoints as indicated in the Time and Events Tables (Table 9 and Table 10). Contrast-enhanced MRI of the abdomen and pelvis with CT of the chest should be substituted for full CT scanning if the CT frequency prescribed in the Time and Events Table is not permitted per country or ethics requirements or if CT contrast is contraindicated. The method of imaging should be consistent throughout the study (i.e. if CT is done at screening/baseline, CT will be done at all future timepoints.

Revised text:
- Diagnostic quality, contrast-enhanced CT for Chest/Abdomen/Pelvis should be performed at baseline and subsequent timepoints as indicated in the Time and Events Tables (Table 10 and Table 11). Contrast-enhanced MRI of the chest, abdomen and pelvis should be substituted for full CT scanning if the CT frequency prescribed in the Time and Events Table is not permitted per country or ethics requirements or if CT contrast is contraindicated. The method of imaging should be consistent throughout the study (i.e. if CT is done at screening, CT will be done at all future timepoints). All CTs/MRIs will be collected; instructions are provided in the Study Procedures Manual (SPM).
Reason for change: Updated language for MRI substitution requirements and added collection of all CT/MRI scans.

Previous text:
A baseline MRI of the brain is required for all subjects. CT may be performed only if MRI contraindicated or unavailable. Subsequent brain scans should only be performed as clinically indicated (e.g. symptoms suggestive of CNS recurrence).

Revised text:
- A baseline MRI of the brain is required for all subjects. CT may be performed only if MRI contraindicated or unavailable. Subsequent brain scans should only be performed as clinically indicated (e.g. symptoms suggestive of CNS recurrence). MRI/CT of the brain will be collected; instructions are provided in the Study Procedures Manual (SPM).

Reason for change: Added collection of CT/MRI brain scans.

New text added:
- Clinical examination
- Biopsy of suspected recurrences is strongly recommended, both to confirm the diagnosis and to obtain tissue for exploratory analyses (Section 7.7.2).

SECTION 7.2.1.4 ASSESSMENT GUIDELINES

New text added:
Clinical examination: New lesions detected by clinical examination must be biopsied, where possible, to confirm disease recurrence. If a biopsy cannot be obtained then CT/MRI must be done to confirm disease recurrence.
SECTION 7.3.3.1 PREGNANCY TEST AND PREVENTION

*New text added:* Male contraception language added for clarity.

Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described above from the day of randomization, throughout the treatment period and for 16 weeks after the last dose of study treatments.

If a subject becomes pregnant during the treatment period of the study, the study treatments should be stopped immediately.

*Reason for change:* The provision for male contraception is stated in the inclusion criteria, but does not appear anywhere else in the protocol; it has been added to this section to provide clarity on the requirements for this the study.

SECTION 7.3.5 OPHTHALMIC EXAMINATION

*Previous:* Subjects are required to have a standard ophthalmic examination performed by a qualified professional at Screening, Months 1, 3, 6, and 12 or at discontinuation if discontinuation occurs prior to Month 12.

*Revised:* Subjects are required to have a standard ophthalmic examination performed by an ophthalmologist at Screening, Months 1, 3, 6, and 12 or at discontinuation if discontinuation occurs prior to Month 12.

SECTION 7.3.7 PHYSICAL EXAMINATIONS

*New text added:* Refer to the SPM for additional detail regarding the exam requirements for the inspection of the head and neck region.

SECTION 7.3.8 DERMATOLOGIC EXAMINATION

*New text added:* Refer to the SPM for additional detail regarding the dermatologic examination including exam requirements and required training for investigators that will be performing the exam.

SECTION 7.5.4 MEALS AND DIETARY RESTRICTIONS

*Previous:* Subjects shall abstain from ingestion of any food or drink containing grapefruit and grapefruit juice, Seville oranges or pomellos within 7 days prior to the first dose of dabrafenib until the end of the study, as these have been shown to inhibit CYP3A4 activity.

*Revised:*
Subjects shall abstain from ingestion of any food or drink containing grapefruit and grapefruit juice, Seville oranges or pommelos within 24 hours prior to the first dose of dabrafenib until the end of the study, as these have been shown to inhibit CYP3A4 activity.

Reason for change: Per new information.

SECTION 7.7.3 CIRCULATING CELL-FREE DNA (CFDNA) ANALYSIS

Previous:
cfDNA blood/plasma samples will be collected at baseline, at intervals on-treatment (refer to the Time and Events Tables, Table 9 and Table 10) and at relapse for assessment of cfDNA levels as a marker for reappearance of tumor burden. The cfDNA samples may also be explored to determine whether mutations in the cfDNA, including but not limited to BRAF V600, also correlate to mutations in tumor tissue from which it is derived wherever feasible. The cfDNA burden and mutation analysis results may be correlated to patient clinical endpoints.

Revised:
cfDNA blood/plasma samples will be collected at baseline and relapse on all subjects for assessment of cfDNA levels as a marker for reappearance of tumor burden. cfDNA blood/plasma samples will also be collected in a subset of approximately 100 subjects at selected sites at intervals on-treatment (refer to the Time and Events Tables, Table 10 and Table 11). The cfDNA samples may also be explored to determine whether mutations in the cfDNA, including but not limited to BRAF V600, also correlate to mutations in tumor tissue from which it is derived wherever feasible. The cfDNA burden and mutation analysis results may be correlated to patient clinical endpoints.

Reason for change: Number of samples collected during the study reduced to reduce the study budget.
SECTION 9.2.1 SAMPLE SIZE ASSUMPTIONS

Summary of Changes:
Deleted interim analysis for efficacy.
Deleted “With 467 events, it will be possible to detect an improvement as low as 20.0% (HR = 0.833 which equates to median RFS of 15 and 18 months in the placebo arm and the combination therapy arm, respectively) with statistical significance [Carroll, 2009].”
Deleted “or otherwise lost to follow-up” from OS final analysis definition and added “(i.e. 597 deaths)”. This change has been made throughout the document where applicable.
Inserted “(one-sided)” in the following sentence to provide additional clarity:
“Specifically, Lan-DeMets method [Lan, 1983] with O’Brien-Fleming type stopping boundary (as in EAST 5.3) will be used to maintain the cumulative type-I error rate at 2.5% (one-sided).”
Deleted “An extension of median OS from 48 months to 60 months, equating to a hazard ratio of 0.8, would be of interest to detect; under these assumptions, at the anticipated time of the RFS analysis (roughly 32 months), there would be 209 OS events which would only afford approximately 36% power.”
New text added: “Randomization to the Stage IIIa strata will be capped at 40% of the total number of subjects. Randomization to the Stage IIIb and IIIc strata will not be capped.”

SECTION 9.2.2 SAMPLE SIZE SENSITIVITY

Previous:
Table 13 shows the various power scenarios at the time of the RFS analysis under the assumed percent improvement (40%) and for scenarios where percent improvement and underlying medians vary assuming 467 events (relapses and all-cause deaths) have accrued.

<table>
<thead>
<tr>
<th>Median RFS</th>
<th>Placebo</th>
<th>Combination Therapy</th>
<th>% Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 months</td>
<td>20 months</td>
<td>42.8%</td>
<td>0.7</td>
<td>96.9%</td>
<td></td>
</tr>
<tr>
<td>15 months</td>
<td>21 months</td>
<td>40%</td>
<td>0.714</td>
<td>95%</td>
<td></td>
</tr>
<tr>
<td>16 months</td>
<td>21 months</td>
<td>31.3%</td>
<td>0.762</td>
<td>83.1%</td>
<td></td>
</tr>
<tr>
<td>16 months</td>
<td>22 months</td>
<td>37.5%</td>
<td>0.727</td>
<td>92.7%</td>
<td></td>
</tr>
</tbody>
</table>

Revised:
Table 14 shows the various power scenarios at the time of the RFS analysis under the assumed percent improvement (40%) and for scenarios where percent improvement and underlying medians vary assuming 467 events (relapses and all-cause deaths) have accrued.
TABLE 14  STATISTICAL POWER SCENARIO FOR RFS ANALYSIS

<table>
<thead>
<tr>
<th>Median RFS</th>
<th>Placebos</th>
<th>Combination Therapy</th>
<th>% Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 months</td>
<td>20 months</td>
<td></td>
<td>42.8%</td>
<td>0.7</td>
<td>98.9%</td>
</tr>
<tr>
<td>15 months</td>
<td>21 months</td>
<td></td>
<td>40%</td>
<td>0.714</td>
<td>95%</td>
</tr>
<tr>
<td>16 months</td>
<td>21 months</td>
<td></td>
<td>31.3%</td>
<td>0.762</td>
<td>83.1%</td>
</tr>
<tr>
<td>16 months</td>
<td>22 months</td>
<td></td>
<td>37.5%</td>
<td>0.727</td>
<td>92.7%</td>
</tr>
</tbody>
</table>

The final OS analysis will be performed when 597 deaths are observed. Table 15 shows the power to detect various treatment effects. For example with 597 deaths, the study would have 77% power to detect a hazard ratio of 0.80. Under these assumptions, at the anticipated time of the RFS analysis (roughly 32 months), there would be 209 OS events which would only afford approximately 36% power.

TABLE 15  STATISTICAL POWER SCENARIO FOR OS ANALYSIS

<table>
<thead>
<tr>
<th>Median PFS</th>
<th>Placebo</th>
<th>Combination Therapy</th>
<th>Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>47 months</td>
<td>59 months</td>
<td></td>
<td>25.5%</td>
<td>0.797</td>
<td>79%</td>
</tr>
<tr>
<td>48 months</td>
<td>60 months</td>
<td></td>
<td>25.0%</td>
<td>0.8</td>
<td>77%</td>
</tr>
<tr>
<td>48 months</td>
<td>58 months</td>
<td></td>
<td>20.8%</td>
<td>0.828</td>
<td>63%</td>
</tr>
<tr>
<td>49 months</td>
<td>60 months</td>
<td></td>
<td>22.4%</td>
<td>0.817</td>
<td>65%</td>
</tr>
<tr>
<td>49 months</td>
<td>61 months</td>
<td></td>
<td>24.5%</td>
<td>0.803</td>
<td>76%</td>
</tr>
</tbody>
</table>

Reason for Changes: Added table showing statistical power scenario for OS analysis.

SECTION 9.3.2 ANALYSIS DATA SETS

Previous:
The primary objective will be supported by the test for superiority of combination therapy over placebo in relation to RFS (refer to Section 9.1) using the ITT population. The final analysis for RFS will be performed at the time 467 relapses or all-cause deaths have occurred. The time of final analysis may be modified based on death rate and will be evaluated at a later point. Subjects will continue to be followed for OS until approximately 70 percent of the total number of randomized subjects have died or are otherwise lost to follow-up.

Revised:
The primary objective will be supported by the test for superiority of combination therapy over placebo in relation to RFS (refer to Section 9.1) using the ITT population.
The final analysis for RFS will be performed at the time 467 relapses or all-cause deaths have occurred. Subjects will continue to be followed for OS until approximately 70 percent of the total number of randomized subjects have died (i.e. 597 deaths).

SECTION 9.3.4 INTERIM ANALYSIS & IDMC

Previous:
An independent data monitoring committee (IDMC) will be chartered to review accumulating safety data to provide an opportunity to terminate the study early if there are concerns regarding safety. The IDMC will be convened after approximately 100 subjects have been randomized, and will review safety data at intervals specified in the IDMC Charter.

The IDMC responsibilities, review schedules and mechanism for communicating recommendations will be outlined in an IDMC charter.

There will be one formal interim analysis for the primary endpoint RFS. Once all the subjects are enrolled and 40% of the total RFS events (i.e. approximately 187 RFS events) have occurred, an interim analysis for efficacy will be performed. Overall Type I error for the primary endpoint will be controlled using Haybittle-Peto method. The IDMC will review the interim efficacy data. The recommendations of the IDMC will be communicated to GSK, and in the event of a recommendation to halt the trial early due to safety concerns or due to superiority to the appropriate regulatory agencies.
Revised:
No interim analyses will be performed for efficacy or futility for the primary endpoint RFS unless otherwise requested by the independent data monitoring committee (IDMC).

An interim analysis of OS will be conducted at the time of the final RFS analysis. Subjects will continue to be followed for survival until 70% of the total enrolled population has died and final OS analysis will be performed when 597 deaths are observed.

An IDMC will be chartered to review accumulating safety data to provide an opportunity to terminate the study early if there are concerns regarding safety. The IDMC will be convened after approximately 100 subjects have been randomized, and will review safety data at intervals specified in the IDMC Charter. The recommendations of the IDMC will be communicated to GSK, and in the event of a recommendation to halt the trial early due to safety concerns to the appropriate regulatory agencies. The IDMC responsibilities, review schedules and mechanism for communicating recommendations will be outlined in an IDMC charter.

Reason for change: Deleted formal interim analysis. Added detail regarding the interim OS analysis at the time of the final RFS analysis.

SECTION 9.3.5.1.1 PRIMARY ANALYSIS
Previous:
If a subject has neither relapsed or died or started new anti-cancer therapy, then RFS will be censored at the date of last assessment. If no post-baseline disease assessments exist, the subject will be censored at the date of randomization. In the primary analysis if a non-protocol anti-cancer therapy is started before the occurrence of a RFS event, then RFS will be censored on the day of such therapy treatment starts. Definition of “adequate assessment” and censoring rules will be detailed in the RAP.

Revised:
If a subject has neither relapsed or died or started new anti-cancer therapy, then RFS will be censored at the date of last adequate assessment. If no post-baseline disease assessments exist, the subject will be censored at the date of randomization. In the primary analysis if a non-protocol anti-cancer therapy is started before the occurrence of a RFS event, then RFS will be censored at the last adequate assessment prior to such therapy treatment starts. Censoring rules will be detailed in the RAP.

SECTION 10.8 INDEPENDENT DATA MONITORING COMMITTEE
Previous:
An Independent Data Monitoring Committee (IDMC) will be utilized in this study to ensure external objective medical and/or statistical review of safety and/or efficacy issues in order to protect the ethical and safety interests of subjects and to protect the scientific
validity of the study. The schedule of any planned interim analysis and the analysis plan for IDMC review is described in the charter.

Revised:
An Independent Data Monitoring Committee (IDMC) will be utilized in this study to ensure external objective medical and/or statistical review of safety and/or efficacy issues in order to protect the ethical and safety interests of subjects and to protect the scientific validity of the study. The schedule and the analysis plan for IDMC review are described in the charter.

Reason for change: Removed text describing interim analysis.

REFERENCES


12.12 Appendix 12: Protocol Changes for Amendment 02

AMENDMENT NUMBER 02

Amendment 02 includes the addition of a table in Section 5.8.3.3.2 for the management and dose modification of hypertension and the addition of a table in Section 5.8.2 for the management and dose modification of renal insufficiency.
12.13 Appendix 13: Protocol Changes for Amendment 03

AMENDMENT NUMBER 03
This amendment is applicable to all investigational study sites in all countries.

SECTION 4.1.2 INCLUSION CRITERIA #9 & #10

Previous:
9. Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, as defined in Section 7.3.3 from 14 days prior to randomization, throughout the treatment period and for 30 days after the last dose of study treatment.

10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in Section 7.3.3 from the day of randomization, throughout the treatment period and for 16 weeks after the last dose of study treatment.

Revised:
9. Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, as defined in Section 7.3.3 from 14 days prior to randomization, throughout the treatment period and for 4 months after the last dose of study treatment.

10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in Section 7.3.3 from the day of randomization and throughout the treatment period.

Reason for change: Female contraception requirements updated to align with GSK1120212 IB (Version 4). The male contraception requirement is no longer necessary.

SECTION 4.1.3 EXCLUSION CRITERION #12

Previous:
12. History of interstitial lung disease or pneumonitis.

Revised:
12. History of interstitial lung disease or pneumonitis.

Reason for change: Clarification.

TABLE 11 TIME AND EVENTS TABLE – FOLLOW-UP ASSESSMENTS

Change:
Added Month 21 CT/MRI scan.

Reason for change: The Month 21 CT/MRI scan was previously removed in Amendment 1, but has been added back in to Amendment
SECTION 7.3.3.1 PREGNANCY TEST AND PREVENTION

Previous:
The need for a screening pregnancy test depends on whether a female subject is of childbearing potential or non-childbearing potential.

A female of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) is defined as any female who has had a hysterectomy, bilateral oophorectomy (ovariectomy) or bilateral tubal ligation, or is post-menopausal.

A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile, e.g., age appropriate, >45 years in the absence of hormone replacement therapy (HRT). In questionable cases, the subject must have a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).

A female of child-bearing potential is defined as any female who does not meet the criteria of non-childbearing potential as described in the previous paragraph.

If a female subject is of childbearing potential, she must have a serum β-HCG pregnancy test performed within 7 days prior to the first dose of study treatment. Subjects with positive pregnancy test result must be excluded from the study. Subjects with negative pregnancy test result must agree to use an effective contraception method as described below during the study until 30 days following the last dose of study treatment.

GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:

- An intrauterine device with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject’s entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days prior to first dose of study treatment, through the dosing period, and for at least 30 days after the last dose of study treatment.

Note: Abstinence is acceptable only when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

- Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository).

Note: Hormonal-based methods (e.g., oral contraceptives) are not recommended due to potential drug-drug interactions with dabrafenib.

Female subjects who are lactating must discontinue nursing prior to the first dose of study treatment and must refrain from nursing throughout the treatment period and for 30 days following the last dose of study treatment.

Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described above from the day of randomization, throughout the treatment period and for 16 weeks after the last dose of study treatments.

If a subject becomes pregnant during the treatment period of the study, the study treatments should be stopped immediately.

Revised:
The need for a screening pregnancy test depends on whether a female subject is of childbearing potential or non-childbearing potential.

**A female of non-childbearing potential** (i.e., physiologically incapable of becoming pregnant) is defined as any female who has had a hysterectomy, bilateral oophorectomy (ovariectomy) or bilateral tubal ligation, or is post-menopausal.

A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile, e.g., age appropriate, >45 years in the absence of hormone replacement therapy (HRT). In questionable cases, the subject must have a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).

**A female of child-bearing potential** is defined as any female who does not meet the criteria of non-childbearing potential as described in the previous paragraph.

If a female subject is of childbearing potential, she must have a serum β-1CG pregnancy test performed within 7 days prior to the first dose of study treatment. Subjects with positive pregnancy test result must be excluded from the study. Subjects with negative pregnancy test result must agree to use an effective contraception method as described below during the study until 4 months following the last dose of study treatment.

GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:

- An intrauterine device with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject’s entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days prior to first dose of study treatment, through the dosing period, and for at least 4 months after the last dose of study treatment.

Note: Abstinence is acceptable only when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

- Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository).

**Note:** Hormonal-based methods (e.g., oral contraceptives) are not recommended due to potential drug-drug interactions with dabrafenib.

Female subjects who are lactating must discontinue nursing prior to the first dose of study treatment and must refrain from nursing throughout the treatment period and for 4 months following the last dose of study treatment.

If a subject becomes pregnant during the treatment period of the study, the study treatments should be stopped immediately.

*Reason for Change:* The female contraception requirement has been updated to align with the GSK1120212 IB (Version 4). The male contraception requirement is no longer necessary.

**SECTION 9.2.2 SAMPLE SIZE SENSITIVITY**

*Previous:*
Table 14 shows the various power scenarios at the time of the RFS analysis under the assumed percent improvement (40%) and for scenarios where percent improvement and underlying medians vary assuming 467 events (relapses and all-cause deaths) have accrued.

Table 14  Statistical Power Scenario for RFS Analysis

<table>
<thead>
<tr>
<th>Median RFS</th>
<th>Placebos</th>
<th>Combination Therapy</th>
<th>% Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 months</td>
<td>14 months</td>
<td>20 months</td>
<td>42.8%</td>
<td>0.7</td>
<td>96.9%</td>
</tr>
<tr>
<td>15 months</td>
<td>15 months</td>
<td>21 months</td>
<td>40%</td>
<td>0.714</td>
<td>95%</td>
</tr>
<tr>
<td>18 months</td>
<td>18 months</td>
<td>21 months</td>
<td>31.3%</td>
<td>0.762</td>
<td>83.1%</td>
</tr>
<tr>
<td>16 months</td>
<td>16 months</td>
<td>22 months</td>
<td>37.5%</td>
<td>0.727</td>
<td>92.7%</td>
</tr>
</tbody>
</table>

The final OS analysis will be performed when 597 deaths are observed. Table 15 shows the power to detect various treatment effects. For example with 597 deaths, the study would have 77% power to detect a hazard ratio of 0.80. Under these assumptions, at the anticipated time of the RFS analysis (roughly 32 months), there would be 209 OS events which would only afford approximately 36% power.

Table 15  Statistical Power Scenario for OS Analysis

<table>
<thead>
<tr>
<th>Median PFS</th>
<th>Placebo</th>
<th>Combination Therapy</th>
<th>Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>47 months</td>
<td>47 months</td>
<td>59 months</td>
<td>25.5%</td>
<td>0.797</td>
<td>79%</td>
</tr>
<tr>
<td>48 months</td>
<td>48 months</td>
<td>60 months</td>
<td>25.0%</td>
<td>0.8</td>
<td>77%</td>
</tr>
<tr>
<td>49 months</td>
<td>49 months</td>
<td>58 months</td>
<td>20.8%</td>
<td>0.828</td>
<td>63%</td>
</tr>
<tr>
<td>49 months</td>
<td>49 months</td>
<td>60 months</td>
<td>22.4%</td>
<td>0.817</td>
<td>69%</td>
</tr>
<tr>
<td>49 months</td>
<td>49 months</td>
<td>61 months</td>
<td>24.5%</td>
<td>0.803</td>
<td>76%</td>
</tr>
</tbody>
</table>

Revised:
Table 14 shows the various power scenarios at the time of the RFS analysis under the assumed percent improvement (40%) and for scenarios where percent improvement and underlying medians vary assuming 467 events (relapses and all-cause deaths) have accrued.

Table 14  Statistical Power Scenario for RFS Analysis
<table>
<thead>
<tr>
<th>Placebos</th>
<th>Combination Therapy</th>
<th>% Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 months</td>
<td>20 months</td>
<td>42.8%</td>
<td>0.7</td>
<td>96.9%</td>
</tr>
<tr>
<td>15 months</td>
<td>21 months</td>
<td>40%</td>
<td>0.714</td>
<td>95%</td>
</tr>
<tr>
<td>16 months</td>
<td>21 months</td>
<td>31.3%</td>
<td>0.762</td>
<td>83.1%</td>
</tr>
<tr>
<td>16 months</td>
<td>22 months</td>
<td>37.5%</td>
<td>0.727</td>
<td>92.7%</td>
</tr>
</tbody>
</table>

The final OS analysis will be performed when 597 deaths are observed. Table 15 shows the power to detect various treatment effects. For example with 597 deaths, the study would have 80% power to detect a hazard ratio of 0.793. Under these assumptions, at the anticipated time of the RFS analysis (roughly 32 months), there would be 201 OS events which would only afford approximately 37% power.
Table 15  
Statistical Power Scenario for OS Analysis

<table>
<thead>
<tr>
<th>Median PFS</th>
<th>Improvement</th>
<th>Hazard Ratio</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>Combination Therapy</td>
<td>26.0%</td>
<td>0.793</td>
</tr>
<tr>
<td>48 months</td>
<td>60.5 months</td>
<td>25.5%</td>
<td>0.797</td>
</tr>
<tr>
<td>47 months</td>
<td>59 months</td>
<td>25.0%</td>
<td>0.8</td>
</tr>
<tr>
<td>48 months</td>
<td>60 months</td>
<td>20.8%</td>
<td>0.828</td>
</tr>
<tr>
<td>48 months</td>
<td>58 months</td>
<td>22.4%</td>
<td>0.817</td>
</tr>
<tr>
<td>49 months</td>
<td>60 months</td>
<td>24.5%</td>
<td>0.803</td>
</tr>
<tr>
<td>49 months</td>
<td>61 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reason for change: Revisions to include 80% OS power calculation, per FDA request.

9.3.5.1.1 PRIMARY ANALYSIS

New text added:

The Pike estimator, which is a nonparametric estimator of the HR, has been specifically developed for survival data and is used as a measure of the relative survival experience of two groups. Within the range of values of the ratio of the hazard rates of interest in clinical trials, Pike estimator is more efficient in terms of mean square error than the Cox proportional hazard method [Bernstein, 1981].

Reason for change: To provide the rationale for use of the Pike estimator of the treatment hazard ratio.

SECTION 11 REFERENCES

12.14 Appendix 14: Protocol Changes for Amendment 04

AMENDMENT NUMBER 04
Amendment 04 [redacted] to include Risk/Benefit Assessment in Section 1 [redacted]
12.15 Appendix 15: Additional monitoring

CUTANEOUS SQUAMOUS CELL CARCINOMA (CUSCC) AND NEW PRIMARY MELANOMA

Dermatological examinations should be performed prior to initiation of study treatment, monthly during treatment, and monthly for 6 months following discontinuation of dabrafenib or until initiation of another anti-neoplastic therapy, whichever comes first. Subjects should be instructed to immediately inform their physician if new lesions develop. Any cuSCC or new primary melanoma should be reported as a protocol-specific SAE and treated according to standard clinical practice.

NON-CUTANEOUS SECONDARY/RECURRENT MALIGNANCY

Prior to initiation of study treatment subjects should undergo a head and neck examination with minimally visual inspection of oral mucosa and lymph node palpation, as well as chest/abdomen Computed Tomography (CT) scan. During treatment subjects should be monitored as clinically appropriate which may include a head and neck examination every 3 months and a chest/abdomen CT scan every 6 months. Anal examinations and pelvic examinations are recommended before the start of and at the end of treatment or when considered clinically indicated. Complete blood cell counts should be performed as clinically indicated. Following discontinuation of dabrafenib monitoring for non-cutaneous secondary/recurrent malignancies should continue for up to 6 months or until initiation of another anti-neoplastic therapy, whichever comes first. Any non-cutaneous secondary/recurrent malignancy should be reported as a protocol-specific SAE and treated according to standard clinical practice.
12.16 Appendix 16: Protocol Changes for Amendment 05

AMENDMENT NUMBER 05
This amendment is applicable to all investigational study sites in all countries.

ADMINISTRATIVE CHANGES
Added 'THxID BRAF Assay' under Trademarks not owned by the GlaxoSmithKline group of companies.
Updated Primary and Secondary Medical Monitor Contact information.
Added Universal Trial Number (UTN).
Added ‘/placebo’ after dabrafenib and trametinib throughout, where appropriate.
Numbering of exclusion criteria updated due to deletion of Exclusion # 8 "A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency".
Corrected column heading from “Median PFS” to “Median OS” in Table 15.

SECTION 4.1.2 INCLUSION CRITERIA

Previous:
3. Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis >1 mm), IIIb or IIIc; refer to Appendix 1 for Staging Guidelines] cutaneous melanoma determined to be V600E/K mutation positive using the bioMerieux (bMX) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The testing will be conducted by a central reference laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.

4. Must be surgically rendered free of disease no more than 12 weeks before randomization.

Revised:
3. Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis >1 mm), IIIb or IIIc; refer to Appendix 1 for Staging Guidelines] cutaneous melanoma determined to be V600E/K mutation positive using the bioMerieux (bMX) THxID BRAF Assay. The testing will be conducted by a central reference laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible. Patients with an unknown primary melanoma are not eligible.

4. Must be surgically rendered free of disease (defined as the date of the most recent surgery) no more than 12 weeks before randomization.

Reason for change: Updated assay description due to approval of the assay in multiple countries. Clarified that patient population and timeframe from surgery to randomization.

SECTION 4.1.3 EXCLUSION CRITERIA

Previous:
3. Prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) and radiotherapy for melanoma. Prior surgery for melanoma is allowed.

8. A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.

9. History of another malignancy including melanoma or a concurrent malignancy except as noted below:

   Exceptions: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ, multiple primary melanomas, or other malignancies for which the patient has been disease free for > 5 years.

10e. Patients with intra-cardiac defibrillators or permanent pacemakers.

12. Interstitial lung disease or pneumonitis.

Revised:

3. Prior anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) including radiotherapy for melanoma. Prior surgery for melanoma is allowed.

8. History of another malignancy including melanoma or a concurrent malignancy except as noted below. Patients who have previously had Stage III melanoma or any malignancy with confirmed activating RAS mutation at any time are not eligible. Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.

Exceptions:

- Patients with a history of any malignancy that have been disease-free for at least 5 years are eligible except those with confirmed activating RAS mutations.

- Patients with a history of completely resected non-melanoma skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma) are eligible irrespective of the time since the resection.

- Patients with successfully treated in situ carcinoma are eligible.

- Patients presenting with multiple primary melanomas are eligible only if the lesions are concurrent. Patients who have concurrent multiple primary melanomas that are “distant” are eligible provided each lesion is considered local disease or resectable regional disease. These cases should be discussed with the Medical Monitor.

9e. Patients with intra-cardiac defibrillators.

11. History of clinically significant or active interstitial lung disease or pneumonitis.
**Reason for change:** Clarifications and updates. Exclusion for G6PD deficiency (Exclusion #8) removed based on FDA feedback. Exclusion for other malignancies updated to exclude prior malignancies with RAS mutation for safety reasons since activating RAS is the mechanism underlying non-cutaneous malignancies in the presence of a BRAF inhibitor. Exclusion of subjects with permanent pacemakers removed. Exclusion criteria renumbered as a result of deleting the exclusion for G6PD deficiency.

**SECTION 4.2 PERMANENT DISCONTINUATION FROM STUDY TREATMENT AND SUBJECT COMPLETION CRITERIA**

**Previous:**
Subjects will receive study treatments for twelve months or until disease recurrence. During the protocol defined treatment period study treatment(s) may be permanently discontinued for the following reasons:

- death
- unacceptable adverse event, including meeting stopping criteria for liver chemistry defined in Section 5.9.1 and/or for hematologic and other non-hematologic toxicity.
- deviation(s) from the protocol
- request of the subject or proxy
- investigator’s discretion
- subject is lost to follow-up
- study is closed or terminated.

The primary reason each study treatment was permanently discontinued must be documented in the subject’s medical records and in the electronic case report form (eCRF). Refer to Section 5.2 for additional information on discontinuation of dabrafenib and/or trametinib.

If disease recurs prior to the completion of the 12 month treatment period, study treatment should be discontinued and follow-up assessments should be conducted according to the schedule for “Follow-up after recurrence” (Table 11). Such follow-up assessments should start at the next regularly scheduled disease assessment visit (i.e. Month 3, 6, 9 or 12) and continue every 3 months thereafter according to Table 11. For example, if disease recurrence is observed at Month 6, the subject would complete the discontinuation visit and follow-up assessments after recurrence would start at Month 9, and continue every 3 months until Month 15 at which point the visit schedule in the Time and Events Table (Table 11) will be followed.

If the subject voluntarily discontinues from treatment due to toxicity, ‘adverse event’ will be recorded as the primary reason for permanently discontinuation in the eCRF.

All subjects who permanently discontinue from study treatment will have assessments at the time of discontinuation and during post study treatment follow-up as specified in Time and Events Tables (See Section 7). In addition, all subjects who permanently discontinue study treatment without evidence of disease recurrence will also be followed for disease recurrence according to the protocol schedule until:
Withdrawal of consent

Death, or

Study completion (as defined in Section 3)

Follow-up for survival, new anti-cancer therapy (including radiotherapy) and response to new anti-cancer therapy will continue for all subjects including those with disease recurrence, according to the Time and Events Tables (Table 10 and Table 11) until the study is considered to be complete after which all protocol-required assessments and procedures will be discontinued. The study will be considered complete, and the final OS analysis will be conducted when approximately 70% of the total number of randomized subjects have died (i.e. 597 deaths). Follow-up contact to assess survival and new anti-cancer therapy may be made via clinic visit or another form of communication (e.g. phone, email, mail etc.). Additional information on declaring subjects lost to follow-up can be found in the SPM.

Revised:

Subjects will receive study treatments for twelve months or until disease recurrence. During the protocol defined treatment period study treatment(s) may be permanently discontinued for the following reasons:

- death
- unacceptable adverse event, including meeting stopping criteria for liver chemistry defined in Section 5.9.1 and/or for hematologic and other non-hematologic toxicity.
- deviation(s) from the protocol
- request of the subject or proxy
- investigator’s discretion
- subject is lost to follow-up
- study is closed or terminated.

The primary reason each study treatment was permanently discontinued must be documented in the subject’s medical records and in the electronic case report form (eCRF). Refer to Section 5.2 for additional information on discontinuation of dabrafenib and/or trametinib.

If disease recurs prior to the completion of the 12 month treatment period, study treatment should be discontinued and follow-up assessments should be conducted according to the schedule for “Follow-up after recurrence” (Table 11). Such follow-up assessments should start at the next regularly scheduled disease assessment visit (i.e. Month 3, 6, 9 or 12) and continue thereafter according to Table 11. For example, if disease recurrence is observed at Month 6, the subject would complete the discontinuation visit and follow-up assessments after recurrence would start at Month 9, and continue according to the visit schedule in the Time and Events Table (Table 11).  

If the subject voluntarily discontinues from treatment due to toxicity, ‘adverse event’ will be recorded as the primary reason for permanently discontinuation in the eCRF.
All subjects who permanently discontinue from study treatment will have assessments at the time of discontinuation and during post study treatment follow-up as specified in Time and Events Tables (See Section 7). In addition, all subjects who permanently discontinue study treatment without evidence of disease recurrence will also be followed for disease recurrence according to the protocol schedule until:
Withdrawal of consent
Death, or
Study completion (as defined in Section 3)

Subjects that permanently discontinue from study treatment before the end of the 12 month treatment period without evidence of disease recurrence will return for disease assessment visits starting at the next regularly scheduled disease assessment visit (i.e. Month 3, 6, 9 or 12) and continue thereafter according to Table 11. If a subject experiences disease recurrence at any time subsequent follow up visits should be conducted according to the “After Recurrence” follow-up schedule in Table 11.

Follow-up for survival, new anti-cancer therapy (including radiotherapy) and response to new anti-cancer therapy will continue for all subjects including those with disease recurrence, according to the Time and Events Tables (Table 10 and Table 11) until the study is considered to be complete after which all protocol-required assessments and procedures will be discontinued. The study will be considered complete, and the final OS analysis will be conducted when approximately 70% of the total number of randomized subjects have died (i.e. 597 deaths). Follow-up contact to assess survival and new anti-cancer therapy may be made via clinic visit or another form of communication (e.g. phone, email, mail etc.). Additional information on declaring subjects lost to follow-up can be found in the SPM.

Reason for change: To provide clarification on the follow-up assessments required for subjects that discontinue treatment prior to Month 12 with no evidence of disease recurrence.

SECTION 5.2 DOSAGE AND ADMINISTRATION

Previous:
If a subject misses a dose, the subject may take the dose immediately if the next dose is scheduled for at least 8 hours later. If the next scheduled dose is due in less than 8 hours, the subject should skip the dose and resume dosing at the next scheduled dose.

Subjects should abstain from ingestion of any food or drink containing grapefruit and grapefruit juice, Seville oranges, or pommelos within 24 hours prior to randomization until treatment discontinuation, as these have been shown to inhibit CYP3A4 activity.

Revised:
If a subject misses a dose of dabrafenib or dabrafenib placebo, the subject may take the dose immediately if the next dose is scheduled for at least 6 hours later. If the next scheduled dose is due in less than 6 hours, the subject should skip the dose and resume dosing at the next scheduled dose. If a subject misses a dose of trametinib or trametinib placebo, the subject may take the dose immediately if the next dose is scheduled for at least 12 hours later.
Reason for change: Updated to align with the GSK1120212 + GSK2118436 Investigator’s Brochure.

SECTION 5.8.3.1 PYREXIA

Previous:
Subjects experiencing pyrexia associated with rigors, severe rigors/chills, dehydration, hypotension, or renal function should be monitored carefully and oral corticosteroids should be started after the event resolves (see Table 4).

Revised:
In subjects experiencing pyrexia associated with rigors, severe chills, dehydration, or hypotension, renal function should be monitored carefully and oral corticosteroids should be started after the event resolves (see Table 4).

Reason for change: Clarification.

SECTION 5.8.3.2 VISUAL CHANGES

Previous:
Disorders associated with visual disturbances, including Central Serous Retinopathy (CSR) and Retinal Vein Occlusion (RVO) have been observed with trametinib. Symptoms such as blurry vision, decreased acuity, and other visual phenomena have been reported in the clinical trials with trametinib. Adequate ophthalmologic evaluations should be performed according to the Time and Events Table (Table 10). Additional ophthalmic exams must be performed if patients report visual disturbances at any time while on trametinib therapy. If a retinal abnormality is diagnosed, follow the dose modification schedule in Table 5. In patients who experience retinal vein occlusion, treatment with trametinib should be permanently discontinued.

TABLE 5 MANAGEMENT AND DOSE MODIFICATION GUIDELINES FOR VISUAL CHANGES

<table>
<thead>
<tr>
<th>Grade*</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Grade</td>
<td>• <strong>Blood</strong> sample for pharmacokinetics analysis must be drawn as close as possible to the time of the event.</td>
</tr>
<tr>
<td>Grade 1</td>
<td>• <strong>Continue</strong> treatment and monitor as clinically indicated</td>
</tr>
</tbody>
</table>
| Grade 2 or Grade 3 | • **Interrupt** trametinib.  
• **Refer** subject for ophthalmologic evaluation.  
• Once toxicity is Grade 0-1 reduce trametinib by one dose level when resuming therapy. |
| Grade 4 | • **Trametinib must be permanently discontinued.** |

Revised:
Episodes of visual changes have been observed in subjects receiving trametinib. The causal relationship between a change in vision and the study treatment should be
carefully explored and an ophthalmologist should be consulted. Special attention should be given to retinal (e.g., CSR) or retinal vein abnormalities (e.g., RVO). For events of visual changes regardless of severity, a blood sample for PK analysis must be drawn as close as possible to the time of the event.

Guidelines regarding management and dose reduction for visual changes considered to be related to study treatment are provided in Table 5.

**TABLE 6 DOSE MODIFICATION GUIDELINES AND STOPPING CRITERIA FOR LVEF DECREASE**

<table>
<thead>
<tr>
<th>Clinic</th>
<th>LVEF-drop (%) or CTCAE grade</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Asymptomatic   | Absolute decrease of >10% in LVEF compared to baseline and ejection fraction below the institution’s low LLN | • Interrupt study treatment and repeat ECHO within 2 weeks<sup>a</sup>  
  • If the LVEF recovers within 4 weeks (defined as LVEF ≥ LLN and absolute decrease ≤ 10% compared to baseline)  
    ○ Consult with the GSK medical monitor and request approval for restart  
    ○ Restart with trametinib reduced by one dose level  
    ○ Restart dabrafenib at previous dose level  
    ○ Repeat ECHO 2, 4, 8 and 12 weeks after re-start; continue in intervals of 12 weeks thereafter  
    • If repeat LVEF does not recover within 4 weeks  
      ○ Consult with cardiologist  
      ○ **Permanently discontinue trametinib**  
      ○ Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution  
      ○ Consult with GSK medical monitor<sup>c</sup> |
| Symptomatic<sup>b</sup> | Grade 3: resting LVEF 39-20% or >20% absolute reduction from baseline  
  Grade 4: resting LVEF <20% | • **Permanently discontinue study treatment.**  
  • Consult with cardiologist  
  • Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution |

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; ECHO = echocardiogram; GSK = GlaxoSmithKline; LLN = lower limit of normal; LVEF = left ventricular ejection fraction;

<sup>a</sup> If ECHO does not show LVEF recovery after 2 weeks, repeat ECHO 2 weeks later.

<sup>b</sup> Symptoms may include: dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.

<sup>c</sup> Once LVEF recovers, restarting dabrafenib monotherapy can be considered in consultation with GSK medical monitor.

*Revised:*
<table>
<thead>
<tr>
<th>Clinic</th>
<th>LVEF-drop (%) or CTCAE grade</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Asymptomatic    | Absolute decrease of >10% in LVEF compared to baseline and ejection fraction below the institution’s low LLN | • Interrupt study treatments and repeat ECHO within 2 weeks\(^a\)  
• If the LVEF recovers within 4 weeks (defined as LVEF ≥LLN and absolute decrease ≤10% compared to baseline)  
  ○ Consult with the medical monitor and request approval for restart  
  ○ Restart with trametinib/placebo reduced by one dose level  
  ○ Restart dabrafenib/placebo at previous dose level  
  ○ Repeat ECHO 2, 4, 8 and 12 weeks after re-start; continue in intervals of 12 weeks thereafter  
• If repeat LVEF does not recover within 4 weeks  
  ○ Consult with cardiologist  
  ○ **Permanently discontinue trametinib/placebo**  
  ○ Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution  
  ○ Consult with a medical monitor\(^c\) |
<table>
<thead>
<tr>
<th>Clinic</th>
<th>LVEF-drop (%) or CTCAE grade</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| Symptomaticb | Grade 3: resting LVEF 39-20% or >20% absolute reduction from baseline | • Permanently discontinue trametinib/placebo.  
• Consult with cardiologist  
• Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until resolution |
| Grade 4: resting LVEF <20% | |

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; ECHO = echocardiogram; LLN = lower limit of normal; LVEF = left ventricular ejection fraction;

a. If ECHO does not show LVEF recovery after 2 weeks, repeat ECHO 2 weeks later.
b. Symptoms may include: dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.
c. Once LVEF recovers, restarting dabrafenib monotherapy can be considered in consultation with GSK medical monitor.

**Reason for change:** Updated to align with current guidance for the dabrafenib/trametinib combination.

**SECTION 5.8.3.3.3 QTC PROLONGATION**

**Previous:**
Guidelines for dose modification and stopping criteria due to QTc-prolongation are provided in Table 7 below:

**TABLE 7 WITHHOLDING AND STOPPING CRITERIA FOR QTc-PROLONGATION**

<table>
<thead>
<tr>
<th>QTc-ProLongation</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
</table>
| QTcB ≥501 msec | • Interrupt all study treatments until QTcB prolongation resolves to grade 1 or baseline  
• Restart at current dose levelb  
• If event recurs, permanently discontinue study treatments |

Abbreviations: msec = milliseconds; QTcB = QT interval on electrocardiogram corrected using the Bazett's formula

a. Based on average QTc value of triplicate ECGs. For example, if an ECG demonstrates a prolonged QT interval, obtain two or more ECGs over a brief period, and then use the averaged QTc values of the three ECGs to determine if study treatments should be interrupted or discontinued.
b. If the QTc prolongation resolves to grade 1 or baseline, the subject may resume study treatment if the investigator and medical monitor agree that the subject will benefit from further treatment.

**Revised:**
Guidelines for dose modification and stopping criteria due to QTc-prolongation are provided in Table 7 below:
**TABLE 7  WITHHOLDING AND STOPPING CRITERIA FOR QTc-PROLONGATION**

<table>
<thead>
<tr>
<th>QTc-Prolongationa</th>
<th>Action and Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>QTcB ≥501 msec</td>
<td>• Interrupt all study treatments until QTcB prolongation resolves to grade 1 or baseline</td>
</tr>
<tr>
<td></td>
<td>• <em>Recommend Testing serum potassium, calcium, phosphorus and magnesium. If abnormal, correct per routine clinical practice to within normal limits.</em></td>
</tr>
<tr>
<td></td>
<td>• Review concomitant medication usage for a prolonged QTc.</td>
</tr>
<tr>
<td></td>
<td>• Restart at current dose level®</td>
</tr>
<tr>
<td></td>
<td>• If event recurs, permanently discontinue study treatments</td>
</tr>
</tbody>
</table>

Abbreviations: msec = milliseconds; QTcB = QT interval on electrocardiogram corrected using the Bazett’s formula

a. Based on average QTc value of triplicate ECGs. For example, if an ECG demonstrates a prolonged QT interval, obtain two or more ECGs over a brief period, and then use the averaged QTc values of the three ECGs to determine if study treatments should be interrupted or discontinued.

b. If the QTc prolongation resolves to grade 1 or baseline, the subject may resume study treatment if the investigator and medical monitor agree that the subject will benefit from further treatment.

**Reason for change:** To accommodate request from FDA.

**SECTION 6.2 PROHIBITED MEDICATIONS AND NON-DRUG THERAPIES**

*Previous:*

The use of certain medications and illicit drugs within 28 days or 5 half lives, whichever is shorter, prior to randomization and for the duration of the study will not be allowed. The following medications or non-drug therapies are also prohibited while on treatment in this study:

- Other anti-cancer therapies;
- Other investigational drugs;
- Antiretroviral drugs (Note: Subjects with known HIV are ineligible for study participation);
- Herbal remedies (e.g., St. John’s wort);
- Drugs that are strong inhibitors or inducers of CYP3A and CYP2C8 (for examples see Table 8) may only be used under special circumstances (e.g. as a single use for a procedure) while treatment with study drug is interrupted as they may alter dabrafenib and/or trametinib concentrations; consider therapeutic substitutions for these medications. Approval of the GSK medical monitor is required in these situations. A partial list of these medications is provided in Table 8. The list may be modified based on emerging data. Refer to the SPM for the most current list.
TABLE 8  DRUGS THAT ARE STRONG INHIBITORS OR INDUCERS OF CYP3A AND CYP2C8

<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>Drugs/Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>Clarithromycin, rifamycin class agents (e.g., rifampin, rifabutin, rifapentine), telithromycin, troleandomycin</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>Nefazodone</td>
</tr>
<tr>
<td>Antifungals</td>
<td>Itraconazole, ketoconazole, posaconazole, voriconazole</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>Gemfibrozil</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Amiodarone, bosentan, carbamazepine, conivaptan, mibebranil, phenobarbital, phenytoin, s-mephenytoin</td>
</tr>
</tbody>
</table>

Revised:
The use of certain medications and illicit drugs within 28 days or 5 half lives, whichever is shorter, prior to randomization and for the duration of the study will not be allowed. The following medications or non-drug therapies are also prohibited while on treatment in this study:

- Other anti-cancer therapies;
- Other investigational drugs;
- Antiretroviral drugs (Note: Subjects with known HIV are ineligible for study participation);
- Herbal remedies (e.g., St. John's wort);
- Dabrafenib is metabolized primarily by Cytochrome P450 (CYP) 2C8 and CYP3A4. Co-administration of dabrafenib with ketoconazole, a CYP3A4 inhibitor, or with gemfibrozil, a CYP2C8 inhibitor, resulted in increases in dabrafenib AUC of 71% and 47%, respectively. Drugs that are strong inhibitors or inducers of CYP3A and CYP2C8 (for examples see Table 8) may only be used under special circumstances (e.g. as a single use for a procedure) while treatment with study drug is interrupted as they may alter dabrafenib concentrations; consider therapeutic substitutions for these medications. Approval of the GSK medical monitor is required in these situations. A partial list of these medications is provided in Table 8. The list may be modified based on emerging data. Refer to the SPM for the most current list.
### TABLE 8 PROHIBITED MEDICATIONS

<table>
<thead>
<tr>
<th>PROHIBITED — Strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib may be decreased</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class/Therapeutic Area</strong></td>
</tr>
<tr>
<td>Antibiotics</td>
</tr>
<tr>
<td>Anticonvulsant</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROHIBITED — Strong inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib may be increased</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class/Therapeutic Area</strong></td>
</tr>
<tr>
<td>Antibiotics</td>
</tr>
<tr>
<td>Antidepressant</td>
</tr>
<tr>
<td>Antifungals</td>
</tr>
<tr>
<td>Antiretroviral</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
</tbody>
</table>

*Reason for change: Updated to align with current information which is already in the Study Procedures Manual.*

### SECTION 6.3 MEDICATIONS TO BE USED WITH CAUTION

*Previous:*

The following medications should be used with caution as their concentrations may be altered by dabrafenib or trametinib or they may alter dabrafenib or trametinib concentrations:

- Drugs that are mild/moderate inhibitors or inducers of CYP3A and CYP2C8 as they may alter concentrations of dabrafenib.

- Dabrafenib has been shown to induce CYP3A4 in vivo and may induce CYP2B6. Other enzymes such as CYP2C8, CYP2C9, and CYP2C19 may also be affected. Co-administration of dabrafenib and medications which are affected by the induction of these enzymes (including warfarin) may result in loss of efficacy. If co-administration of these medications is necessary, investigators should monitor subjects for loss of efficacy or consider substitutions of these medications. A partial list of these medications is provided in Table 9 and in the SPM.
TABLE 9  MEDICATIONS TO BE USED WITH CAUTION

USE WITH CAUTION: Concentrations of these drugs may be increased or decreased by dabrafenib

<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>Mild/Moderate CYP3A and CYP2C8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmics</td>
<td>Diltiazem, verapamil</td>
</tr>
<tr>
<td>Antibiotic</td>
<td>Erythromycin</td>
</tr>
<tr>
<td>Antifungal</td>
<td>Fluconazole</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Aprepitant, cimetidine, montelukast</td>
</tr>
</tbody>
</table>

USE WITH CAUTION: Co-administration of these drugs with study treatment may result in loss of efficacy. Monitor subjects for loss of efficacy or substitute with another medication.

<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>CYP3A4, CYP2B6, CYP2C8, CYP2C9, or CYP2C19 Substrates that May be Affected by Induction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Alfentanil, buprenorphine, celecoxib, codeine, fentanyl, methadone, oxycodone</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>Disopyramide, droperidone, mexiletine, propafenone, quinidine</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>Chloramphenicol, doxycycline, erythromycin, moxifloxacin</td>
</tr>
<tr>
<td>Anticoagulants/Antiplatelets</td>
<td>Cilostazole, warfarin</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Divalproex, lamotrigine, valproate, zonisamide</td>
</tr>
<tr>
<td>Antidepressants and Antipsychotics</td>
<td>Arypiprazole, bupropion, buspirone, desipramine, haloperidol, mirtazapine, pimozide, quetiapine, trazodone, amitriptyline, domperidone, imipramine</td>
</tr>
<tr>
<td>Antidiabetics</td>
<td>Glyburide, saxagliptin, tolbutamide, nateglinide, pioglitazone, repaglinide, rosiglitazone</td>
</tr>
<tr>
<td>Antifungals</td>
<td>Caspofungin, fluconazole, terbinafine</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Astemizole, chlorpheniramine, ebastine</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>Amlodipine, diltiazem, felodipine, nilvadipine, nilvadipine, nisoldipine, verapamil</td>
</tr>
<tr>
<td>Antimigraine Agents</td>
<td>Diergotamine, eletriptan, ergotamine</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Dexamethasone, methylprednisolone, oral budesonide</td>
</tr>
<tr>
<td>Erectile Dysfunction Agents</td>
<td>Sildenafil, tadalafl, vardenafil</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>Atorvastatin, lovastatin, simvastatin, cerivastatin</td>
</tr>
<tr>
<td>Hypnotics and Sedatives</td>
<td>Alprazolam, brotizolam, diazepam, estazolam, midazolam, triazolam, zolpidem, zopiclone</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>Everolimus, sirolimus, tacrolimus</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Aprepitant, cisapride, darifenacin, disopyramide, leflunomide, metohexital, oral contraceptives, quinine, ranitidine, solifenacin, sulfasalazine, tramadol, tolvaptan, chloroquine, zopiclone</td>
</tr>
<tr>
<td>Selective Aldosterone Blockers</td>
<td>Eplerenone</td>
</tr>
</tbody>
</table>

Abbreviations: CYP = cytochrome P450; HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A.

Questions regarding concomitant medications should be directed to the GSK Medical Monitor for clarification.

Revised:
The following medications should be used with caution as their concentrations may be altered by dabrafenib or they may alter dabrafenib concentrations:

- Drugs that are moderate inhibitors or inducers of CYP3A and CYP2C8 as they may alter concentrations of dabrafenib.
Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam (CYP3A4 substrate) and S-warfarin (CYP2C9 substrate). Dabrafenib is an in vitro inducer of CYP2B6 and other enzymes such as CYP2C8, CYP2C19, UDP-glucuronyl transferases and transporters may also be affected. Co-administration of dabrafenib and medications which are affected by the induction of these enzymes (including warfarin) and transporters may result in loss of efficacy. If co-administration of these medications is necessary, investigators should consider substitutions of these medications. A partial list of these medications is provided in Table 9. The list may be modified based on emerging data. Refer to the SPM for the most current list.

Therapeutic level dosing of warfarin can be used with approval by the GSK Medical Monitor and close monitoring of PT/INR by the site. Exposure decreased by 37% due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR. Consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate. Prophylactic low dose warfarin may be given to maintain central catheter patency.

Dabrafenib solubility is pH-dependent with decreased solubility at higher pH. Drugs such as proton pump inhibitors that inhibit gastric acid secretion to elevate gastric pH may decrease the solubility of dabrafenib and reduce its bioavailability. No clinical study has been conducted to evaluate the effect of pH on dabrafenib pharmacokinetics. In an ad-hoc analysis, no differences in C_max and AUC were noted between subjects who reported taking pH-elevating products relative to other subjects. Due to the theoretical risk that pH-elevating agents may decrease oral bioavailability and exposure to dabrafenib, these medicinal products that increase gastric pH should be used with caution when administered with dabrafenib.
<table>
<thead>
<tr>
<th>Class/Therapeutic Area</th>
<th>CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or Transporter Substrates that May Be Affected by Induction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Alfentanil, buprenorphine, celecoxib, codeine, fentanyl, methadone, oxycodone</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>Disopyramide, dronedarone, mexiletine, propafenone, quinidine</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>Chloramphenicol, doxycycline, erythromycin, moxifloxacin</td>
</tr>
<tr>
<td>Anticoagulants/Antiplatelets</td>
<td>Clopidogrel, warfarin</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Divalproex, lamotrigine, valproate, zonisamide</td>
</tr>
<tr>
<td>Antidepressants and Antipsychotics</td>
<td>Aripiprazole, buspirone, desipramine, haloperidol, mirtazapine, pimozide, quetiapine, trazodone, amitriptyline, clozapine, imipramine</td>
</tr>
<tr>
<td>Antidiabetics</td>
<td>Glyburide, saxagliptin, tolbutamide, nateglinide, pioglitazone, repaglinide, rosiglitazone</td>
</tr>
<tr>
<td>Antifungals</td>
<td>Caspofungin, fluconazole, terbinafine</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Astemizole, chlorpheniramine, ebastine</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>Amlodipine, diltiazem, felodipine, nilvadipine, nisoldipine, verapamil</td>
</tr>
<tr>
<td>Antimigraine Agents</td>
<td>Diergotamine, eletriptan, ergotamine</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Dexamethasone, methylprednisolone, oral budesonide</td>
</tr>
<tr>
<td>Erectile Dysfunction Agents</td>
<td>Sildenafil, tadalafil, vardenafil</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>Atorvastatin, lovastatin, simvastatin, rosvastatin, pravastatin</td>
</tr>
<tr>
<td>Hypnotics and Sedatives</td>
<td>Alprazolam, brotizolam, diazepam, estazolam, midazolam, triazolam, zolpidem, zopiclone</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>Everolimus, sirolimus, tacrolimus</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Aprepitant, cisapride, darifenacin, disopyramide, leflunomide, methohexital, oral contraceptives, quinine, ranitidine, solifenacin, sulfasalazine, trimadol, tolvaptan, chloroquine, zopiclone</td>
</tr>
<tr>
<td>Selective Aldosterone Blockers</td>
<td>Eplerenone</td>
</tr>
</tbody>
</table>

**USE WITH CAUTION:** Co-administration of drugs that increase gastric pH should be used with caution when administered with dabrafenib.

| pH altering agents              | dexlansoprazole, esomeprazole, famotidine, lansoprazole, omeprazole, pantoprazole, rabeprazole, ranitidine |

**Abbreviations:** CYP = cytochrome P450; HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A.

Questions regarding concomitant medications should be directed to the Medical Monitor for clarification.

*Reason for change:* Updated to align with current information which is already in the Study Procedures Manual.
TIME AND EVENTS TABLE 10

Summary of changes and rationale:
Extended visit window from ±3 days to ±7 days for ECG, ECHO, ophthalmic examination, dermatologic skin assessment and CT scans during treatment to allow greater flexibility for scheduling.
Added clarification of blood samples required for cfDNA and other biomarker testing, cytokine and markers of pyrexia and PK sampling.
Clarified timeline for obtaining informed consent in Footnote #3.
Replaced dermatologic skin assessment at Month 9 with dermatologic skin assessments at Months 8 and 10 to align with Global Data Sheet for dabrafenib.
Clarified requirements for complete physical exam in Footnote #17.
Clarified Footnote #18 to ensure consistency with protocol specific Image Acquisition Guidelines.

TIME AND EVENTS TABLE 11

Summary of changes and rationale:
Added column [“Every 3 months (M3-M12)“] and footnotes (#14 & #15) to clarify assessments required for subjects that discontinue study treatments prior to Month 12 without evidence of disease recurrence.
Clarified timing of “After Recurrence” follow-up assessments.
Clarified requirements for complete physical exam in Footnote #4.
Clarified Footnote #5 to ensure consistency with protocol specific Image Acquisition Guidelines.
Clarified procedure for completing QOL questionnaires during follow-up after disease recurrence in Footnote #6.
Added Footnote #13 to clarify timing of follow up assessments after disease recurrence.
Added Footnote #14 to clarify visit schedule for subjects that discontinue study treatment prior to Month 12 with no evidence of disease recurrence.
Added Footnote #15 to clarify CT requirements at first follow-up visit after treatment discontinuation with no evidence of disease recurrence.
Added Footnote #16 to clarify dermatologic skin assessment requirement for subjects that discontinue study treatments due to disease recurrence.

SECTION 7.2.1.3 EFFICACY ASSESSMENT

Previous:
See the Time and Events Tables (Table 10 and Table 11) for the schedule of efficacy assessments. Assessments must be performed on a calendar schedule and should not be affected by dose interruptions/delays. For post-baseline efficacy assessments Month 1 through Month 12, a window of ±3 days is permitted to allow for flexible scheduling. After Month 12 a post-baseline assessment window of ±14 days is permitted.
The following are required for efficacy assessment:
• Clinical examination
• Diagnostic quality, contrast-enhanced CT for Chest/Abdomen/Pelvis should be performed at baseline and subsequent timepoints as indicated in the Time and Events Tables (Table 10 and Table 11). Contrast-enhanced MRI of the chest, abdomen and pelvis should be substituted for full CT scanning if the CT frequency prescribed in the Time and Events Table is not permitted per country or ethics requirements or if CT contrast is contraindicated. The method of imaging should be consistent throughout the study (i.e. if CT is done at screening, CT will be done at all future timepoints). All CTs/MRIs will be collected; instructions are provided in the Study Procedures Manual (SPM).

• A baseline MRI of the brain is required for all subjects. CT may be performed only if MRI contraindicated or unavailable. Subsequent brain scans should only be performed as clinically indicated (e.g. symptoms suggestive of CNS recurrence). MRI/CT of the brain will be collected; instructions are provided in the Study Procedures Manual (SPM).

• Biopsy of suspected recurrences is strongly recommended, both to confirm the diagnosis and to obtain tissue for exploratory analyses (Section 7.7.2).

Revised:
See the Time and Events Tables (Table 10 and Table 11) for the schedule of efficacy assessments. Assessments must be performed on a calendar schedule and should not be affected by dose interruptions/delays. For post-baseline efficacy assessments Month 1 through Month 12, a window of ±3 days (physical exam) or ±7 days (CT scans, dermatologic skin assessment) is permitted to allow for flexible scheduling. After Month 12 a post-baseline assessment window of ±14 days is permitted. The following are required for efficacy assessment:

• Clinical examination

• Diagnostic quality, contrast-enhanced CT scan of the chest, abdomen and pelvis should be performed at baseline and subsequent timepoints as indicated in the Time and Events Tables (Table 10, Table 11 and Table 12). Intravenous contrast should be used for the CT scans preferably with oral contrast as well. CT contrast of the chest, with contrast-enhanced MRI of the abdomen and pelvis should be substituted for full CT scanning if the CT frequency prescribed in the Time and Events Table is not permitted per country or ethics requirements or if CT contrast is contraindicated. The method of imaging should be consistent throughout the study (i.e. if CT is done at screening, CT will be done at all future timepoints). All CTs/MRIs will be collected; instructions are provided in the Study Procedures Manual (SPM).

• A baseline MRI of the brain is required for all subjects. CT may be performed only if MRI contraindicated or unavailable. Subsequent brain scans should only be performed as clinically indicated (e.g. symptoms suggestive of CNS recurrence). MRI/CT of the brain will be collected; instructions are provided in the Study Procedures Manual (SPM).

• Biopsy of suspected recurrences is strongly recommended, both to confirm the diagnosis and to obtain tissue for exploratory analyses (Section 7.7.2).
Reason for change: Updated to allow for increased visit window of some efficacy assessments and to align with protocol specific Image Acquisition Guidelines.

SECTION 7.3.2.5 TIME PERIOD AND FREQUENCY OF DETECTING AES AND SAEs

Previous:
The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE.

AEs will be collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice.

SAEs will be collected over the same time period as stated above for AEs. In addition, any SAE assessed as related to study participation (e.g., protocol-mandated procedures, invasive tests, or change in existing therapy), study treatment or GSK concomitant medication must be recorded from the time a subject consents to participate in the study up to and including any follow-up contact. All SAEs will be reported to [redacted] within 24 hours, as indicated in Section 7.3.2.6.

After discontinuation of study treatment, the investigator will monitor all AEs/SAEs that are ongoing until resolution or stabilization of the event or until the subject is lost to follow-up. At any time after 30 days from the last dose of study treatment the investigator may report any adverse event that they believe is possibly related to study treatment. Treatment emergent malignancies should be reported regardless of the time from treatment discontinuation to occurrence of the event.
Revised:
The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE.

AEs will be collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice.

SAEs will be collected over the same time period as stated above for AEs. In addition, any new malignancy (defined in Section 7.3.2.2) or any SAE assessed as related to study participation (e.g., protocol-mandated procedures, invasive tests, or change in existing therapy), study treatment or GSK concomitant medication must be recorded from the time a subject consents to participate in the study up to and including any follow-up contact. All SAEs will be reported to GSK within 24 hours, as indicated in Section 7.3.2.6. For any new malignancy, every effort should be made to identify the RAS mutation status; the mutation test should be performed locally and reported within 12 weeks of diagnosis. Additional genetic analysis may be performed depending on the tumor types, and the results reported at the discretion of the investigator.

After discontinuation of study treatment, the investigator will monitor all AEs/SAEs that are ongoing until resolution or stabilization of the event or until the subject is lost to follow-up. At any time after 30 days from the last dose of study treatment the investigator may report any adverse event that they believe is possibly related to study treatment. Treatment emergent malignancies should be reported regardless of the time from treatment discontinuation to occurrence of the event.

Reason for change: As requested by the European Regulatory Authority, information for new malignancies will be collected throughout study treatment and follow-up.

SECTION 7.3.3.1 PREGNANCY TEST AND PREVENTION

Summary of the change:

Replaced “the first dose of study treatment” with “randomization” in the following paragraph:

If a female subject is of childbearing potential, she must have a serum β-hCG pregnancy test performed within 7 days prior to randomization. Subjects with positive pregnancy test result must be excluded from the study. Subjects with negative pregnancy test result must agree to use an effective contraception method as described below during the study until 4 months following the last dose of study treatment.

Reason for change: Clarification.
SECTION 7.3.7 PHYSICAL EXAMINATIONS

Previous:
All physical exams (brief and complete) will include the measurement of height (screening only) and weight using the metric scale, collection of vital signs including blood pressure, body temperature, pulse rate, and respirations as well as assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A complete physical exam will also include a thorough genitourinary (including a PAP smear for female subjects) examination, inspection of the head and neck region, and digital rectal examination for both male and female subjects. Complete physical exams must be performed at Screening, Month 12 or discontinuation if discontinuation occurs prior to Month 12 and Month 18. If the subject has had a genitourinary and rectal exam within 6 months of screening these do not need to be repeated at screening. Brief physical examinations will be performed at all other timepoints as indicated in the Time and Events Tables (Table 10 and Table 11). Refer to the SPM for additional detail regarding the exam requirements for the inspection of the head and neck region.

Revised:
All physical exams (brief and complete) will include the measurement of height (screening only) and weight using the metric scale, collection of vital signs including blood pressure, body temperature, pulse rate, and respirations as well as assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A complete physical exam will also include a thorough genitourinary (pelvic) examination, inspection of the head and neck region, and digital rectal examination for both male and female subjects. For female subjects the genitourinary exam must include a PAP smear. Complete physical exams must be performed at Screening, Month 12 or discontinuation if discontinuation occurs prior to Month 12 and Month 18. If the subject has had a genitourinary and rectal exam within 6 months of randomization these do not need to be repeated at screening. Brief physical examinations will be performed at all other timepoints as indicated in the Time and Events Tables (Table 10, Table 11, Table 12). Refer to the SPM for additional detail regarding the exam requirements for the inspection of the head and neck region.

Reason for change: Clarification.

SECTION 7.3.8 DERMATOLOGIC EXAMINATION

Previous:
Dermatologic exams are required at Screening, Month 2, Month 4, every three months from Month 6 until Month 24, and every 6 months after Month 24. Exams may be performed by the investigator or may be referred to a dermatologist, at the discretion of the investigator. If possible, the same physician should perform each exam for the duration of the study (i.e. if the subject is referred to a dermatologist for the screening exam, the dermatologist should do all follow up dermatologic assessments) to ensure consistency between evaluations. Refer to the SPM for additional detail regarding the dermatologic examination including exam requirements and required training for investigators that will be performing the exam.

Revised:
Dermatologic exams are required at Screening, Month 2, Month 4, Month 6, Month 8, Month 10 and Month 12 (or discontinuation if subject discontinues prior to Month 12), every three months from Month 12 until Month 24, and every 6 months after Month 24. Exams may be performed by the investigator or may be referred to a dermatologist, at the discretion of the investigator. If possible, the same physician should perform each exam for the duration of the study (i.e. if the subject is referred to a dermatologist for the screening exam, the dermatologist should do all follow up dermatologic assessments) to ensure consistency between evaluations. Refer to the SPM for additional detail regarding the dermatologic examination including exam requirements and required training for investigators that will be performing the exam.

Reason for change: Updated to align with Global Data Sheet for dabrafenib monotherapy.

SECTION 7.7.1 BRAF MUTATION ASSAY

Previous:
To determine BRAF V600E/K status, tumor tissue will be assessed from all subjects at Screening. The tissue will be tested for the BRAFV600E or V600K mutations using the bioMerieux BRAF THxID IUO assay (IDE: G120011) and testing will be performed in a CLIA certified central reference laboratory. Tissue from either the primary tumor or metastatic lymph nodes is acceptable, however the most recently obtained tumor tissue (either archived material or fresh biopsy) is preferred.

The tissue requirements for the BRAF mutation assay evaluating patient eligibility for the study are provided in the SPM.

Additional biomarkers related to the activity of dabrafenib and trametinib may also be analyzed as described in Section 7.7.2.

Revised:
To determine BRAF V600E/K status, tumor tissue will be assessed from all subjects at Screening. The tissue will be tested for the BRAFV600E or V600K mutations using the bioMerieux THxID BRAF assay performed in a CLIA certified central reference laboratory. Tissue from either the primary tumor or metastatic lymph nodes is acceptable, however the most recently obtained tumor tissue (either archived material or fresh biopsy) is preferred.

The tissue requirements for the BRAF mutation assay evaluating patient eligibility for the study are provided in the SPM.

Additional biomarkers related to the activity of dabrafenib and trametinib may also be analyzed as described in Section 7.7.2.

Reason for change: Updated assay description due to approval of the assay in multiple countries.

NEW APPENDIX ADDED

APPENDIX 15: ADDITIONAL MONITORING
CUTANEOUS SQUAMOUS CELL CARCINOMA (CUSCC) AND NEW PRIMARY MELANOMA

Dermatological examinations should be performed prior to initiation of study treatment, monthly during treatment, and monthly for 6 months following discontinuation of dabrafenib or until initiation of another anti-neoplastic therapy, whichever comes first. Subjects should be instructed to immediately inform their physician if new lesions develop. Any CUSCC or new primary melanoma should be reported as a protocol-specific SAE and treated according to standard clinical practice.

NON-CUTANEOUS SECONDARY/RECURRENT MALIGNANCY

Prior to initiation of study treatment subjects should undergo a head and neck examination with minimally visual inspection of oral mucosa and lymph node palpation, as well as chest/abdomen Computed Tomography (CT) scan. During treatment subjects should be monitored as clinically appropriate which may include a head and neck examination every 3 months and a chest/abdomen CT scan every 6 months. Anal examinations and pelvic examinations are recommended before the start of and at the end of treatment or when considered clinically indicated. Complete blood cell counts should be performed as clinically indicated. Following discontinuation of dabrafenib monitoring for non-cutaneous secondary/recurrent malignancies should continue for up to 6 months or until initiation of another anti-neoplastic therapy, whichever comes first. Any non-cutaneous secondary/recurrent malignancy should be reported as a protocol-specific SAE and treated according to standard clinical practice.
12.17 **Protocol Changes for Amendment 6 (dated 05-Oct-2016) from Amendment 5 (dated 24-October-2013)**

This amendment applies to all study sites. Bolded text indicates revised text and strike through indicates deleted text.

**Amendment Summary of Main Changes:**

<table>
<thead>
<tr>
<th>Section(s)</th>
<th>Change</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor signatory</td>
<td>Change of sponsor signatory</td>
<td>Change in study sponsor</td>
</tr>
<tr>
<td>Multiple</td>
<td>Delete or replace references for staff with that of sponsor and its authorized agents</td>
<td>To align with the change of sponsorship from</td>
</tr>
<tr>
<td>Multiples</td>
<td>Change &quot;medical monitor&quot; to &quot;Medical Lead&quot;</td>
<td>To align with processes</td>
</tr>
<tr>
<td>Multiple</td>
<td>Make administrative changes</td>
<td>To align with the change of</td>
</tr>
</tbody>
</table>
Reason for change:
Change in study sponsorship